<SEC-DOCUMENT>0001193125-16-801096.txt : 20161222
<SEC-HEADER>0001193125-16-801096.hdr.sgml : 20161222
<ACCEPTANCE-DATETIME>20161222060633
ACCESSION NUMBER:		0001193125-16-801096
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20161222
DATE AS OF CHANGE:		20161222
EFFECTIVENESS DATE:		20161222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-206994
		FILM NUMBER:		162065011

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>d309486dsuppl.htm
<DESCRIPTION>SUPPL #4
<TEXT>
<HTML><HEAD>
<TITLE>SUPPL #4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to General Instruction II.L. of Form F-10 <BR>File No. 333-206994 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#ff4338"><I>A copy of this preliminary prospectus supplement has been filed with the securities regulatory authorities in the provinces of British
Columbia, Alberta and Ontario, but has not yet become final for the purposes of the sale of securities. Information contained in this preliminary prospectus supplement may not be complete and may have to be amended. </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This prospectus supplement, together with the short form base shelf prospectus dated October&nbsp;16, 2015 to which it relates, as amended or supplemented,
and each document incorporated or deemed to be incorporated by reference in the short form base shelf prospectus, constitutes a public offering of securities offered pursuant hereto only in the jurisdictions where they may be lawfully offered for
sale and therein only by persons permitted to sell such securities. See &#147;Plan of Distribution.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Information has been
incorporated by reference in this prospectus supplement from documents filed with securities commissions or similar authorities in Canada.</I></B><I> Copies of the documents incorporated herein by reference may be obtained on request without charge
from the Corporate Secretary of Aurinia Pharmaceuticals Inc. at 1200 Waterfront Centre, 200 Burrard Street, P.O. Box 48600, Vancouver, British Columbia, Canada, V7X 1T2, telephone (604) <FONT STYLE="white-space:nowrap">632-3473,</FONT> and are also
available electronically at www.sec.gov/edgar.shtml or www.sedar.com. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY PROSPECTUS SUPPLEMENT No.&nbsp;4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To the Short Form Base Shelf Prospectus Dated October&nbsp;16, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I><U>New Issue</U></I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>December 22, 2016</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g07r64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,111,111 Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying short form base shelf prospectus dated October&nbsp;16, 2015 qualifies the distribution (the
&#147;<B>Offering</B>&#148;) of 11,111,111 units (each an &#147;<B>Offered Unit</B>&#148;) of Aurinia Pharmaceuticals Inc. (&#147;<B>Aurinia</B> <B>Pharmaceuticals</B>&#148;, the &#147;<B>Company</B>&#148;, &#147;<B>we</B>&#148;,
&#147;<B>us</B>&#148; or &#147;<B>our</B>&#148;), at a price of US$2.25 per Offered Unit (the &#147;<B>Offering Price</B>&#148;). Each Offered Unit consists of one common share (each, a &#147;<B>Unit Share</B>&#148;) of the Company and one-half of
one common share purchase warrant of the Company (each whole common share purchase warrant, a &#147;<B>Warrant</B>&#148;). The Offered Units will separate into Unit Shares and Warrants immediately upon distribution. Each Warrant will entitle the
holder to purchase one common share of the Company (each a &#147;<B>Warrant Share</B>&#148;) at a price of US$3.00, subject to adjustment, at any time prior to 4:30&nbsp;p.m. (New York time) on the date that is five years after the closing of the
Offering. The Offered Units will be issued pursuant to an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) dated December 22, 2016, between the Company, H.C. Wainwright&nbsp;&amp; Co. LLC (the &#147;<B>Lead</B>
<B>Underwriter</B>&#148;) and Cormark Securities Inc. (collectively, the &#147;<B>Underwriters</B>&#148;). The Offering Price was determined by negotiation between us and the Lead Underwriter on its own behalf and on behalf of the other Underwriter.
The Offered Units will be offered in the United States and Canada through the Underwriters, either directly or through their duly registered U.S. or Canadian broker dealer affiliates or agents, as applicable. See &#147;<I>Plan of
Distribution.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common shares are listed and posted for trading on the Toronto Stock Exchange (the &#147;<B>TSX</B>&#148;) under the symbol
&#147;AUP&#148; and on the NASDAQ Global Market (the &#147;<B>NASDAQ</B>&#148;) under the symbol &#147;AUPH.&#148; On December&nbsp;21, 2016, the closing price of the common shares on the TSX was CDN$3.64 and the closing price of the common shares
on the NASDAQ was US$2.72.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have applied to list the Unit Shares and the Warrant Shares offered by this prospectus supplement on the TSX.
Listing will be subject to our fulfillment of all of the requirements of the TSX. We have also applied to list the Unit Shares and the Warrant Shares offered by this prospectus supplement on the NASDAQ. Listing will be
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to our fulfillment of all of the requirements of the NASDAQ. <B>There will be no market in Canada or the</B> <B>United States through which the Warrants may be sold. This may affect the
pricing of the Warrants in the Canadian or the United States secondary market, the transparency and availability of trading prices, the liquidity of such securities, and the extent of issuer regulation.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should carefully read the &#147;</B><B><I><A HREF="#supp309486_8">Risk
Factors</A></I></B><B>&#148; section in this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein, as well as the information under the heading &#147;</B><B><I>Cautionary Note Regarding
Forward Looking Information</I></B><B>&#148; in this prospectus supplement, and consider such notes and information in connection with an investment in any securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Price: US$2.25 per Unit </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;to&nbsp;the&nbsp;Public<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Underwriters&#146;<BR>Fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Proceeds&nbsp;to<BR>the Company<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$2.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$24,999,999.75</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Company intends to allocate US$2.24 of the Offering Price as consideration for the issue of the Unit Share and US$0.01 of the Offering Price as consideration for the issue of the one-half of one Warrant comprising
each Offered Unit. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">In consideration for the services rendered by the Underwriters in connection with the Offering, the Underwriters will be paid an aggregate cash fee of US$&nbsp;&nbsp;&nbsp;&nbsp;per Offered Unit,
representing&nbsp;&nbsp;&nbsp;&nbsp;% of the gross proceeds of the Offering (the &#147;<B>Underwriters&#146; Fee</B>&#148;). See &#147;<I>Plan of Distribution</I>.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">After deducting the Underwriters&#146; Fee, but before deducting expenses of the Offering, including in connection with the preparation and filing of this prospectus supplement, which are estimated to be US$450,000 and
which will be paid from the proceeds of the Offering. Such net proceeds do not include any proceeds received from the exercise of the Warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has granted the Underwriters an over-allotment option (the &#147;<B>Over-Allotment Option</B>&#148;), exercisable in whole or in part, at any time
and from time to time, in the sole discretion of the Underwriters, for a period of 30 days from the date of this prospectus supplement, to purchase up to an additional amount of Offered Units equal to 15% of the Offered Units sold pursuant to the
Offering, being 1,666,666 Offered Units (the &#147;<B>Additional Offered Units</B>&#148;), at the Offering Price, less the Underwriters&#146; Fee, to cover over-allotments, if any, and for market stabilization purposes. The Over-Allotment Option may
be exercisable by the Underwriters in respect of: (i) Additional Offered Units at the Offering Price; or (ii) additional Unit Shares (the &#147;<B>Additional Shares</B>&#148;) at a price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
Additional Share; or (iii) additional Warrants (the &#147;<B>Additional Warrants</B>&#148;) at a price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Additional Warrant; or (iv) any combination of Additional Shares and/or Additional
Warrants (together, the &#147;<B>Additional Securities</B>&#148;), so long as the aggregate number of Additional Shares and Additional Warrants which may be issued under the Over-Allotment Option does not exceed 1,666,666 Additional Shares and
833,333 Additional Warrants. The Additional Securities issuable upon exercise of the Over-Allotment Option are hereby qualified for distribution under this prospectus supplement. A purchaser who acquires Additional Securities issuable on the
exercise of the Over-Allotment Option acquires such Additional Securities under this prospectus supplement regardless of whether the over-allotment position is ultimately filled through the exercise of the Over-Allotment Option or secondary market
purchases. If the Over-Allotment Option is exercised in full, the total Price to the Public, Underwriters&#146; Fee and Net Proceeds to the Company (before payment of the expenses of the Offering and excluding any proceeds received from the exercise
of the Warrants) will be approximately US$28.75 million, US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, respectively. See &#147;Plan of Distribution&#148; and the table
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:80.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriters&#146; Position </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:71.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:53.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:48.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise Price</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Over-Allotment Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1,666,666 Additional</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares and/or 833,333</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additional Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 days following</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">the date of this prospectus
supplement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional Share and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Additional Warrant</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references to the &#147;<B>Offering</B>&#148; in this prospectus
supplement shall include the Over-Allotment Option and all references to &#147;<B>Offered Units</B>&#148; shall include Additional Offered Units, references to &#147;<B>Unit Shares</B>&#148; shall include Additional Shares and references to
&#147;<B>Warrants</B>&#148; shall include &#147;Additional Warrants&#148;, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriters, as principal, conditionally offer the Offered
Units subject to prior sale, if, as and when issued by the Company, and accepted by the Underwriters, in accordance with the conditions contained in the Underwriting Agreement described under &#147;<I>Plan of Distribution</I>&#148; and subject to
the approval of certain legal matters on behalf of the Company by Borden Ladner Gervais LLP, with respect to Canadian legal matters, and by Cooley LLP, with respect to U.S. legal matters, and on behalf of the Underwriters by Stikeman Elliott LLP,
with respect to Canadian legal matters, and by Goodwin Procter LLP, with respect to U.S. legal matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscriptions will be received subject to
rejection or allotment in whole or in part and the right is reserved to close the subscription books at any time without notice. An electronic Deposit ID evidencing the Unit Shares is expected to be registered to CDS Clearing and Depository Services
Inc. (&#147;<B>CDS</B>&#148;) and will be deposited with CDS at the closing of the Offering, which is anticipated to be on or about December&nbsp;28, 2016 or such other date as may be agreed upon between the Company and the Underwriters. A purchaser
of Unit Shares will receive only a customer confirmation from the registered dealer through which the Unit Shares comprising part of the Offered Units are purchased. Certificates representing the Warrants will be available for delivery to purchasers
at closing of this Offering. The Company expects that delivery of the Offered Units will be made against payment therefor on or about the date of closing of the Offering, which is expected to be December&nbsp;28, 2016. Investors who wish to trade
Unit Shares or Warrants prior to the closing date of the Offering should consult their own advisors. See &#147;<I>Plan of Distribution.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities affiliated with the ILJIN SNT Co., Ltd., one of our major stockholders, have submitted an indication of interest to purchase up to
US$3.0&nbsp;million of the Offered Units in this Offering. However, because indications of interest are not binding agreements or commitments to purchase, the Underwriters may determine to sell more, fewer or no Offered Units in this Offering to
these entities, or these entities may determine to purchase more, fewer or no Offered Units in this Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors should rely only on current
information contained in or incorporated by reference into this prospectus supplement as such information is accurate only as of the date of the applicable document. The Company has not authorized anyone to provide investors with different
information. Information contained on the Company&#146;s website shall not be deemed to be a part of this prospectus supplement or incorporated by reference and should not be relied upon by prospective investors for the purpose of determining
whether to invest in the securities. The Company will not make an offer of these securities in any jurisdiction where the offer or sale is not permitted. Investors should not assume that the information contained in this prospectus supplement is
accurate as of any date other than the date on the face page of this prospectus supplement or the date of any documents incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gregory Ayers, Hyuek Joon Lee, David Jayne, Charles A. Rowland Jr. and Lorin Jeffry Randall, each a director of the Company, reside outside of Canada. Each
of these directors has appointed Borden Ladner Gervais LLP, 1200 Waterfront Centre, 200 Burrard Street, P.O. Box 48600, Vancouver, British Columbia V7X 1T2, as agent for service of process in Canada. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person or company that is incorporated, continued or otherwise organized under the laws of a foreign jurisdiction or resides outside of Canada, even if the party has
appointed an agent for service of process. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Offering, subject to applicable laws, the Underwriters may over-allot or effect
transactions that stabilize or maintain the market price of the common shares at levels other than those which otherwise might prevail on the open market. Such transactions, if commenced, may be discontinued at any time. <B>After the Underwriters
have made a reasonable effort to sell all of the Offered Units offered by this prospectus supplement at the Offering Price specified herein, the Offering Price may be decreased, and further changed from time to time. Any such reduction will not
affect the proceeds received by the Company. See &#147;</B><B><I>Plan of Distribution.</I></B><B>&#148;</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>H.C. Wainwright&nbsp;&amp; Co., LLC is not registered as a dealer in the category of investment dealer in any
Canadian jurisdiction and, accordingly, will only sell Offered Units into the United States and will not, directly or indirectly, solicit offers to purchase or sell the Offered Units in Canada. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are permitted under a multijurisdictional disclosure system adopted by the securities regulatory authorities in Canada and the United States to prepare
this prospectus supplement and the accompanying prospectus in accordance with the disclosure requirements of Canada. Prospective investors in the United&nbsp;States should be aware that such requirements are different from those of the United
States. The financial statements incorporated by reference in this prospectus supplement and the accompanying prospectus have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting
Standards Board, and are subject to Canadian auditing and auditor independence standards. As a result, our financial statements may not be comparable to financial statements of United States companies. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospective investors should be aware that the acquisition of the securities described herein may have tax consequences both in Canada and the United
States. Such consequences, for investors who are resident in, or citizens of, the United States, may not be described fully in this prospectus supplement, including the Canadian federal income tax consequences applicable to a foreign controlled
Canadian corporation that acquires Offered Units. Investors should read the tax discussion in this prospectus supplement and the accompanying prospectus and consult their own tax advisors with respect to their own particular circumstances. See the
sections titled &#147;</B><B><I>Certain Canadian Federal Income Tax Considerations</I></B><B>,&#148; &#147;</B><B><I>Material U.S. Federal Income Taxation Considerations</I></B><B>&#148; and &#147;</B><B><I>Risk Factors.</I></B><B>&#148; </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your ability to enforce civil liabilities under the United States federal securities laws may be affected adversely because we are incorporated in Canada,
most of the officers and directors and some of the experts named in this prospectus supplement are not residents of the United States, and many of our assets and all or a substantial portion of the assets of such persons are located outside of the
United States. See &#147;</B><B><I>Enforceability of Certain Civil Liabilities.</I></B><B>&#148; </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the U.S. Securities and Exchange
Commission (the &#147;SEC&#148;) nor any state or Canadian securities regulator has approved or disapproved the securities offered hereby; passed upon the accuracy or adequacy of this prospectus supplement or determined if this prospectus supplement
is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered office is located at #201, 17904 &#150; 105 Avenue,
Edmonton, Alberta T5S 2H5, Canada. Our head office is located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8, Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Book-Running Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Cormark Securities Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_1">IMPORTANT NOTICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_2">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_4">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_4.1">MARKETING MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_5">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_6">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_7">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_8">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_9">CONSOLIDATED FINANCIAL INFORMATION AND CURRENCY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_10">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_11">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_12">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_13">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_14">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_15">DESCRIPTION OF SECURITIES OFFERED UNDER THIS PROSPECTUS
SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_16">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_17">CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_17.1">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-43</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_18">AGENT FOR SERVICE OF PROCESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_19">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_20">ENFORCEABILITY OF CERTAIN CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-51</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-52</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_22">INTEREST OF EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-52</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_23">STATUTORY RIGHTS OF WITHDRAWAL AND RESCISSION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-52</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_24">ELIGIBILITY FOR INVESTMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-53</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_25">CERTIFICATE OF AURINIA PHARMACEUTICALS INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supp309486_26">CERTIFICATE OF THE UNDERWRITERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">C-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_2">PRESENTATION OF FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_4">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_5">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_6">EXCHANGE RATE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_7">CORPORATE STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_8">SUMMARY DESCRIPTION OF BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_9">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_10">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_11">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_12">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_13">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_14">DESCRIPTION OF COMMON SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_15">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_16">DESCRIPTION OF SUBSCRIPTION RECEIPTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_17">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_18">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_19">CERTAIN INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- i - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_20">AUDITORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_21">TRANSFER AGENTS AND REGISTRARS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_22">AGENT FOR SERVICE OF PROCESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_23">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_24">WHERE CAN YOU FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_25">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_26">CANADIAN PURCHASER&#146;S STATUTORY RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_27">CERTIFICATE OF AURINIA PHARMACEUTICALS INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_1"></A>IMPORTANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of the securities we are offering and the
method of distribution of those securities and also supplements and updates information regarding us contained in the accompanying base shelf prospectus. The second part, the accompanying prospectus, gives more general information about securities
we may offer from time to time, some of which may not apply to the Offering. Both documents contain important information you should consider when making your investment decision. This prospectus supplement may add, update or change information
contained in the accompanying prospectus. Before investing, you should carefully read both this prospectus supplement and the accompanying prospectus together with the additional information about us to which we refer you in the sections of this
prospectus supplement titled &#147;<I>Documents Incorporated by Reference</I>&#148; and &#147;<I>Where You Can Find More Information</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
should rely only on information contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus. If information in this prospectus
supplement is inconsistent with the accompanying prospectus or the information incorporated by reference, you should rely on this prospectus supplement. We have not authorized anyone to provide you with information that is different. If anyone
provides you with any different or inconsistent information, you should not rely on it. We are offering the Offered Units only in jurisdictions where such offers are permitted by law. The information contained in this prospectus supplement and the
accompanying prospectus is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus and you should not assume otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference into this prospectus supplement and the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_2"></A>ABOUT THIS
PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of a &#147;shelf&#148; registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> that
we filed with the SEC. The shelf registration statement was declared effective by the SEC on November&nbsp;5, 2015. This prospectus supplement does not contain all of the information contained in the registration statement, certain parts of which
are omitted in accordance with the rules and regulations of the SEC. You should refer to the registration statement and the exhibits to the registration statement for further information with respect to us and our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, unless stated otherwise or the context requires, all dollar amounts are expressed in U.S. dollars. All references to &#147;$ or
&#147;US$&#148; are to the lawful currency of the United States and all references to &#147;CDN$&#148; are to the lawful currency of Canada. This prospectus supplement and the documents incorporated by reference contain translations of some Canadian
dollar amounts into U.S. dollars solely for your convenience. See the section titled &#147;<I>Exchange Rate Information.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market data and
certain industry forecasts used in this prospectus supplement and the documents incorporated by reference herein or therein were obtained from market research, publicly available information and industry publications. We believe that these sources
are generally reliable, but the accuracy and completeness of this information is not guaranteed. We have not independently verified such information, and we do not make any representation as to the accuracy of such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and
therein, unless the context otherwise requires, references to &#147;<B>we</B>&#148;, &#147;<B>us</B>&#148;, &#147;<B>our</B>&#148; or similar terms, as well as references to &#147;<B>Aurinia Pharmaceuticals</B>&#148; or the
&#147;<B>Company</B>&#148;, refer to Aurinia Pharmaceuticals Inc., together with our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is deemed to be
incorporated by reference into the accompanying prospectus solely for the purposes of the Offering. Other documents are also incorporated or deemed to be incorporated by reference into this prospectus supplement and into the accompanying prospectus.
See the section titled &#147;<I>Documents Incorporated by Reference.</I>&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein contain &#147;forward-looking
statements&#148; or &#147;forward-looking information&#148; within the meaning of applicable securities legislation. Forward-looking information is provided as of the date of this prospectus supplement and we do not intend, and do not assume any
obligation, to update this forward-looking information, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement is forward-looking when it uses what we know and expect
today to make a statement about the future. Forward-looking statements may include words such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;goal&#148;, &#147;may&#148;, &#147;outlook&#148;,
&#147;plan&#148;, &#147;seek&#148;, &#147;should&#148;, &#147;strive&#148;, &#147;target&#148;, &#147;could&#148;, &#147;continue&#148;, &#147;potential&#148; and &#147;estimated&#148;, or the negative of such terms or comparable terminology. You
should not place undue reliance on the forward-looking statements, particularly those concerning anticipated events relating to the development, clinical trials, regulatory approval, and marketing of our products and the timing or magnitude of those
events, as they are inherently risky and uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities laws encourage companies to disclose forward-looking information so that investors can get
a better understanding of our future prospects and make informed investment decisions. These statements, made in this prospectus supplement or a document incorporated by reference herein, may include, among other things, statements with respect to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Offering, including the terms, potential completion and expected closing date of the Offering and the intended use of proceeds of the Offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials or plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of commencement and completion of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek additional corporate alliances and collaborative agreements to support the commercialization and development of our product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
differentiation with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> status for the treatment of lupus nephritis (&#147;<B>LN</B>&#148;) outside of Japan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to initiate, and the timing of, the LN Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that the LN Phase 3 clinical trial will be <FONT STYLE="white-space:nowrap">de-risked</FONT> based upon the <FONT STYLE="white-space:nowrap">AURA-LV</FONT> results; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief in the market size and potential of lupus nephritis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements reflect our current views with respect to future events and are subject to risks and
uncertainties and are necessarily based on a number of estimates and assumptions that, while considered reasonable by management, as at the date of such statements, are inherently subject to significant business, economic, competitive, political,
scientific and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. The factors and assumptions used by management to develop such forward-looking statements include, but are not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to reach agreements with regulatory agencies on executable development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that recruitment to clinical trials will occur as projected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will successfully complete our clinical programs on a timely basis, including conducting the required LN Phase 3 clinical trial and meet regulatory requirements for approval of marketing
authorization applications and new drug approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption the regulatory requirements will be maintained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to manufacture and secure a sufficient supply of voclosporin to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our patent portfolio is sufficient and valid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that there is a potential commercial value for other indications for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that market data and reports reviewed by us are accurate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the availability of capital on terms that are favourable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that we will be able to attract and retain skilled staff; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption that general business and economic conditions will be maintained; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumptions relating to the feasibility of future clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to know that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual results could be materially different from what we expect if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. As a result, we cannot guarantee that any
forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">forward-looking statements do not take into account the effect that transactions or <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other special items announced or occurring after the statements are made may
have on our business. For example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the
forward-looking statements are made. The financial impact of such transactions and <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other special items can be complex and necessarily depends on the facts particular to each of them.
Accordingly, the expected impact cannot be meaningfully described in the abstract or presented in the same manner as known risks affecting our business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we disclaim any intention and assume no obligation to update any forward-looking statements even if new information becomes available, as a result of future events, new information, or for any other reason except as
required by law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The factors discussed below and other considerations discussed in the &#147;<I>Risk Factors</I>&#148; section of this
prospectus supplement, the accompanying prospectus, and the documents incorporated herein and therein, could cause our actual results to differ significantly from those contained in any forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause
our actual results, performance, or achievements to differ materially from any further results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause such differences include, among
other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional capital in the longer term to fund our development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures we may experience in the conduct of and reporting of results of our clinical trials for voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in the manufacture and securing a sufficient supply of voclosporin on a timely basis to successfully complete the development and commercialization of voclosporin; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures in obtaining appropriate reimbursement from payors for voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties we may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of our product. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. These forward-looking statements are made as of the date of this prospectus supplement and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_4"></A>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus supplement is deemed to be incorporated by reference into the accompanying prospectus solely for the purposes of the Offering. Other
documents are also incorporated, or are deemed to be incorporated by reference, into the accompanying prospectus and reference should be made to the accompanying prospectus for full particulars thereof. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information has been incorporated by reference in this prospectus supplement from documents filed with the securities commissions or similar authorities in
Canada.</B> Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of Aurinia Pharmaceuticals Inc. at 1200 Waterfront Centre, 200 Burrard Street, P.O. Box 48600, Vancouver,
British Columbia V7X 1T2, Canada, Telephone: (604) <FONT STYLE="white-space:nowrap">632-3473,</FONT> and are also available electronically at www.sedar.com. Documents filed with, or furnished to, the SEC are available through the SEC&#146;s
Electronic Data Gathering and Retrieval System (&#147;<B>EDGAR</B>&#148;) at www.sec.gov. Our filings through the System for Electronic Document Analysis and Retrieval (&#147;<B>SEDAR</B>&#148;) and through EDGAR are not incorporated by reference in
this prospectus supplement, except as specifically set out herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents, filed with the securities commissions or similar regulatory
authorities in British Columbia, Alberta and Ontario, and filed with, or furnished to, the SEC are specifically incorporated by reference into, and form an integral part of, this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">our annual information form dated March&nbsp;18, 2016 for the fiscal year ended December&nbsp;31, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">our audited consolidated balance sheets as at December&nbsp;31, 2015 and 2014, and the consolidated statements of operations, changes in shareholders&#146; equity and cash flows for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2015, including the notes thereto and the auditors&#146; report thereon; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">our unaudited comparative consolidated interim financial statements as at and for the three and nine month periods ended September&nbsp;30, 2016 and 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">our Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December&nbsp;31, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">our Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the three month period ended March 31, 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">our Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the three and six month periods ended June 30, 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">our Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine month periods ended September&nbsp;30, 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">our management information circular dated April&nbsp;27, 2016 in connection with the annual general meeting of our shareholders held on June&nbsp;8, 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated April&nbsp;13, 2016 announcing a change in our chief executive officer position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated June&nbsp;23, 2016 announcing the June 2016 Private Placement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated July&nbsp;29, 2016 announcing the entering into of a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp; Co.; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated August&nbsp;22, 2016 announcing positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from the Phase 2b <FONT STYLE="white-space:nowrap">AURA-LV</FONT> clinical trial;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated November&nbsp;9, 2016 announcing completion of the End of Phase 2 meeting with the U.S. Food&nbsp;&amp; Drug Administration (&#147;<B>FDA</B>&#148;) and our plans to initiate a LN Phase
3 clinical trial; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top">our material change report dated November 9, 2016 announcing the entry into of a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any document of the type referred to item 11.1 of Form <FONT STYLE="white-space:nowrap">44-101F1</FONT> <I>Short Form Prospectus </I>under National Instrument
<FONT STYLE="white-space:nowrap">44-101</FONT> <I>Short Form Prospectus Distributions </I>of the Canadian Securities Administrators filed by Aurinia Pharmaceuticals with any securities commissions or similar regulatory authorities in Canada after
the date of this prospectus supplement disclosing additional or updated information filed pursuant to the requirements of applicable securities legislation in Canada during the period that this prospectus supplement is effective shall be deemed to
be incorporated by reference in this prospectus supplement. These documents are available on SEDAR, which can be accessed at www.sedar.com. In addition, to the extent that any document or information incorporated by reference in this prospectus
supplement is included in a report that is filed or furnished to the SEC on Form <FONT STYLE="white-space:nowrap">40-F,</FONT> <FONT STYLE="white-space:nowrap">20-F</FONT> or <FONT STYLE="white-space:nowrap">6-K</FONT> (or any respective successor
form), such document or information shall also be deemed to be incorporated by reference as an exhibit to the registration statement. In addition, if and to the extent indicated therein, we may incorporate by reference in this prospectus supplement,
documents that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any statement contained in this prospectus
supplement or in any document incorporated or deemed to be incorporated by reference in this prospectus supplement for the purpose of the Offering shall be deemed to be modified or superseded for the purposes of this prospectus supplement to the
extent that a statement contained herein, or in any other subsequently filed document which also is incorporated or is deemed to be incorporated by reference herein, modifies or supersedes such statement. The modifying or superseding statement need
not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement will not be deemed an admission for any
purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not
misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed in its unmodified or superseded form to constitute a part of this prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon filing a new annual information form and the related annual financial statements and management&#146;s discussion and analysis with applicable securities
regulatory authorities during the currency of this prospectus supplement, the previous annual information form, the previous annual financial statements and management&#146;s discussion and analysis and all quarterly financial statements,
supplemental information, material change reports and information circulars filed prior to the commencement of our financial year in which the new annual information form is filed will be deemed no longer to be incorporated into this prospectus
supplement for purposes of future offers and sales of the securities under this prospectus supplement. Upon interim consolidated financial statements and the accompanying management&#146;s discussion and analysis being filed by us with the
applicable securities regulatory authorities during the duration of this prospectus supplement, all interim consolidated financial statements and the accompanying management&#146;s discussion and analysis filed prior to the new interim consolidated
financial statements shall be deemed no longer to be incorporated into this prospectus supplement for purposes of future offers and sales of securities under this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to our website in any documents that are incorporated by reference into this prospectus supplement do not incorporate by reference the information
on such website into this prospectus supplement or the accompanying prospectus, and we disclaim any such incorporation by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_4.1"></A>MARKETING MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any &#147;template version&#148; of any &#147;marketing materials&#148; (as such terms are defined under applicable Canadian securities laws) that are used by
the Underwriters in connection with the Offering are not part of this prospectus supplement to the extent that the contents of the template version of the marketing materials have been modified or superseded by a statement contained in this
prospectus supplement. Any template version of any marketing materials that has been, or will be, filed under the Company&#146;s profile on SEDAR at www.sedar.com before the termination of the distribution under the Offering (including any
amendments to, or an amended version of, any template version of any marketing materials) is deemed to be incorporated by reference into this prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_5"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the documents specified in this prospectus supplement under the section titled &#147;<I>Documents Incorporated by Reference</I>,&#148; the
following documents have been or will be (through post-effective amendment or incorporation by reference) filed with the SEC as part of the registration statement insofar as required by the SEC&#146;s Form
<FONT STYLE="white-space:nowrap">F-10:</FONT> (i) the form of Underwriting Agreement with H.C. Wainwright&nbsp;&amp; Co., LLC and Cormark Securities Inc. described in this prospectus supplement; (ii)&nbsp;powers of attorney from our directors and
officers; and (iii)&nbsp;the consents of auditors and legal counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_6"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of the Company is derived from selected information about the Company contained in the documents incorporated by reference and
does not contain all of the information about us and our business that should be considered before investing in the securities. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein
should be reviewed and considered by prospective purchasers in connection with their investment in the Offered Units. This prospectus supplement may add to, update or change information in the accompanying prospectus. You should carefully read this
entire prospectus supplement and the accompanying prospectus, including the risks and uncertainties discussed in the section titled &#147;Risk Factors,&#148; and the information incorporated by reference in this prospectus supplement, including our
consolidated financial statements, before making an investment decision. If you invest in our securities, you are assuming a high degree of risk. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name, Address and Incorporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage
pharmaceutical company with a registered office located at #201, 17904 &#150; 105 Avenue, Edmonton, Alberta T5S 2H5, Canada. Our head office is located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8, Canada and incorporates our
clinical, regulatory and business development functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are organized under the <I>Business Corporations Act </I>(Alberta). Our common shares are
currently listed and traded on the NASDAQ under the symbol &#147;AUPH&#148; and on the TSX under the symbol &#147;AUP.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intercorporate
Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the following wholly-owned subsidiaries: Aurinia Pharma Corp. (British Columbia incorporated), Aurinia Pharmaceuticals, Inc.
(Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business of the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on the development of our novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of LN. Voclosporin is a next
generation calcineurin inhibitor (&#147;<B>CNI</B>&#148;) which has clinical data in over 2,000 patients across multiple indications. It has been studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an
ophthalmic disease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since September&nbsp;20, 2013, we have rebranded, restructured and refocused around a strategy that focuses on the development of
voclosporin for the treatment of LN. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in LN when added to mycophenolate mofetil
(&#147;<B>MMF</B>&#148;), the current standard of care for LN. By inhibiting calcineurin, voclosporin blocks <FONT STYLE="white-space:nowrap">IL-2</FONT> expression and <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated immune responses.
Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule which has shown a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency, an altered metabolic profile, and potential for
flat dosing. Clinical doses of voclosporin studied to date range from 13 &#150; 70 mg BID. The mechanism of action of voclosporin, a CNI, has been validated with certain first generation CNIs for the prevention of rejection in patients undergoing
solid organ transplants and in several autoimmune indications, including dermatitis, keratoconjunctivitis sicca (Dry Eye Syndrome), psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that voclosporin possesses pharmacologic properties
with the potential to demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> differentiation with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
regulatory approval status for the treatment of LN outside of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on published data, we believe the key benefits of voclosporin in the treatment
of LN are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increased potency compared to cyclosporine A, allowing lower dosing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited inter and intra patient variability, allowing flat dosing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less cholesterolemia than cyclosporine A; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Limited incidence of glucose intolerance and diabetes at targeted doses compared to tacrolimus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
pursuing <FONT STYLE="white-space:nowrap">out-license</FONT> opportunities for our nanomicellar technology formulation patents for the delivery of voclosporin to the ocular surface for conditions such as dry eye to extract value from this
intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lupus Nephritis (LN) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN in an inflammation of the kidney caused by systemic lupus erythematosus (&#147;<B>SLE</B>&#148;) and represents a serious progression of SLE. SLE is a
chronic, complex and often disabling disorder that affects over 1,000,000 people in the United States (mostly women). SLE is highly heterogeneous, affecting a wide range of organs and tissue systems. It is estimated that as many as 60% of all SLE
patients have a form of LN that requires treatment. Unlike SLE, LN has straightforward disease measures where an early response correlates with long-term outcomes, measured by proteinuria. In patients with LN, renal damage results in proteinuria
and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (&#147;<B>eGFR</B>&#148;), and increased serum creatinine levels. Rapid control and reduction of proteinuria in lupus patients measured at
6&nbsp;months shows a reduction in the need for dialysis at 10 years. LN can be debilitating and costly and if poorly controlled, can lead to permanent and irreversible tissue damage within the kidney. Recent literature suggests severe LN progresses
to <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease (&#147;<B>ESRD</B>&#148;), within 15 years of diagnosis in <FONT STYLE="white-space:nowrap">10%-30%</FONT> of patients, thus making LN a serious and potentially life-threatening
condition. Mean annual medical cost for patients (both direct and indirect) with LN who progress to ESRD have been estimated to exceed US$60,000 per patient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>LN Standard of Care </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While at Aspreva Pharmaceuticals,
members of Aurinia&#146;s management and clinical teams executed the Aspreva Lupus Management Study (&#147;<B>ALMS</B>&#148;) which established CellCept <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or mycophenolate mofetil
(&#147;<B>MMF&#148;</B>) as the current standard of care for treating LN. The ALMS study was published in 2009 in both the Journal of the American Society of Nephrology and The New England Journal of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The American College of Rheumatology recommends that intravenous cyclophosphamide or MMF/CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> be
used as first-line immunosuppressive therapy for LN. Despite their use, the ALMS study showed that the majority of patients failed to achieve Complete Remission (&#147;<B>CR&#148;</B>), or renal response at 24 weeks for both of these therapeutics.
Based upon the results of the ALMS study, we believe that a better solution is needed to improve renal response rates for LN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the data outlined
from the AURA Phase 2b clinical trial, we believe that voclosporin has the potential to address the critical need for LN by controlling active disease rapidly, lowering the steroid burden, impacting extra-renal disease and doing so with a convenient
treatment regimen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Market Potential and Commercial Considerations </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recently conducted our own market research which surveyed approximately 900 rheumatologists and nephrologists across the United States, Europe and Japan to
outline the potential market size, pricing considerations and treatment paradigms in the United States, Europe and Japan. Using the U.S. MarketScan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> data set (with approximately 170,000,000
insured lives in the United States) there were 445,346 SLE patients (between January 2006 and December 2015) based on specific SLE diagnosis codes. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that up to 60% of
people with SLE are diagnosed with LN. Using claims database research and additional physician research, we believe the diagnosed range of LN&nbsp;patients to be approximately 125,000 to 200,000 in the United States. The surveys also indicated that
one in five LN&nbsp;patients are thought to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undiagnosed due to referring physicians being inefficient and inaccurate in diagnosing the condition. Mean frequency of LN&nbsp;flares in otherwise controlled patients as reported by the surveyed
physicians was approximately 14 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LN has a destructive cycle which is depicted below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g83f14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the survey results, it is estimated that 58% of LN patients are controlled (maintenance phase); 25% poorly
controlled and 17% have active disease (induction phase). Physicians indicated that if available, they would use voclosporin in a portion of patients in both the maintenance and induction phases. Only 18% of physicians were very satisfied or
extremely satisfied with currently available and unapproved therapies&#146; ability to achieve a CR within 6 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the pricing research we
have conducted, we believe that the price range for voclosporin can be between US$50,000 and US$100,000 per patient per year in the United States. We believe that the U.S. market will provide the most opportunity and while the European population is
likely larger than the United States, the pricing and market opportunity is more limited. We believe that the initial estimates of voclosporin peak sales may yield a global opportunity in excess of $1&nbsp;billion (with greater than $1&nbsp;billion
in the United States; over $300&nbsp;million in the European Union; and over $80&nbsp;million Japan). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing Collaboration Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
entered into a long-term agreement with Lonza Ltd. (&#147;<B>Lonza</B>&#148;) for the manufacture of voclosporin active pharmaceutical ingredient (&#147;<B>API</B>&#148;). This agreement follows a successful multi-year clinical manufacturing
relationship where the Company and Lonza have been refining the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza has agreed to produce cGMP-grade voclosporin drug
substance for use in our Phase 3 LN clinical trial program and for future commercial use. The agreement also provides an option to have Lonza exclusively supply API for up to 20&nbsp;years. We submitted a binding purchase order in the amount of CHF
2.05&nbsp;million to Lonza for the manufacture of API for future use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of New Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2016, we announced the appointment of Lorin Jeffry &#147;Jeff&#148; Randall to our board of directors and Chairman of the Audit Committee.
Mr.&nbsp;Randall currently serves on the boards of directors of Athersys, Inc., where he serves as Chairman of the Audit and Compensation Committees, and Acorda Therapeutics, Inc., where he serves on the Audit, Compliance and Nominations and
Governance Committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Randall has over 30 years of experience serving in financial and operating roles spanning biotechnology, pharmaceuticals
and manufacturing. He has led a number of companies through multi-million dollar financings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and mergers and acquisitions. In addition to his current board positions, Mr.&nbsp;Randall served on the board of directors of Nanosphere, Inc. from 2008 to 2016, most recently as Chairman of the
Board. From 2004 to 2006, Mr.&nbsp;Randall, a financial consultant, was Senior Vice President and Chief Financial Officer of Eximias Pharmaceutical Corporation, a development-stage drug development company. Mr.&nbsp;Randall holds a B.S. in
Mathematics and Accounting from Pennsylvania State University and an M.B.A. from Northeastern University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA End of Phase 2 Meeting and Plans for
Single LN Phase 3 Clinical Trial </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2016, we announced the FDA&#146;s preference for a single LN Phase 3 clinical trial for
voclosporin in the treatment of LN, to be entitled &#147;<B>AURORA</B>&#148;. Pursuant to our recent End of Phase 2 meeting with the FDA Division of Pulmonary, Allergy and Rheumatology Products, we believe this LN Phase 3 clinical trial, the design
of which is consistent with the ongoing AURA clinical trial, will, if successful, support a New Drug Application (&#147;<B>NDA</B>&#148;) submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
AURORA clinical trial will be a global <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind, placebo controlled study of approximately 320 patients. We are finalizing the study protocol and regulatory submissions and in parallel are working
on site selection with trial initiation anticipated in Q2 2017. Patients will be randomized 1:1 to either 23.7 mg of voclosporin BID and MMF or MMF and placebo, with both arms receiving a stringent oral corticosteroid taper. The study population
will be comprised of patients with biopsy-proven active LN who will be evaluated on the primary efficacy endpoint of renal response at 24 weeks, a composite which includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Urinary/protein creatinine ratio (&#147;<B>UPCR</B>&#148;) of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.7 mg/mg </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Normal, stable renal function (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73 m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> or no confirmed decrease from baseline in eGFR of &gt;20%)
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10 mg prednisone from week <FONT STYLE="white-space:nowrap">16-24)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The readout of the primary endpoint of renal response at 24 weeks
will occur after database lock at 52 weeks. Patients completing the 52 week study will then have the option to roll-over into a 104 week blinded continuation study. These data will allow us to assess long-term outcomes in LN patients that will be
valuable in a post-marketing setting in addition to future interactions with various regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While voclosporin has received fast track
designation, the FDA has informed us that voclosporin is not eligible for breakthrough therapy designation at this time. We will continue to benefit from fast track designation, which includes more frequent communications with the FDA, potential for
priority review of the NDA and an option to submit a rolling NDA submission, which may expedite the review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial forecast is that the
AURORA clinical trial will cost in the range of $70&nbsp;million to $80&nbsp;million. However, we are still in the process of obtaining quotes from suppliers and CROs and determining the optimum number of countries and sites in which to conduct the
AURORA clinical trial and as a result this forecast may change. In addition, the initial estimate of the cost of the continuation study is in the range of $20&nbsp;million to $25&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, we announced that we had received the final End of Phase 2 meeting minutes from the FDA Division of Pulmonary, Allergy and
Rheumatology Products and that the minutes are consistent with the preliminary responses that were issued to us prior to the meeting which took place on October&nbsp;25, 2016. We are currently having discussions with the European Medicines Agency
(&#147;<B>EMA</B>&#148;) and the Japanese Pharmaceuticals and Medical Devices Agency (&#147;<B>PMDA</B>&#148;) regarding regulatory requirements for these jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AURION Clinical Trial Update </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURION trial is a <FONT STYLE="white-space:nowrap">single-arm,</FONT> twin center, exploratory study assessing the predictive value of an early reduction
in proteinuria in subjects receiving 23.7mg of voclosporin BID with the current standard of care in patients with active LN. The primary objective of the AURION clinical trial is to examine biomarkers of disease activity at eight weeks and their
ability to predict response at 24 and 48 weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study Design: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g11h44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary analysis is the number of patients achieving each of the following biomarkers and the number of these patients
who go on to achieve week 24 or week 48 remission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biomarkers: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% reduction in urinary protein creatinine ratio (UPCR) at 8 weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C3 complement normalization at 8 weeks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">C4 complement normalization at 8 weeks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Anti-dsDNA (double-stranded DNA) normalization at 8 weeks. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The secondary analysis includes the 24 and 48 week
outcomes, markers of SLE and pharmacokinetics and pharmacodynamics (PK/PD) of voclosporin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2016, we announced 24 week data in all 10
patients from the AURION clinical trial, an open-label exploratory study to assess the short-term predictors of response using voclosporin (23.7 mg BID) in combination with MMF and oral corticosteroids in patients with active LN. The data was
presented by Robert Huizinga, Vice President of Clinical Affairs at Aurinia Pharmaceuticals at the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual European Lupus Meeting in Venice, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the trial is to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this trial, 70% (7/10) patients achieved complete remission (&#147;<B>CR</B>&#148;) at 24 weeks as measured by a UPCR of
<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>&nbsp;0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of &lt;5 mg/day. Of the 10 patients that achieved a reduction of UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 25% at 8
weeks, 80% were responders (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% reduction in UPCR over baseline) at 24 weeks and 70% were in CR at 24 weeks, proteinuria levels decreased by a mean of 61% from baseline through the first 24 weeks of the
study. In addition, inflammatory markers such as C3, C4 and anti-dsDNA all continued to normalize to 24 weeks. Voclosporin was well-tolerated with no unexpected safety signals observed. Renal function, as measured by eGFR, also remained stable over
the 24 weeks. We believe that the results of the AURION study supports the use of the 23.7 mg twice daily dose in further studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the results are below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:30.40pt; font-size:8pt; font-family:Times New Roman"><B>Patient&nbsp;#</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attained
</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>25%<BR>reduction in</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>UPCR at 8 weeks</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attained</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Partial Remission*</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>at 8
weeks</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attained</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Partial Remission*</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>at 24
weeks</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attained</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CR</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>at 8 weeks</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Attained</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CR</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>at 24
weeks</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Y</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTALS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>100% (10/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70%&nbsp;(7/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>80% (8/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>50% (5/10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>70% (7/10)</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"><I>Retrospectively defined by </I><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><I></I><I>50% reduction in UPCR</I> </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">AURA-LV</FONT> (AURA) Phase 2b Clinical Trial &#150; Positive <FONT STYLE="white-space:nowrap">Top-Line</FONT> Results
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2016, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from the Phase 2b <FONT
STYLE="white-space:nowrap">AURA-LV</FONT> (AURA) clinical trial in patients with active LN. The trial achieved its primary endpoint, demonstrating statistically significantly greater CR at 24 weeks (and confirmed at 26 weeks) in patients treated
with 23.7 mg of voclosporin twice daily (p=0.045). This was the first global study of LN to meet its primary end point. Both treatment arms, 23.7 mg and 39.5 mg twice daily also showed a statistically significant improvement in the rate of achieving
partial remission (&#147;<B>PR</B>&#148;) at 24 weeks (p=0.007; p=0.024). Each arm of the study included the current standard of care of MMF as background therapy, and a forced steroid taper. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">AURA-LV</FONT> Trial Design </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURA&#150;LV clinical trial or &#147;Aurinia Urinary protein Reduction Active &#150; Lupus with Voclosporin&#148; compared the efficacy of voclosporin
added to current standard of care of MMF, also known as CellCept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, against standard of care with placebo in achieving CR in patients with active LN. It enrolled 265 patients at centers in 20
countries worldwide. On entry to the trial, patients were required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features indicative of active lupus nephritis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients were randomized to one of two dosage groups of voclosporin (23.7 mg BID and 39.5 mg BID) or placebo, with all patients also receiving MMF and oral
corticosteroids as background therapy. All patients had an initial IV dose of steroids <FONT STYLE="white-space:nowrap">(500-1000</FONT> mg) and then were started on <FONT STYLE="white-space:nowrap">20-25</FONT> mg/daily, which was tapered down to a
low dose of 5 mg daily by week 8 and 2.5 mg daily by week 16. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g79i39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint was a measure of the number of patients who achieved CR at 24 weeks which had to be confirmed at 26
weeks. CR required the following four elements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protein/creatinine ratio of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>0.5 mg/mg </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">normal stable renal function (eGFR <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>60 mL/min/1.73m2 or no confirmed decrease from baseline in eGFR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>20%) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Presence of sustained, low dose steroids (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>10mg/day of prednisone from week 16 - 24) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No administration of rescue medications throughout the treatment period </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Summary of Results</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The groups were generally well-balanced for age, gender and race, however, when considered together, the proteinuria and GFR data suggest that disease severity
was greater for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint of CR was met for the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin group in the ITT analysis (p=0.045). 32.6% of patients on low dose achieved CR, compared to 27.3% on high dose and
19.3% in the control arm. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The odds ratio indicates that patients were twice as likely to achieve CR at 24 weeks compared to the control arm (OR=2.03). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint was <FONT STYLE="white-space:nowrap">re-analyzed</FONT> using the <FONT STYLE="white-space:nowrap">24-hour</FONT> urine data in place of First Morning Void collections, confirming the finding that
patients were twice as likely to achieve CR at 24 weeks compared to the control arm (p=0.047; OR=2.12). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Both voclosporin groups had a significantly faster time to CR (UPCR <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 0.5 mg/mg) than the control arm. Results of time to CR for
<FONT STYLE="white-space:nowrap">co-variate</FONT> analyses were broadly consistent with overall efficacy rates in those <FONT STYLE="white-space:nowrap">sub-groups.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The secondary endpoint of PR (50% reduction in UPCR over baseline with no administration of rescue medication throughout the treatment period) was met for both voclosporin groups in the ITT analysis with 69.7% of
patients on low dose achieving PR (p=0.007) and 65.9% in the high dose group (p=0.024). 49.4% of patients in the control arm achieved PR. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Time to PR was similar (4 weeks) in the two voclosporin groups and was shorter than what was observed in the control group (6.6 weeks). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of adverse events (&#147;<B>AEs</B>&#148;) was similar across all groups. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall rate of serious adverse events (&#147;<B>SAEs</B>&#148;) was higher in both voclosporin groups but the nature of SAEs is consistent with highly active LN. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall pattern of AEs and SAEs was consistent with that observed in other LN studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Overall renal function remained stable throughout the study period. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There were 13 deaths across the trial: two in the high-dose voclosporin arm; 10 in the <FONT STYLE="white-space:nowrap">low-dose</FONT> voclosporin arm; and one in the control arm, with the majority of overall deaths
(11/13) occurring in Asia. All deaths were assessed by the Investigator as being unrelated to study treatment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016,
we announced that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of CR at 24 weeks, both doses of voclosporin when added to the current standard of care of MMF and a forced oral corticosteroid taper have met all <FONT
STYLE="white-space:nowrap">24-week</FONT> <FONT STYLE="white-space:nowrap">pre-specified</FONT> secondary endpoints vs the control group. These <FONT STYLE="white-space:nowrap">pre-specified</FONT> endpoints include: PR, which is measured by a <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the <FONT
STYLE="white-space:nowrap">24-week</FONT> treatment period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:116.35pt; font-size:8pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-specified</FONT> Secondary
Endpoint</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Control</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low&nbsp;Dose&nbsp;VCS</B><br><B>(23.7mg BID)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High&nbsp;Dose&nbsp;VCS</B><br><B>(39.5mg BID)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"><B>Time to Complete Remission</B> <B>(&#147;TTCR&#148;)</B> [median]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">Not&nbsp;achieved</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">19.7&nbsp;weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">23.4&nbsp;weeks</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p&lt;.001</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p=.001</I></B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Partial Remission </B>(as measured by UPCR reduction of <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% from baseline)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">49%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66%</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I></I></B><B></B><B><I>p=.007</I></B><B></B><B><I></I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p=.024</I></B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Time to Partial Remission</B> <B>(&#147;TTPR&#148;)</B> [median]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">6.6 weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.1 weeks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.4 weeks</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p=.002</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I></I></B><B></B><B><I>p=.003</I></B><B></B><B><I></I></B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SLEDAI Reduction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">-4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7.1</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p=.003</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I></I></B><B></B><B><I>p=.003</I></B><B></B><B><I></I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reduction in UPCR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">-2.216&nbsp;mg/mg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3.769&nbsp;mg/mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2.792&nbsp;mg/mg</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p&lt;.001</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><I>p=.006</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>All <FONT STYLE="white-space:nowrap">p-values</FONT> are vs control </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2016, we presented detailed results on the <FONT STYLE="white-space:nowrap">AURA-LV</FONT> Phase 2b clinical trial. These included a
number of <FONT STYLE="white-space:nowrap">pre-specified</FONT> subset and <FONT STYLE="white-space:nowrap">co-variate</FONT> analyses and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses on the data, which show rapid proteinuria reduction
and early remission. Based on recent literature suggesting that using a UPCR of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>.7mg/mg has better predictive power regarding long-term renal outcomes in LN patients, we performed a post hoc analysis
applying this measure. In doing so, we saw both a greater treatment difference between the 23.7mg BID voclosporin arm and the control arm, and better statistical power, which improves from a <FONT STYLE="white-space:nowrap">p-value</FONT> of .045 to
less than .01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these data we believe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voclosporin has shown statistically significant efficacy in multiple dimensions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">pre-specified</FONT> and <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses have provided valuable insight; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the LN Phase 3 clinical trial will be <FONT STYLE="white-space:nowrap">de-risked</FONT> based upon the <FONT STYLE="white-space:nowrap">AURA-LV</FONT> results; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">biomarker data suggest significant effect on the underlying immunologic process of the disease. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also
released detailed safety data for the trial including an <FONT STYLE="white-space:nowrap">in-depth</FONT> mortality assessment. The safety and tolerability of voclosporin has been well-documented in numerous studies. In previous studies, over 2,000
patients have been treated with voclosporin across multiple indications with no unexpected SAEs. Clinical doses of voclosporin studies to date range from <FONT STYLE="white-space:nowrap">13-70</FONT> mg BID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In comparing four global LN trials: AURA, Aspreva Lupus Management Study (ALMS), Ocrelizumab and Abatacept, it is evident that the AURA clinical trial
enrolled the most severe patients, as measured by proteinuria at baseline. The difference in UPCR and the eGFR in the low dose voclosporin arm at baseline indicates patients had more severe disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No new safety signals were observed with the use of voclosporin in LN patients and voclosporin was well-tolerated. The overall safety profile of voclosporin
is consistent with other immunomodulators. The summary of AEs by system organ class (SOC) across arms in the study is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">System Organ Class (SOC)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">N=88</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Voclosporin&nbsp;23.7mg&nbsp;BID</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">N=89</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Voclosporin&nbsp;39.5mg&nbsp;BID</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">N=88</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any AE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">74&nbsp;(84.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">81 (91.0)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">84 (95.5)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thirteen deaths have been reported in the AURA clinical trial&#151;a pattern that is consistent with other global active LN
studies.<I> </I>Eleven of thirteen deaths occurred at sites with compromised access to standard of care; and patients who died in the trial had a statistically different clinical baseline picture, indicating a more severe form of LN, potential
comorbid conditions and poor nutrition. The last death in the study occurred in February 2016. Both the FDA and Data Safety Monitoring Board have reviewed in detail each death that occurred in the trial. The AURA clinical trial remains ongoing to
its <FONT STYLE="white-space:nowrap">48-week</FONT> secondary endpoint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2016, at the American College of Rheumatology annual
meeting, we presented speed of remission data from the AURA trial in a late-breaking abstract titled &#147;Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study. The data presented are a
<FONT STYLE="white-space:nowrap">post-hoc</FONT> responder analysis (median time to CR for those who achieve CR), demonstrating 7.3 weeks to CR for voclosporin 23.7mg BID vs the control arm of 12 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;21, 2016, at the American Society of Nephrology Kidney Week 2016, we presented renal function data for the AURA trial in a late breaking
session titled &#147;High Impact Clinical Trials&#148;. These data showed that in the voclosporin treatment arms, the renal function as measured by eGFR was stable and not significantly different from the control arm during the course of the trial.
Mean blood pressure was slightly reduced and was similar between all treatment groups. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Facility &#150; July&nbsp;22, 2016 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2016 we announced that we had entered
into a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. pursuant to which the Company was authorized to sell, from time to time, through
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offerings (the &#147;<B>July</B> <B>ATM</B>&#148;) with Cantor Fitzgerald&nbsp;&amp; Co. acting as sales agent, such common shares as would have an
aggregate offer price of up to US$10,000,000. We also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange
Commission, which supplemented our short form base shelf prospectus dated October&nbsp;16, 2015, and our shelf registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> dated October&nbsp;16, 2015, declared effective on
November&nbsp;5, 2015. Sales in the July ATM were only conducted in the United States through NASDAQ at market prices. No sales were conducted in Canada or through the Toronto Stock Exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;3, 2016, sales pursuant to the July ATM were concluded. We issued 3,306,085 common shares,
receiving gross proceeds in the aggregate of US$8,000,000 ($6,142,000 in the third quarter of 2016 and $1,858,000 subsequent to the quarter end), (being the maximum value permissible in accordance with Canadian securities laws). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Facility &#150; November&nbsp;9, 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016 we announced that we had entered into a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. pursuant to
which the Company was authorized to sell, from time to time, through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offerings (the &#147;<B>November</B> <B>ATM</B>&#148;) with Cantor
Fitzgerald&nbsp;&amp; Co. acting as sales agent, such common shares as would have an aggregate offer price of up to US$8,000,000. We also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British
Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplemented our short form base shelf prospectus dated October&nbsp;16, 2015, and our shelf registration statement on Form <FONT
STYLE="white-space:nowrap">F-10</FONT> dated October&nbsp;16, 2015, declared effective on November&nbsp;5, 2015. Sales in the November ATM will only conducted in the United States through NASDAQ at market prices. No sales will be conducted in Canada
or through the Toronto Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 21, 2016, we had issued 138,986 common shares and received gross proceeds of US$396,354. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2016, we
completed a private placement (the &#147;<B>June 2016 Private Placement</B>&#148;) of 3,000,000 units (&#147;<B>Units</B>&#148;) at US$2.36 per Unit for aggregate gross proceeds of US$7,080,000. Each Unit consisted of one common share and a 0.35 of
one common share purchase warrant exercisable for a period of two years from the date of issuance at an exercise price of US$2.77. Further information regarding the terms of the June 2016 Private Placement and the Units issued thereunder can be
found in our material change report dated June&nbsp;23, 2016, which is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and other proprietary rights are essential to our business. Our policy has been to file patent applications to protect technology, inventions, and
improvements to our inventions that we consider important to the development of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2016, we owned 11 granted United
States patents and two United States patent applications related to cyclosporin analogs, including granted United States patents covering voclosporin composition of matter, methods of use, formulations and synthesis, which expire between 2018 and
2024, and 151 corresponding granted patents and four corresponding patent applications in other jurisdictions, excluding Canada, South Africa and Israel, which expire between 2018 and 2022. The corresponding Canadian, South African and Israeli
patents are owned by Paladin Labs Inc.&nbsp;We anticipate that upon regulatory approval, patent protection for voclosporin will be extended in the United States and certain other major markets, including Europe and Japan, until at least October 2027
under the Hatch-Waxman Act and comparable laws in other countries. In addition to patent rights, we also expect to receive &#147;new chemical entity&#148; exclusivity for voclosporin in certain countries, which provides from five years in the United
States to up to ten years in Europe of data exclusivity beyond the date of regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have licensed the development and distribution rights
to voclosporin for China, Hong Kong and Taiwan to 3Sbio Inc. This license is royalty bearing and we will also supply finished product to 3Sbio Inc. on a cost plus basis. We do not expect to receive any royalty revenue pursuant to this license in the
foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2016, we also owned two granted United States patents related to ophthalmic formulations
of calcineurin inhibitors or mTOR inhibitors, including voclosporin, and one granted United States patent related to ophthalmic formulations of dexamethasone, which expire between 2028 and 2031. We also own 14 corresponding granted patents and four
corresponding patent applications in other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Near-term Events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue our ongoing dialogue with the EMA and the PMDA to define the regulatory and clinical requirements to attain registration approvals in
these jurisdictions over the next several months. Additionally, we expect to release the AURA 48 week results sometime during the first quarter of 2017. These results will be considered secondary end points and will include similar measures as
compared to the already released 24 week end points. We also expect to enroll the first patients into the Phase 3 AURORA study sometime during the second quarter of 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_7"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offered Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11,111,111 Units (or 12,777,777 Units if the Over-Allotment Option is exercised in full). Each Offered Unit consists of one Unit Share and one-half of one warrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terms of Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Each Warrant will entitle the holder to purchase one Warrant Share at a price of US$3.00 at any time prior to 4:30&nbsp;p.m. (New York time) on the date that is five years after the closing of the Offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares to be Outstanding After This Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">49,905,600 common shares (or 51,572,266 common shares if the Over-Allotment Option is exercised in full).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of Proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds from the Offering are expected to be approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the Over-Allotment Option is exercised in
full) after deducting the Underwriters&#146; Fee of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the Over-Allotment Option is exercised in full) and our expenses of the Offering, which are estimated to be US$450,000 and excluding any proceeds received
from the exercise of Warrants.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We expect to use the net proceeds of the for research
and development activities including the LN Phase&nbsp;3 clinical trial activities, and for working capital purposes. See the section titled &#147;<I>Use of Proceeds</I>&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-30</FONT> of this
prospectus supplement.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk Factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investing in our common shares involves a high degree of risk. Please read the information contained in and incorporated by reference under the section titled &#147;<I>Risk Factors</I>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-21</FONT> of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;AUPH&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TSX Symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;AUP&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of common shares that will be outstanding immediately after this Offering as shown above is based on 38,794,489
common shares outstanding as of September&nbsp;30, 2016. The number of shares outstanding as of September&nbsp;30, 2016 as used throughout this prospectus supplement, unless otherwise indicated, excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,098,137 common shares issuable upon exercise of outstanding options outstanding as of September&nbsp;30, 2016, with a weighted average exercise price of US$2.84; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,927,223 common shares issuable upon exercise of warrants outstanding as of September&nbsp;30, 2016, with a weighted average exercise price of US$3.07; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">951,174 common shares reserved for future issuance under our stock option plans as of September&nbsp;30, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,235,971 common shares issued subsequent to September 30, 2016. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information
in this prospectus supplement assumes no exercise by the Underwriters of the Over-Allotment Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_8"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities is speculative and involves a high degree of risk. In addition to the other information included or incorporated by
reference in this prospectus supplement and the accompanying prospectus, you should carefully consider the risks and uncertainties described under the heading &#147;Risk Factors&#148; in the accompanying prospectus, together with all of the other
information contained in this prospectus supplement and the accompanying prospectus, before purchasing our securities. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of
operations and future prospects. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. These risks are not the only risks we face; risks and uncertainties not currently known to
us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition and results of operations. Investors should also refer to the other information set forth or incorporated by reference in this
prospectus supplement and the accompanying prospectus, including our consolidated financial statements and related notes. This prospectus supplement also contains forward-looking statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in the forward-looking statements as a result of a number of factors. See the section titled &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An investment in
the Offered Units may result in the loss of an investor&#146;s entire investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in the Offered Units is speculative and may result
in the loss of an investor&#146;s entire investment. Only potential investors who are experienced in high risk investments and who can afford to lose their entire investment should consider an investment in Aurinia Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No market for the Warrants currently exists. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has applied to list the Unit Shares and the Warrant Shares on the TSX. Listing will be subject to the Company fulfilling all of the requirements of the TSX. The Company has also applied to list the Unit Shares and the Warrant Shares on the
NASDAQ. Listing will be subject to the Company fulfilling all of the requirements of the NASDAQ. <B>There will be no market in either Canada or United States through which the Warrants may be sold. This may affect the pricing of the Warrants in the
secondary market, the transparency and availability of trading prices, the liquidity of such securities, and the extent of issuer regulation.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the price per share of the Offered Units is substantially higher than the net tangible book value per share of our common shares, you will suffer
substantial dilution in the net tangible book value of the common shares you purchase in this Offering. Based on the public offering of 11,111,111 units at the price of US$2.25 per Offered Unit, after deducting Underwriters&#146; Fees and estimated
Offering expenses payable by us, and based on a net tangible book value of our common shares as of September 30, 2016, as adjusted to give effect to this Offering, if you purchase units in this Offering, you will suffer immediate dilution of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share in the net tangible book value of common shares. The exercise of outstanding stock options and warrants (including Warrants held by other purchasers) could result
in further dilution of your investment. See the section titled &#147;<I>Dilution</I>&#148; below for a more detailed illustration of the dilution you would incur if you participate in this Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Warrants are not listed on a national securities exchange or other nationally recognized trading system, the Underwriters are unable to satisfy any
over-allotments without exercising the Underwriters&#146; Over-Allotment Option. Therefore, if the Underwriters exercise the Over-Allotment Option as to the Warrants in full, but not with respect to the Additional Shares, then the Warrant coverage
will be higher than the initial 50% stated and you will be subject to further dilution. See the section titled &#147;<I>Dilution</I>&#148; in this prospectus supplement for a more detailed discussion of the dilution you will incur if you purchase
Offered Units in this Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent offerings will result in dilution to our shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell additional equity securities in subsequent offerings (including through the sale of securities convertible into equity securities) and may issue
additional equity securities to finance operations, acquisitions or other projects. We cannot predict the size of future issuances of equity securities or the size and terms of future issuances of debt instruments or other securities convertible
into equity securities or the effect, if any, that future issuances and sales of our securities will have on the market price of our common shares. Any transaction involving the issuance of previously authorized but unissued common shares, or
securities convertible into common shares, would result in dilution, possibly substantial, to securityholders. Exercises of presently outstanding share options may also result in dilution to securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to authorize certain offers and sales of additional securities without the vote of, or prior notice to, our
shareholders. Based on the need for additional capital to fund expected expenditures and growth, it is likely that we will issue additional securities to provide such capital. Such additional issuances may involve the issuance of a significant
number of our common shares at prices less than the current market price for the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, holders of stock options and warrants
exercisable for our common shares (including other purchasers of Warrants) may elect to exercise their options or warrants into common shares. Such exercises could further dilute your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common shares is subject to volatility, and your investment may suffer a decline in value. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market prices for the securities of biotechnology companies, including ours, have historically been volatile. The market has from time to time experienced
significant price and volume fluctuations that are unrelated to the operating performance of any particular company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common
shares could continue to be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including the results and adequacy of our preclinical studies and clinical trials, as well as those of our
collaborators, or our competitors; other evidence of the safety or effectiveness of our products or those of our competitors; announcements of technological innovations or new products by us or our competitors; governmental regulatory actions;
developments with collaborators; developments (including litigation) concerning our patent or other proprietary rights of competitors; concern as to the safety of our products;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in operating results; changes estimates of our performance by securities analysts; market conditions for biotechnology stocks in general;
and other factors not within our control could have a significant adverse impact on the market price of our common shares, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#146;s
securities, securities class action litigation has often been instituted. A class action suit against us could result in substantial costs, potential liabilities and the diversion of management&#146;s attention and resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that an active trading market for our common shares will be maintained on the TSX and /or NASDAQ. Investors may not be able to sell
their common shares quickly or at the latest market price if the trading in our common shares is not active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to issue common shares in the
future. Future issuances of common shares, or the perception that such issuances are likely to occur, could affect the prevailing trading prices of the common shares. In addition, the existence of warrants may encourage short selling by market
participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of common shares could cause a decline in the market price of our common shares. Two of our major shareholders (venBio Global
Strategic Fund, L.P. and ILJIN SNT Co., Ltd. and its affiliates) own an aggregate of approximately 29.54% of our outstanding common shares as at December 21, 2016. Any sales of common shares by these shareholders or other existing shareholders or
holders of options may have an adverse effect on our ability to raise capital and may adversely affect the market price of our common shares. Entities affiliated with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ILJIN SNT Co., Ltd. have submitted an indication of interest to purchase up to US$3.0 million of the Offered Units in this Offering. However, because indications of interest are not binding
agreements or commitments to purchase, the Underwriters may determine to sell more, fewer or no Offered Units in this Offering to these entities, or these entities may determine to purchase more, fewer or no Offered Units in this Offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance of a sufficient liquid trading market for our common shares in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders may be unable to sell significant quantities of common shares into the public trading markets without a significant reduction in the price of
their common shares, or at all. There can be no assurance that there will be sufficient liquidity of our common shares on the trading market, and that we will continue to meet the listing requirements of the TSX or the NASDAQ or achieve listing on
any other public listing exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of equity securities by us or sales by our existing shareholders may cause the price of the
common shares to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of the common shares could decline as a result of issuances of securities or sales by our existing
shareholders in the market, or the perception that these sales could occur. Sales of common shares by shareholders might also make it more difficult for us to sell common shares at a time and price that we deem appropriate. With an additional sale
or issuance of common shares, investors will suffer dilution of their voting power and may experience dilution in earnings per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have
broad discretion in the use of the net proceeds of the Offering and may not use them to effectively manage our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will have broad
discretion over the use of the net proceeds from this Offering. Because of the number and variability of factors that will determine our use of such proceeds, our ultimate use might vary substantially from our planned use. Investors may not agree
with how we allocate or spend the proceeds from this Offering. We may pursue acquisitions, collaborations or clinical trials that do not result in an increase in the market value of the common shares, and may increase our losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common shares. We intend, for the foreseeable future, to retain our future earnings, if any, to finance our
commercial activities and further research and the expansion of our business. As a result, the return on an investment in common shares will likely depend upon any future appreciation in value, if any, and on a shareholder&#146;s ability to sell
common shares. The payment of future dividends, if any, will be reviewed periodically by our board of directors and will depend upon, among other things, conditions then existing including earnings, financial conditions, cash on hand, financial
requirements to fund our commercial activities, development and growth, and other factors that our board of directors may consider appropriate in the circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a passive foreign investment company, which may result in adverse U.S. federal income tax consequences for U.S. Holders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the average quarterly value of our assets are held for
the production of, or produce, passive income, we would be characterized as a passive foreign investment company (&#147;<B>PFIC</B>&#148;) for U.S. federal income tax purposes. Our status as a PFIC may also depend on how quickly we use the cash
proceeds from this offering in our business. Based on the nature of our income and the value and composition of our assets, we do not believe we were a PFIC during 2015. While we also do not believe we will be a PFIC for the current taxable year,
because PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, there can be no assurance that we will not be a PFIC for the current or future taxable years. If we are characterized as a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PFIC, our shareholders who are U.S. Holders (as defined in &#147;<I>Material U.S. Federal Income Taxation Considerations</I>&#148;) may suffer adverse tax consequences, including the treatment of
gains realized on the sale of Unit Shares, Warrants and Warrant Shares as ordinary income, rather than as capital gain, the loss of the preferential rate applicable to dividends received on Unit Shares, Warrants and Warrant Shares by individuals who
are U.S. Holders, and the addition of interest charges to the tax on such gains and certain distributions. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a &#147;qualified electing
fund&#148; election, or, to a lesser extent, a &#147;mark to market&#148; election. However, we do not intend to provide the information necessary for U.S. Holders to make qualified electing fund elections if we are classified as a PFIC. In
addition, special PFIC rules may apply to Warrants and Warrant Shares acquired upon exercise of such Warrants, and certain of the elections described above may not be available with respect to Warrants and Warrant Shares. This paragraph is qualified
in its entirety by the discussion in the section titled &#147;<I>Material U.S. Federal Income Taxation Considerations</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may be unable
to enforce actions against us, certain of our directors and officers, or the experts named in this prospectus supplement under U.S. federal securities laws. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a corporation organized under the laws of Alberta, Canada. Most of our directors and officers, as well as the experts named in this prospectus
supplement, reside principally in Canada or outside of the United States. Because all or a substantial portion of our assets and the assets of these persons are located outside of the United&nbsp;States, it may not be possible for investors to
effect service of process within the United States upon us or those persons. Furthermore, it may not be possible for investors to enforce against us or those persons not in the United States, judgments obtained in U.S. courts based upon the civil
liability provisions of the U.S. federal securities laws or other laws of the United States. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities based upon U.S. federal securities laws and as to the
enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities laws. Therefore, it may not be possible to enforce those actions against us, certain of our
directors and officers or the experts named in this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_9"></A>CONSOLIDATED FINANCIAL INFORMATION AND CURRENCY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements incorporated by reference in this prospectus supplement have been prepared in accordance with IFRS and are reported in
United States dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless stated otherwise or if the context otherwise requires, all references to dollar amounts in this prospectus supplement are
references to U.S. dollars. References to &#147;$&#148; or &#147;US$&#148; are to U.S. dollars and references to &#147;CDN$&#148; are to Canadian dollars. In this prospectus supplement, where applicable, and unless otherwise indicated, amounts are
converted from Canadian dollars to U.S. dollars and vice versa by applying the noon rate of exchange for conversion of one Canadian dollar to U.S. dollars as reported by the Bank of Canada on December&nbsp;21, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth for each period indicated: (i)&nbsp;the noon exchange rates in effect at the end of the period; (ii)&nbsp;the high and low noon
exchange rates during such period; and (iii)&nbsp;the average noon exchange rates for such period, for one Canadian dollar, expressed in U.S. dollars, as quoted by the Bank of Canada. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">On December&nbsp;21, 2016, the noon exchange rate as quoted by the Bank of Canada was CDN$1.00 = US$0.7462.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_10"></A>CONSOLIDATED CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since September&nbsp;30, 2016, the date of our most recently filed interim unaudited condensed consolidated financial statements, there have been no changes
in our share capital on a consolidated basis other than as outlined under &#147;<I>Prior Sales.</I>&#148; For information on the issuance of common shares pursuant to a private placement completed on June&nbsp;22, 2016, the July ATM, the November
ATM,<B> </B>the exercise of options pursuant to our incentive stock option plan, and the exercise of certain outstanding warrants, see the section titled &#147;<I>Prior Sales.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and short term investments and capitalization as of September&nbsp;30, 2016 on an actual basis and
as adjusted to give effect to the common shares issued pursuant to the July ATM, the November ATM, the common shares issued upon the exercise of options and warrants to the date of this prospectus supplement and this Offering, as though they had
occurred on such date. This table should be read in conjunction with our unaudited condensed consolidated interim financial statements as at and for the three and nine month periods ended September&nbsp;30, 2016 and 2015. Figures are in thousands of
U.S. dollars except share data. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at September&nbsp;30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As</B><br><B>Adjusted<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of common shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,794,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,141,571<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">15,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">4,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">US$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,628<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital&nbsp;&#150;&nbsp;common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributed surplus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">24,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Excluding any exercise of the <FONT STYLE="white-space:nowrap">Over-Allotment</FONT> Option and any proceeds we may receive from the exercise of the Warrants. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Change in common shares in the amount of 12,347,082 is comprised of shares issued: (a)&nbsp;pursuant to the July ATM &#150; 687,903; (b) exercise of June&nbsp;26, 2013 warrants &#150; 122,222; (c) exercise of options
&#150; 30,000; (d)&nbsp;cashless exercise of 800,432 February&nbsp;14, 2014 warrants &#150; 256,860; (e)&nbsp;pursuant to the November ATM&nbsp;&#150;&nbsp;138,986; and (f) pursuant to this Offering &#150; 11,111,111. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">This amount includes the estimated fair value of $10.16 million calculated using the Black-Scholes pricing model allocated to Warrants issued pursuant to this Offering and is net of the fair value ($1.83 million)
allocated to the 800,432 warrants exercised pursuant to the cashless exercise option at the time of exercise. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_11"></A>TRADING PRICE AND VOLUME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common shares are listed and posted
for trading on the TSX in Canada under the trading symbol &#147;AUP&#148; and on the NASDAQ in the United States under the trading symbol &#147;AUPH.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the reported high and low prices (in Canadian dollars) and volume of common shares traded for each
month on the TSX. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,985,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,121,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1&nbsp;&#150;&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">651,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on December&nbsp;21, 2016, the last trading day prior to the date of this prospectus supplement, the
price of the common shares as quoted by the TSX was CDN$3.64. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the reported high and low prices
(in United States dollars) and the volume of common shares traded for each month on NASDAQ. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman"><B>Month</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Range&nbsp;(US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,558,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,368,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,439,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,162,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,439,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1&nbsp;&#150;&nbsp;21, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,662,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the close of business on December 21, 2016, the last trading day prior to the date of this prospectus supplement, the price
of the common shares quoted by the NASDAQ was US$2.72. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_12"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes details of
the common shares we issued during the 12 month period prior to the date of this prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:63.05pt; font-size:8pt; font-family:Times New Roman"><B>Month of Issuance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price per Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:72.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Units<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$2.51<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,148,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$2.22<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$2.70<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$3.2204<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$3.2204<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$3.25<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$2.84<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">common shares<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CDN$3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,743,041</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="6" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Issued pursuant to the June 2016 Private Placement. Each Unit was comprised of one common share and 0.35 of a common share purchase warrant exercisable until June&nbsp;26, 2018 at an exercise price of US$2.77.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Issued upon exercise of previously issued stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Issued upon exercise of previously issued warrants. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Issued pursuant to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> distribution pursuant to Prospectus Supplement No.&nbsp;2 dated July&nbsp;22, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Average selling price. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Issued pursuant to a cashless exercise option. Calculation was determined by the number of warrants to be exercised (618,516) multiplied by a five day weighted average market price (US$5.0451) less the exercise price
(US$3.2204), with the difference divided by the weighted average market price. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Issued pursuant to a cashless exercise option. Calculation was determined by the number of warrants to be exercised (181,916) multiplied by a five day weighted average market price (US$3.9382) less the exercise price
(US$3.2204), with the difference divided by the weighted average market price. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Issued pursuant to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> distribution pursuant to Prospectus Supplement No.&nbsp;3 dated November&nbsp;9, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes details of the stock options we granted during the 12 month period prior to the date of this prospectus supplement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:54.60pt; font-size:8pt; font-family:Times New Roman"><B><BR>Month of Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant Price per Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:84.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(CDN$)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:72.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,735,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_13"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the Offering will be approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the Over-Allotment Option is exercised in full) after deducting the Underwriters&#146; Fee of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the Over-Allotment Option is exercised in full) and our expenses of the
Offering, which are estimated to be US$450,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to use the net proceeds of the Offering (without giving effect to the exercise of the
Over-Allotment Option) as follows: approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for research and development activities including the LN Phase&nbsp;3 clinical trial activities and approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Over-Allotment Option is exercised in full, we intend to
allocate the additional net proceeds of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to research and development activities including the LN Phase&nbsp;3 clinical trial activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing discussion does not include any proceeds we may receive from the exercise of Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we intend to use the net proceeds from the Offering as set forth above, there may be circumstances where, for sound business reasons, a reallocation
of funds may be deemed prudent or necessary, and may vary materially from that set forth above. Any unallocated funds from the net proceeds of the Offering, if any, may be added to the general working capital of the Company and expended at the
discretion of management. See &#147;<I>Risk Factors</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual amount that we spend in connection with each of the intended uses of proceeds
may vary significantly from the amounts specified above, and will depend on a number of factors, including those listed under the heading &#147;<I>Risk Factors</I>&#148; in or incorporated by reference in this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_14"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in the Offered Units, your interest will be diluted to the extent of the difference between the public offering price per share of our common
shares in this Offering and the net tangible book value per share of our common shares after this Offering. As of September&nbsp;30, 2016, we had a historical net tangible book value of US$4.2&nbsp;million, or US$0.11 per common share. Our net
tangible book value represents total tangible assets less total liabilities, divided by the number of common shares outstanding on September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the issue of 11,111,111 Units in this Offering (and assuming no exercise of the Warrants) at a public offering price of US$2.25 per
Offered Unit, and after deducting the Underwriters&#146; Fee and estimated Offering expenses, our as adjusted net tangible book value as of September&nbsp;30, 2016 would have been US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in as adjusted net tangible book value of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing shareholders and an immediate
dilution of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors. The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per Offered Unit (and assuming no exercise of the Warrants)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this Offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Underwriters fully exercise the Over-Allotment Option to purchase Additional Offered Units (and assuming no exercise of
the Additional Warrants), the adjusted net tangible book value after this Offering would increase to US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and there would be an immediate dilution of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion and table above assume (i)&nbsp;the sale by us of
11,111,111 Units, (ii)&nbsp;no exercise of the Underwriters&#146; Over-Allotment Option, (iii)&nbsp;no exercise of Warrants offered in this Offering, and (iv)&nbsp;no receipt of cash upon the exercise of the Warrants. Upon the exercise of the
Warrants, if any, holders of the Warrants will experience additional dilution. The discussion and table above do not take into account further dilution to new investors that could occur upon the exercise of outstanding options and warrants having a
per share exercise price less than the Offering Price in this Offering. To the extent that outstanding options and warrants are exercised, new investors will experience further dilution. In addition, we may choose to raise additional capital due to
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the
issuance of these securities could result in further dilution to our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above is based on the
number of common shares outstanding as of September&nbsp;30, 2016 and excludes the following, in each case as of such date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,098,137 common shares issuable upon the exercise of outstanding options outstanding as of September&nbsp;30, 2016, with a weighted-average exercise price of US$2.84; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,927,223 common shares issuable upon exercise of warrants outstanding as of September&nbsp;30, 2016 with a weighted average exercise price of US$3.07; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">951,174 common shares reserved for future issuance under our stock option plans as of September&nbsp;30, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,235,971 common shares issued subsequent to September 30, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_15"></A>DESCRIPTION OF SECURITIES OFFERED UNDER THIS PROSPECTUS SUPPLEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering consists of 11,111,111 Offered Units (1,666,666 Additional Offered Units in the event the Over-Allotment Option is exercised in full).
Each Offered Unit will consist of one Unit Share and one-half of one common share purchase warrant, with each Warrant entitling the holder to purchase one Warrant Share at an exercise price of US$3.00, subject to adjustment, at any time until 4:30
p.m. (New York time) on the date that is five years after the closing of the Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue an unlimited number of common shares, without nominal or par value. As of December&nbsp;21, 2016, there were 40,030,460 common
shares issued and outstanding, 4,078,137 common shares issuable upon exercise of outstanding stock options and 5,004,569 common shares issuable upon exercise of common share purchase warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of common shares are entitled to one vote per share held at meetings of shareholders, to receive such dividends as declared and to receive a share
of the remaining property and assets upon dissolution or winding up of Aurinia Pharmaceuticals. The common shares are not subject to any future call or assessment and there are no statutory <FONT STYLE="white-space:nowrap">pre-emptive,</FONT>
conversion or redemption rights attached to such common shares. Provisions as to the modification, amendment or variation of the rights attached to the Common Shares are contained in the Company&#146;s bylaws and the <I>Business Corporations Act</I>
(Alberta). Generally speaking, substantive changes to the authorized share structure require the approval of the shareholders of the Company by special resolution (at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2014, we granted the subscribers in a private placement of our common shares a right of first refusal to participate in any future private
placement of common shares or any other class or series of our share capital (or securities convertible into common shares or any other class or series of our share capital), up to their pro rata share of such private placement. This right of first
refusal expires upon the earlier of a subscriber no longer holding at least 66<SUP STYLE="vertical-align:top">&nbsp;2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the common shares purchased in the February 2014 private placement or
February 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid any dividends to date on the common shares. We do not currently expect to pay any dividends on the common shares for the
foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants will be
issued as individual warrant agreements to the investors. The material terms and provisions of the Warrants offered hereby are summarized below. The following description is subject to, and qualified in its entirety by, the form of Warrant, which we
will file on SEDAR under our profile at www.sedar.com and with the SEC as an exhibit to a Report on Form&nbsp;6-K following closing of this Offering. You should review a copy of the form of Warrant for a complete description of the terms and
conditions applicable to the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Unit Shares and the Warrants comprising the Units will separate immediately upon the closing of this Offering.
The Warrants are exercisable beginning on the date of issuance, and at any time prior to 4:30 p.m. (New York time) on the date that is five&nbsp;years after the closing of this Offering. The Warrants will be exercisable, at the option of each
holder, in whole or in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of common shares purchased upon such exercise (except in the case of a cashless exercise as discussed below). No fractional
common shares will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price. The holder will not have the right to
exercise any portion of the Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% of the number of our common shares outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, at any time during the term of the Warrants, the issuance of Warrant Shares is not covered by an effective
registration statement, the holder is permitted to effect a cashless exercise of the Warrants (in whole or in part) by having the holder deliver to us a duly executed exercise notice, canceling a portion of the Warrant in payment of the purchase
price payable in respect of the number of common shares purchased upon such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to deliver to the investor a certificate representing
the Warrant Shares by the third trading day after the exercise date as required by the Warrant, and if the investor purchases common shares after that third trading day to deliver in satisfaction of a sale by the investor of the underlying Warrant
Shares that the investor anticipated receiving from us, then, within three trading days of receipt of the investor&#146;s request, we, at the investor&#146;s option, will either (i)&nbsp;pay cash to the investor in an amount equal to the
investor&#146;s total purchase price (including brokerage commissions, if any) for the common shares purchased less the exercise price (as described below), or the buy-in price, at which point our obligation to deliver the Warrant (and to issue the
underlying Warrant Shares) will terminate, (ii)&nbsp;reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honoured (in which case such exercise shall be deemed rescinded) or (iii)&nbsp;promptly
honour our obligation to deliver to the investor a certificate or certificates representing the Warrant Shares and pay cash to the investor in an amount equal to the excess (if any) of the buy-in price over the product of (A)&nbsp;the number of
common shares, times (B)&nbsp;the per share closing price of our common shares on the date of the event giving rise to our obligation to deliver the certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Warrant represents the right to purchase one common share at an exercise price equal to US$3.00 per share, subject to adjustment. The exercise price is
subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common shares and also upon any distributions of assets, including cash,
stock or other property to our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we consummate any merger, consolidation, sale or other reorganization event in which our common shares
are converted into or exchanged for securities, cash or other property, or if we consummate certain sales or other business combinations, then following such event, the holders of the Warrants will be entitled to receive upon exercise of the
Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no public trading market for the Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the
Warrants on any securities exchange or other trading system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the Warrants or by virtue of such holder&#146;s ownership of
our common shares, the holder of a Warrant does not have the rights or privileges of a holder of our common shares, including any voting rights, until the holder exercises the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>There is no market through which the Warrants may be sold and purchasers may not be able to resell the Warrants purchased under this prospectus supplement.
This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of such Warrants, and the extent of issuer regulation. See &#147;</B><B><I>Risk Factors.</I></B><B>&#148;
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_16"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Underwriting Agreement, the Company has agreed to sell and the Underwriters have agreed to purchase on the closing of the Offering, an
aggregate of 11,111,111 Offered Units at a price of US$2.25 per Offered Unit, payable against delivery of the Offered Units, subject to the terms and conditions stated in the Underwriting Agreement. In consideration for their services in connection
with this Offering, the Underwriters will be paid the Underwriters&#146; Fee equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the gross proceeds of this Offering ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Offered Unit, for an
aggregate fee payable by us of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, exclusive of the Over-Allotment Option). H.C. Wainwright&nbsp;&amp; Co., LLC will be
acting as Lead Underwriter in respect of the Offering. The Offering Price was determined by negotiation between us and the Lead Underwriter on its own behalf and on behalf of the other Underwriter. Subject to the terms and conditions of the
Underwriting Agreement, we have agreed to sell to the Underwriters, and each Underwriter has severally agreed to purchase, at the Offering Price less the Underwriting Fee set forth on the cover page of this prospectus supplement, the number of
Offered Units listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Offered&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,888,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormark Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,111,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the Underwriters under the Underwriting Agreement may be terminated at the discretion of the Lead
Underwriter upon the occurrence of certain stated events. The Underwriters are obligated under the Underwriting Agreement to take up and pay for all of the Offered Units if any of the Offered Units are purchased. The Underwriters are offering the
Offered Units, subject to prior sale, if, as and when issued to and accepted by it, subject to certain conditions contained in the Underwriting Agreement, such as receipt by the Underwriters of officers&#146; certificates and legal opinions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has granted the Underwriters an Over-Allotment Option, exercisable in whole or in part, at any time and from time to time, in the sole discretion
of the Underwriters, for a period of 30 days from the date of this prospectus supplement, to purchase up to an additional 1,666,666 of Offered Units at the Offering Price, less the Underwriting Fee, to cover over-allotments, if any, and for market
stabilization purposes. The purchase price of one Additional Offered Unit pursuant to the Over-Allotment Option will be equal to the Offering Price. The Over-Allotment Option may be exercisable by the Underwriters in respect of: (i) Additional
Offered Units at the Offering Price; or (ii) Additional Shares at a price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Additional Share; or (iii) Additional Warrants at a price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
Additional Warrant; or (iv) any combination of the Additional Securities, so long as the aggregate number of Additional Shares and Additional Warrants which may be issued under the Over-Allotment Option does not exceed Additional Shares and
Additional Warrants. The Additional Securities issued upon exercise of the Over-Allotment Option are qualified for distribution under this short form prospectus. A person who acquires Additional Securities issuable on the exercise of the
Over-Allotment Option acquires such Additional Securities under this prospectus supplement regardless of whether the over-allotment position is ultimately filled through the exercise of the Over-Allotment Option or secondary market purchases. If the
Over-Allotment Option is exercised in full, the total price to the public, the Underwriters&#146; Fee and the net proceeds to the Company (before payment of the expenses of the Offering) will be approximately US$28.75 million,
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants
will be issued as individual warrant agreements to the investors. Each Warrant will entitle the holder thereof to purchase one common share at a price of US$3.00 at any time prior to 4:30 p.m. (New York time) on the date that is five years after the
closing of the Offering, after which time the Warrants will expire and be void and of no value. The warrant agreements will contain provisions designed to protect the holders of Warrants against dilution upon the happening of certain events. No
fractional common shares will be issued upon the exercise of any Warrants. <B>There is currently no market through which the Warrants may be sold and</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>purchasers may not be able to resell such securities. This may affect the pricing of the Warrants in the</B> <B>secondary market, the transparency and availability of trading prices, the
liquidity of such securities, and the extent of issuer regulation.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made in the provinces of British Columbia, Alberta and
Ontario and in the United States pursuant to the multijurisdictional disclosure system implemented by the SEC and the securities regulatory authorities in Canada. The Offered Units will be offered in Canada by the Underwriters either directly or
through their duly registered Canadian <FONT STYLE="white-space:nowrap">broker-dealer</FONT> affiliates or agents, as applicable. <B>H.C. Wainwright</B><B></B><B>&nbsp;&amp; Co., LLC is not registered as a dealer in the category of investment dealer
in any Canadian jurisdiction and, accordingly, will only sell Offered Units into the United States and will not, directly or indirectly, solicit offers to purchase or sell the Offered Units in Canada.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscriptions for Offered Units will be received by the Underwriters subject to rejection or allotment in whole or in part and the right is reserved to close
the subscription book at any time without notice. It is expected that delivery of the Offered Units offered hereby will be made against payment therefor on or about the closing date, which will be the third business day following the date of this
prospectus supplement (this settlement cycle being referred to as &#147;<B>T+3</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities affiliated with the ILJIN SNT Co., Ltd., one of our
major stockholders have submitted an indication of interest to purchase up to US$3.0&nbsp;million of the Offered Units in this Offering. However, because indications of interest are not binding agreements or commitments to purchase, the Underwriters
may determine to sell more, fewer or no Offered Units in this Offering to these entities, or these entities may determine to purchase more, fewer or no Offered Units in this Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed in the Underwriting Agreement to reimburse the Underwriters for their legal fees and other expenses in connection with this Offering,
in an amount not to exceed US$200,000. The Company has also agreed to indemnify the Underwriters, each of its affiliates and each of its and their directors, officers, partners, employees and agents against certain liabilities and expenses or will
contribute to payments that the Underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also agreed, pursuant to the terms of the
Underwriting Agreement that it will not, without the prior written consent of the Lead Underwriter, from the date of execution of the Underwriting Agreement and continuing to and including the date 45 days after the date of this prospectus
supplement (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), (A)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any common shares or any securities convertible into or exercisable or exchangeable for common shares or (B)&nbsp;enter into any swap
or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares, whether any such transaction described in clause (A)&nbsp;or (B)&nbsp;above is to be settled by delivery of common shares or
such other securities, in cash or otherwise, except for (1)&nbsp;sales of the Offered Units to the Underwriters pursuant to the Underwriting Agreement, (2) the issuance of Warrant Shares on the exercise of Warrants, (3)&nbsp;grants of options or the
issuance of common shares by the Company pursuant to equity incentive plans, or (4)&nbsp;issuance of shares upon exercise or conversion of securities outstanding as of the date thereof. The Company further agreed pursuant to the Underwriting
Agreement not to accelerate the vesting of any option or warrant or the lapse of any repurchase right prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period except immediately prior to the closing of a transaction that
would involve the sale of all of the common shares of the Company to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a condition precedent to the Underwriters&#146; obligation to
close the Offering, subject to customary exemptions permitting dispositions to trusts for the direct or indirect benefit of the director or officer and/or the immediate family of such person, tenders to a take-over bid or acquisition transaction and
pursuant to any existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, all directors and officers of the Company shall be required to execute and deliver written undertakings in favour of the Underwriters agreeing not to sell, transfer,
pledge (other than as disclosed to the Underwriters in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing), assign, or otherwise dispose of any securities of the Company owned, directly or indirectly by such directors or officers, until 45 days following the date of this prospectus
supplement, without the prior written consent of the Lead Underwriter on behalf of the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriters propose to offer the Offered Units
initially at the public Offering Price on the cover page of this prospectus supplement. After the Underwriters have made a reasonable effort to sell all of the Offered Units offered by this prospectus supplement at the Offering Price specified
herein, the Offering Price may be decreased, and further changed from time to time and the compensation realized by the Underwriters will be decreased by the amount that the aggregate price paid by the purchasers for the Offered Units is less than
the gross proceeds paid by the Underwriters to the Company. Any such reduction will not affect the proceeds received by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In order to
facilitate the Offering, the Underwriters may engage in transactions that stabilize, maintain or otherwise affect the market price of the common shares in accordance with Regulation M under the Exchange Act. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriters may over-allot common shares in connection with the Offering, thus creating a short position for its own account. Short sales involve the
sale by the Underwriters of a greater number of shares than they are committed to purchase in the Offering. To cover these short sales positions or to stabilize the market price of the common shares, the Underwriters may bid for, and purchase,
common shares in the open market. These transactions may be effected on the TSX, the NASDAQ or otherwise. Additionally, the representatives, on behalf of the Underwriters, may also reclaim selling concessions allowed to another underwriter or
dealer. Similar to other purchase transactions, the Underwriters&#146; purchases to cover the syndicate short sales or to stabilize the market price of the common shares may have the effect of raising or maintaining the market price of the common
shares or preventing or mitigating a decline in the market price of the common shares. As a result, the price of the common shares may be higher than the price that might otherwise exist in the open market. No representation is made as to the
magnitude or effect of any such stabilization or other activities. The Underwriters are not required to engage in these activities and, if commenced, may discontinue any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to rules and policy statements of certain Canadian securities regulators, the Underwriters may not, at any time during the period ending on the date
the selling process for the Offered Units ends and all stabilization arrangements relating to the Offered Units are terminated, bid for or purchase common shares. The foregoing restrictions are subject to certain exceptions including (a)&nbsp;a bid
for or purchase of common shares if the bid or purchase is made through the facilities of the TSX, in accordance with the Universal Market Integrity Rules of Market Regulation Services Inc., (b) a bid or purchase on behalf of a client, other than
certain prescribed clients, provided that the client&#146;s order was not solicited by the Underwriters, or if the client&#146;s order was solicited, the solicitation occurred before the commencement of a prescribed restricted period, and (c)&nbsp;a
bid or purchase to cover a short position entered into prior to the commencement of a prescribed restricted period. The Underwriters may engage in market stabilization or market balancing activities on the TSX where the bid for or purchase of the
common shares is for the purpose of maintaining a fair and orderly market in the common shares, subject to price limitations applicable to such bids or purchases. Such transactions, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has applied to list the Unit Shares and the Warrant Shares on the TSX. Listing will be subject to the Company fulfilling all of the requirements
of the TSX. The Company has also applied to list the Unit Shares and the Warrant Shares on the NASDAQ. Listing will be subject to the Company fulfilling all of the requirements of the NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus in electronic format may be made available on the websites maintained by one or more of the
Underwriters or their U.S. affiliates participating in this Offering. The Underwriters may agree to allocate a number of Offered Units to the Underwriters and their U.S. affiliates for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriters and their U.S. affiliates that may make Internet distributions on the same basis as other allocations. Other than the prospectus supplement and the accompanying prospectus in
electronic format, the information on these websites is not part of this prospectus supplement or the registration statement of which this prospectus supplement forms a part, has not been approved or endorsed by us or any Underwriter in its capacity
as underwriter, and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Underwriters and their affiliates have provided in the past to us and our
affiliates, and may provide from time to time in the future, certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and
may continue to receive customary fees and commissions. In addition, from time to time, certain of the Underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or
their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement also covers
the distribution of the Warrant Shares by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_17"></A>CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this summary, an otherwise undefined term that first appears in quotation marks has the meaning ascribed to it in the <I>Income Tax Act</I> (Canada) (the
&#147;<B>Tax Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of Borden Ladner Gervais LLP, Canadian legal counsel to Aurinia Pharmaceuticals, and Stikeman Elliott LLP,
Canadian legal counsel to the Underwriters, the following fairly summarizes the principal Canadian federal income tax considerations under the Tax Act generally applicable as of this date to an investor who acquires Offered Units pursuant to the
Offering and who, at all relevant times for the purposes of the Tax Act, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deals at arm&#146;s length with Aurinia Pharmaceuticals and the Underwriters, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is not affiliated with Aurinia Pharmaceuticals or the Underwriters, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">holds all Unit Shares and Warrants, and will hold all Warrant Shares acquired on exercise of a Warrant as capital property, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and is not </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exempt from tax under Part I of the Tax Act, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;financial institution&#148; for the purposes of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> property rules in the Tax Act, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;specified financial institution&#148;, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an entity or partnership an interest in which is a &#147;tax shelter investment&#148;, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a taxpayer who reports its &#147;Canadian tax results&#148; in a currency other than Canadian currency, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a taxpayer that has or will enter into a &#147;derivative forward agreement&#148; with respect to Unit Shares Warrant Shares or Warrants, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(each such investor, in this summary, a &#147;<B>Holder</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this summary, unless the context otherwise requires, a reference to a Share means a Unit Share or a Warrant Share as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Holder&#146;s Shares or Warrants, as applicable, will generally be considered to be capital property of the Holder provided that the Holder does not use the
Shares or Warrants in the course of carrying on a business of trading or dealing in securities, and has not acquired or been deemed to have acquired the Shares or Warrants in one or more transactions considered to be an adventure or concern in the
nature of trade. A Holder who is resident in Canada and whose Shares might not otherwise be capital property may, subject to certain restrictions and limitations in the Tax Act, be entitled to elect irrevocably pursuant to subsection 39(4) of the
Tax Act that the Holder&#146;s Shares, and every other &#147;Canadian security&#148; of the Holder, be capital property. Any Holder who is considering making a subsection 39(4) election should consult the Holder&#146;s Canadian tax advisers before
making the election. A subsection 39(4) election will not apply to, or to a disposition of, Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is based on the current provisions of
the Tax Act and the <I>Income Tax Regulations </I>(Canada) (the &#147;<B>Regulations</B>&#148;) in force as of the date hereof, all specific proposals to amend the Tax Act or Regulations publicly announced by or on behalf of the Minister of Finance
of Canada on or before the date hereof, and counsel&#146;s understanding of the current published administrative policies and assessing practices of the Canada Revenue Agency (the &#147;<B>CRA</B>&#148;). It is assumed that all such amendments will
be enacted as currently proposed and that there will be no other change to the Tax Act, the Regulations, or the CRA&#146;s administrative policies and assessing practices, although no assurance can be given in these respects. This summary does not
otherwise take into account or anticipate any change in law or administrative policy or assessing practice whether by legislative, governmental, or judicial decision or action, and does not take into account or consider any provincial, territorial
or foreign income tax considerations, which may differ significantly from the Canadian federal income tax considerations discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional considerations, not discussed in this summary, may be applicable to a Holder that is a corporation
resident in Canada, and is, or becomes, or does not deal at arm&#146;s length for purposes of the Tax Act with a corporation resident in Canada that is or becomes, as part of a transaction or event or series of transactions or events that includes
the acquisition of the Offered Units, controlled by a <FONT STYLE="white-space:nowrap">non-resident</FONT> corporation for purposes of the &#147;foreign affiliate dumping&#148; rules in section 212.3 of the Tax Act. Such Holders should consult their
Canadian tax advisers with respect to the consequences of acquiring Offered Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This summary is of a general nature only, is not exhaustive of all
possible Canadian federal income tax considerations and is not intended to be, and should not be construed to be, legal or tax advice to any particular Holder. Each Holder should consult the Holder&#146;s own tax advisers with respect to the tax and
legal consequences of acquiring Offered Units, and the holding and disposition of Unit Shares, Warrants or Warrant Shares, applicable to the Holder&#146;s particular circumstances. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Currency Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions that
are not discussed in this summary, all amounts relevant to computing a Holder&#146;s liability for tax (including dividends, adjusted cost base, and proceeds of disposition) under the Tax Act must, for the purposes of the Tax Act, be determined in
Canadian dollars based on the daily noon rate quoted by the Bank of Canada for the applicable day (or, if such day is after March&nbsp;1, 2017, the single rate quoted by the Bank of Canada for the applicable day) or such other rate of exchange that
is acceptable to the CRA. The amount of any dividend required to be included in a Holder&#146;s income, or of any capital gain or capital loss realized by a Holder, may be affected by fluctuations in the Canadian dollar against other currencies.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allocation of Cost and Adjusted Cost Base </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
Holder must allocate the Offering Price of an Offered Unit on a reasonable basis between the Unit Share and the one-half of one Warrant included in the Unit to determine the cost of each to the Holder for purposes of the Tax Act. The Company intends
to allocate US$2.24 of the Offering Price to the Unit Share and US$0.01 of the Offering Price to the one-half of one Warrant included in an Offered Unit. Although the Company believes this allocation to be reasonable, it is not binding on the CRA or
the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Holder&#146;s initial adjusted cost base of the Unit Share included in an Offered Unit will be determined by averaging the cost of the Unit
Share with the adjusted cost base to the Holder of all Shares owned by the Holder as capital property immediately before such acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, a
Holder&#146;s initial adjusted cost base of each whole Warrant acquired pursuant to the Offering initially will be the average cost of all Warrants so acquired by the Holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resident Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following section of this summary
applies solely to Holders each of whom at all relevant times is or is deemed to be resident solely in Canada for the purposes of the Tax Act (each a &#147;<B>Resident Holder</B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise or Expiry of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder
who exercises a Warrant in a taxation year and thereby acquires a Warrant Share will not thereby realize any capital gain or capital loss. The Holder&#146;s cost of the Warrant Share will equal the Holder&#146;s adjusted cost base of the Warrant
plus the exercise price paid for the Warrant Share. The Holder&#146;s adjusted cost base of the Warrant Share so acquired will be determined by averaging its cost with the Holder&#146;s adjusted cost base of all of the Holder&#146;s Shares
determined immediately before the acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder of a Warrant that expires before exercise will generally realize a capital loss equal to the
Resident Holder&#146;s adjusted cost base of the Warrant. The tax treatment of capital gains and capital losses is discussed below under the subheading &#147;<I>Capital Gains and Capital Losses</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who is an individual
(other than certain trusts) and receives or is deemed to receive a dividend on the holder&#146;s Shares in a taxation year will generally be required to include the amount of the dividend in income for the taxation year, subject to the <FONT
STYLE="white-space:nowrap">gross-up</FONT> and dividend tax credit rules applicable to a &#147;taxable dividend&#148; received from a &#147;taxable Canadian corporation&#148;, including the enhanced <FONT STYLE="white-space:nowrap">gross-up</FONT>
and dividend tax credit rules applicable to any dividend that Aurinia Pharmaceuticals designates as an &#147;eligible dividend&#148; in accordance with the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder that is a corporation will generally be required to include the amount of any such dividend in its income for the taxation year, and
entitled to deduct an equivalent amount from its taxable income for the year. In certain circumstances, subsection 55(2) of the Tax Act may deem some or all of the dividend to be a gain from the disposition of capital property rather than a
dividend, in which case the rules described below under &#147;Capital Gains and Losses&#148; would apply. Corporate Resident Holders should consult their own tax advisers regarding the potential application of subsection 55(2) to their particular
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder that is a &#147;private corporation&#148; or &#147;subject corporation&#148; may be subject to a refundable tax under
Part IV of the Tax Act to the extent that the dividend is deductible in computing the corporation&#146;s taxable income. This refundable tax generally will be refunded to the corporate Resident Holder if it pays sufficient taxable dividends while it
is a private corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposition of Shares or Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who disposes or is deemed to dispose of a Warrant (other than on the exercise or expiry thereof) or Share in a taxation year will generally
realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of the Share or Warrant, as applicable, net of any reasonable costs of disposition, are greater (or less) than adjusted cost base of the security to
the Resident Holder. The tax treatment of capital gains and capital losses is discussed in greater detail below under the subheading &#147;<I>Capital Gains and Capital Losses</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Gains and Capital Losses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident
Holder who realizes or is deemed to realize a capital gain or capital loss in a taxation on the disposition of a Share or Warrant will generally be required to include one half of any such capital gain (a &#147;taxable capital gain&#148;) in income
for the year, and entitled to deduct one half of any such capital loss (an &#147;allowable capital loss&#148;) from taxable capital gains realized by the Resident Holder in the year or, to the extent not so deductible, in any of the Holder&#146;s
three preceding taxation years or any subsequent taxation year, subject to the detailed rules in the Tax Act regarding the deductibility of allowable capital losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of any capital loss realized on the disposition or deemed disposition of a Share by a Resident Holder that is a corporation may be reduced by the
amount of dividends that the Resident Holder received or is deemed to have received on the Share or a share substituted therefor, to the extent and in the circumstances specified by the Tax Act. Similar rules may apply to a Share owned by a
partnership or trust of which a corporation, trust or partnership is a member or beneficiary, as the case may be. Resident Holders to whom these rules may be relevant should consult their own tax advisers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder that is throughout the relevant taxation year a &#147;Canadian-controlled private corporation&#148; may be liable to pay an additional
refundable tax on certain investment income including taxable capital gains. This refundable tax generally will be refunded to the corporate Resident Holder if it pays sufficient taxable dividends while it is a private corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Minimum Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resident Holder who is an individual (including certain trusts) and realizes a capital gain or receives a dividend may thereby be subject to minimum tax
under the Tax Act. Such Resident Holders should consult their own tax advisers in this regard. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-resident</FONT>
Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following section of this summary is applicable solely to Holders each of whom, at all relevant times for the purposes of the Tax Act,
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is not resident in Canada, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not use or hold, and is not deemed to use or hold, Shares or Warrants in connection with carrying on a business in Canada, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is not an &#147;authorized foreign bank&#148;, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is not an insurer that carries on business in Canada and elsewhere, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(each a &#147;<B><FONT
STYLE="white-space:nowrap">Non-resident</FONT> Holder</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposition of Shares or Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder who disposes or is deemed to dispose of a Share or Warrant generally will not be subject to tax
under the Tax Act in respect of any capital gain, or entitled to deduct any capital loss, thereby realized unless the Share or Warrant, at the time of the disposition, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is &#147;taxable Canadian property&#148;, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is not &#147;treaty-protected property&#148;, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the <FONT STYLE="white-space:nowrap">Non-resident</FONT>
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder&#146;s Share or Warrant, as applicable, should not be taxable Canadian
property to the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder at the time of disposition if at that time the Shares are listed on a designated stock exchange (which currently includes the TSX and NASDAQ) unless, at the time of
disposition or at any time in the preceding 60 months, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder, one or more persons with whom the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder did not deal at arm&#146;s length for the purposes of the
Tax Act, or one or more partnerships in which the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder or persons with whom the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder did not deal at arm&#146;s length holds or held a
membership interest (either directly or indirectly through one or more partnerships), alone or in any combination owned 25% or more of the issued shares of any class or series of shares of Aurinia Pharmaceuticals, and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Share derived more than 50% of its fair market value directly or indirectly from, or from any combination of, real or immovable property situated in Canada, &#147;Canadian resource properties&#148;, &#147;timber
resource properties&#148;, or options in respect of, interests in, or for civil law purposes rights in, any such property, whether or not the property exists, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or the Share was otherwise deemed by a provision of the Tax Act to be taxable Canadian property at the time of disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder&#146;s Shares or Warrants will be treaty-protected property at the time of
disposition if, at that time, the terms of a tax treaty between Canada and another country exempt the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder from tax under Part I of the Tax Act on any gain from the disposition of the Shares or
Warrants, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-resident</FONT> Holders should consult their own tax advisers regarding
whether their Shares or Warrants are taxable Canadian property or treaty-protected property. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-resident</FONT>
Holder who disposes or is deemed to dispose of a Share or Warrant in a taxation year at a time when the Share or Warrant is taxable Canadian property and is not treaty&#150;protected property of the Holder generally will be required to file a
Canadian tax return to report the disposition. The <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder generally will be required to include any resulting taxable capital gain in the <FONT STYLE="white-space:nowrap">Non-resident</FONT>
Holder&#146;s taxable income earned in Canada for the taxation year, and entitled to deduct any resulting allowable capital loss from taxable capital gains included in the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder&#146;s taxable
income earned in Canada for the year or, to the extent not so deductible, in any of the Holder&#146;s three preceding taxation years or any subsequent taxation year, subject to the detailed rules regarding the deductibility of allowable capital
losses in the Tax Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">Non-resident</FONT> Holder to whom a dividend is or is deemed to be paid or credited on the <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder&#146;s Shares will generally be subject to Canadian withholding tax
equal to 25% of the gross amount of the dividend, or such lower rate as may be provided by an applicable income tax treaty between Canada and another country. The rate of withholding tax under the
<I><FONT STYLE="white-space:nowrap">Canada-U.S.</FONT> Income Tax Convention (1980)</I> (the &#147;<B>U.S. Treaty</B>&#148;) applicable to a dividend paid or credited to a <FONT STYLE="white-space:nowrap">Non-resident</FONT> Holder who beneficially
owns the dividend, and is a resident of the United States under the U.S. Treaty and entitled to its benefits, generally is 15%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_17.1"></A>MATERIAL U.S. FEDERAL INCOME TAXATION CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) relating to the acquisition, ownership
and disposition of Units acquired pursuant to this Offering, the acquisition, ownership and disposition of the Unit Shares acquired as part of the Units, the exercise, disposition and lapse of Warrants acquired as part of the Units, and the
acquisition, ownership and disposition of Warrant Shares received upon exercise of the Warrants. This discussion applies to U.S. Holders that purchase Units pursuant to the Offering and hold such Units, Unit Shares, Warrants and Warrant Shares as
capital assets within the meaning of Section&nbsp;1221 of the U.S. Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder and administrative and
judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to
specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, broker-dealers and traders in securities
or other persons that generally mark their securities to market for U.S. federal income tax purposes, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities, retirement plans, regulated investment companies, real estate investment trusts,
certain former citizens or residents of the United States, persons who hold Units, Unit Shares, Warrants, or Warrant Shares as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or
integrated investment, persons who received their Units as compensatory payments, persons that have a &#147;functional currency&#148; other than the U.S. dollar, persons that own directly, indirectly or through attribution 10% or more of the voting
power of our shares, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in such pass-through entities). This discussion does not address any U.S. state or local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this
discussion, the term &#147;<B>U.S. Holder</B>&#148; means a beneficial owner of Units, Unit Shares, Warrants, or Warrant Shares that is, for U.S. federal income tax purposes, (1)&nbsp;an individual who is a citizen or resident of the United States,
(2)&nbsp;a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3)&nbsp;an estate the income of which
is subject to U.S. federal income tax regardless of its source or (4)&nbsp;a trust (x)&nbsp;with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United States persons
have the authority to control all of its substantial decisions or (y)&nbsp;that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income tax purposes holds Units, Unit Shares, Warrants, or Warrant Shares, the U.S. federal income tax
consequences relating to an investment in the Units, Unit Shares, Warrants, or Warrant Shares will depend in part upon the status and activities of such entity and the particular partner. Any such entity should consult its own tax advisor regarding
the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of Units, Unit Shares, Warrants and Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons considering an investment in Units should consult their own tax advisors as to the particular tax consequences applicable to them relating to the
purchase, ownership and disposition of Units, Unit Shares, Warrants and Warrant Shares, including the applicability of U.S. federal, state and local tax laws and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition of Units </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no authority directly
addressing the treatment, for U.S. federal income tax purposes, of securities with terms substantially the same as the Units, and, therefore, such treatment is not entirely clear. We intend to treat the acquisition by a U.S. Holder of a Unit as the
acquisition of one Unit Share and one-half of one Warrant for U.S. federal income tax purposes. The purchase price for each Unit will be allocated between these two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
components in proportion to their relative fair market values at the time the Unit is purchased by the U.S. Holder. This allocation of the purchase price for each Unit will establish a U.S.
Holder&#146;s initial tax basis for U.S. federal income tax purposes in the Unit Share and one-half of one Warrant that comprise each Unit. For this purpose, we will allocate US$2.24 of the purchase price for the Unit to the Unit Share and US$0.01
of the purchase price for each Unit to the one-half of one Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our view of the characterization of the Units, and the purchase price allocation, are
not, however, binding on the IRS or the courts. Because there are no authorities that directly address instruments that are similar to the Units, no assurance can be given that the IRS or the courts will agree with the characterization described
above or the discussion below. Accordingly, prospective investors are urged to consult their own tax advisors regarding the U.S. federal tax consequences of an investment in a Unit (including alternative characterizations of a Unit) and with respect
to any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction. Unless otherwise stated, the following discussions are based on the assumption that the characterization of the Units and the allocation described
above are accepted for U.S. federal income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Foreign Investment Company Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a corporation organized outside the United States will be treated as a passive foreign investment company, (&#147;<B>PFIC</B>&#148;), for any
taxable year in which either (1)&nbsp;at least 75% of its gross income is &#147;<B>passive income</B>&#148;, or the &#147;<B>PFIC income test</B>&#148;, or (2)&nbsp;on average at least 50% of its assets, determined on a quarterly basis, are assets
that produce passive income or are held for the production of passive income (the &#147;<B>PFIC asset test</B>&#148;). Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the
sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and
other assets that may produce passive income. Generally, in determining whether a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly
or indirectly, at least a 25% interest (by value) is taken into account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe we were a PFIC for the year ended December&nbsp;31, 2015.
While we also do not believe we will be a PFIC for the current taxable year, because PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, there can be no assurance that we will not be a
PFIC for the current or future taxable years. Because we may hold a substantial amount of cash and cash equivalents following this offering, and because the calculation of the value of our assets may be based in part on the value of common shares,
which may fluctuate considerably, we may also be a PFIC in future taxable years under the PFIC asset test. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that
the IRS would not successfully challenge our position. Our status as a PFIC is a fact-intensive determination made on an annual basis. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status and also expresses no opinion
with regard to our expectations regarding our PFIC status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC in any taxable year during which a U.S. Holder owns Unit Shares, Warrants or
Warrant Shares, the U.S. Holder could be liable for additional taxes and interest charges under the &#147;PFIC excess distribution regime&#148; upon (1)&nbsp;a distribution paid during a taxable year that is greater than 125% of the average annual
distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#146;s holding period for the Unit Shares, Warrants or Warrant Shares, and (2)&nbsp;any gain recognized on a sale, exchange or other disposition, including a
pledge, of the Unit Shares, Warrants or Warrant Shares, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over
the U.S. Holder&#146;s holding period for Unit Shares, Warrants or Warrant Shares. The amount allocated to the current taxable year (i.e.,&nbsp;the year in which the distribution occurs or the gain is recognized) and any year prior to the first
taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as
applicable, to ordinary income for each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax. Under proposed Treasury Regulations that are prospectively effective until
finalized, if a U.S. Holder has an option, warrant, or other right to acquire stock of a PFIC (such as the Warrants), such option, warrant or right is considered to be PFIC stock subject to the PFIC excess distribution regime. Under the proposed
Treasury Regulations, a U.S. Holder&#146;s holding period for the Warrant Shares will begin on the date the U.S. Holder acquires the Units. This will adversely impact the availability of the QEF Election (defined below) and
&#147;mark-to-market&#148; election (described below) with respect to the Warrant Shares. Thus, a U.S. Holder may have to account for Warrant Shares and Unit Shares under the PFIC rules and the applicable elections differently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any year during which a U.S. Holder holds Unit Shares, Warrants or Warrant Shares, we must generally continue to be treated as a PFIC by
that holder for all succeeding years during which the U.S. Holder holds the Unit Shares, Warrants or Warrant Shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#147;deemed sale&#148; election with respect
to the Unit Shares, Warrants or Warrant Shares. If the election is made, the U.S. Holder will be deemed to sell the Unit Shares, Warrants or Warrant Shares it holds at their fair market value on the last day of the last taxable year in which we
qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holder&#146;s Unit Shares, Warrants or Warrant Shares would not be treated as
shares of a PFIC unless we subsequently become a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds Unit Shares, Warrants or
Warrant Shares and one of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporate subsidiaries is also a PFIC (i.e.,&nbsp;a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the
lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of
those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on Unit Shares or
Warrant Shares if such U.S. Holder makes a valid <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election for such shares. A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available to a U.S. Holder only for &#147;marketable stock.&#148; Our common shares will be marketable stock as long as they remain listed on
the NASDAQ and are regularly traded, other than in de minimis quantities, on at least 15&nbsp;days during each calendar quarter. If a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is in
effect, a U.S. Holder generally would take into account, as ordinary income each year, the excess of the fair market value of common shares held at the end of such taxable year over the adjusted tax basis of such common shares. The U.S. Holder would
also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such common shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in
income over ordinary losses deducted as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. The U.S. Holder&#146;s tax basis in common shares would be adjusted to reflect any
income or loss recognized as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. Any gain from a sale, exchange or other disposition of common shares in any taxable year in which
we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains previously included in income) and thereafter as capital loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will not apply to common shares for any taxable year
during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries that we may organize
or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs that we may organize or acquire in the future notwithstanding the U.S.
Holder&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election for the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
mark-to-market election made by a U.S. Holder for the Unit Shares will also apply to such U.S. Holder&#146;s Warrant Shares. As a result, if a mark-to-market election has been made by a U.S. Holder with respect to Unit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares, any Warrant Shares received will automatically be marked-to-market in the year of exercise of the Warrant. Because, under the proposed Treasury Regulations referenced above, a U.S.
Holder&#146;s holding period for Warrant Shares includes the period during which such U.S. Holder held the Warrants, a U.S. Holder will be treated as making a mark-to-market election with respect to its Warrant Shares after the exercise of the
Warrant unless the Warrant Shares are acquired in the same tax year as the year in which the U.S. Holder acquired its Units. Consequently, the excess distribution regime provisions described above generally will apply to the mark-to market gain
realized in the tax year in which Warrant Shares are received. However, the general mark-to-market rules will apply to subsequent tax years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax
consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid qualified electing fund (&#147;<B>QEF</B>&#148;) election. At this time we do not expect to provide U.S.
Holders with the information necessary for a U.S. Holder to make a QEF election, prospective investors should assume that a QEF election will not be available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form&nbsp;8621 containing such information as
the U.S. Treasury Department may require. The failure to file IRS Form&nbsp;8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with
respect to the impact of PFIC status on the purchase, ownership and disposition of Units, Unit Shares, Warrant Shares and Warrants, the consequences to them of an investment in a PFIC, any elections available with respect to the common shares and
the IRS information reporting obligations with respect to the purchase, ownership and disposition of Units, Unit Shares, Warrant Shares and Warrants of a PFIC. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise and Disposition of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
discussion is subject in its entirety to the rules described above under the heading <I>&#147;&#151;Passive Foreign Investment Company Consequences.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exercise of Warrants </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder will not recognize
gain or loss on the exercise of a Warrant and related receipt of a Warrant Share (unless, and to the extent that, cash is received in lieu of the issuance of a fractional Warrant Share). A U.S. Holder&#146;s initial tax basis in the Warrant Share
received on the exercise of a Warrant will be equal to the sum of (a) such U.S. Holder&#146;s tax basis in such Warrant plus (b) the exercise price paid by such U.S. Holder on the exercise of such Warrant. If we are a PFIC, a U.S. Holder&#146;s
holding period for the Warrant Share received on the exercise of a Warrant should begin on the date on which such U.S. Holder acquired its Warrants. If we are not a PFIC with respect to a U.S. Holder, the holding period for the Warrant Shares
received by the U.S. Holder will begin on the date following the date of exercise and will not include the period during which the U.S. Holder held its Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of Warrants into Warrant Shares. The U.S. federal income tax
treatment of a cashless exercise of Warrants into Warrant Shares is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Warrant described in the preceding paragraph. U.S. Holders should
consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Disposition of Warrants </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder will recognize gain or loss on the sale or other taxable disposition of a Warrant in an amount equal to the difference, if any, between (a) the
amount of cash plus the fair market value of any property received and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(b) such U.S. Holder&#146;s tax basis in the Warrant sold or otherwise disposed of. Subject to the PFIC rules discussed above, any such gain or loss generally will be a capital gain or loss,
which will be long term capital gain or loss if the Warrant is held for more than one year. Deductions for capital losses are subject to complex limitations under the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Expiration of Warrants Without Exercise </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the lapse
or expiration of a Warrant, a U.S. Holder will recognize a loss in an amount equal to such U.S. Holder&#146;s tax basis in the Warrant. Any such loss generally will be a capital loss and will be long-term capital loss if the Warrants are held for
more than one year. Deductions for capital losses are subject to complex limitations under the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Certain Adjustments to the Warrants </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section 305 of the Code, an adjustment to the number of Warrant Shares that will be issued on the exercise of the Warrants, or an adjustment to the
exercise price of the Warrants, may be treated as a constructive distribution to a U.S. Holder of the Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. Holder&#146;s proportionate interest in our
&#147;earnings and profits&#148; or our assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to the shareholders). Adjustments to the exercise price
of Warrants made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution of the interest of the holders of the Warrants should generally not be considered to result in a constructive distribution. Any such
constructive distribution would be taxable whether or not there is an actual distribution of cash or other property. (See more detailed discussion of the rules applicable to distributions made by us at &#147;&#151;&nbsp;<I>Distributions on Unit
Shares or Warrant Shares</I>&#148; below). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Unit Shares or Warrant Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion above under &#147;&#151;<I>&nbsp;Passive Foreign Investment Company Consequences</I>,&#148; a U.S. Holder that receives a
distribution with respect to Unit Shares or Warrant Shares generally will be required to include the gross amount of such distribution in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#146;s pro
rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#146;s pro rata
share of our current and accumulated earnings and profits, it will be treated first as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#146;s Unit Shares
or Warrant Shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#146;s Unit Shares or Warrant Shares, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in
accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. Distributions on Unit Shares or Warrant Shares that are treated as dividends generally will constitute income from
sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Such dividends will not be eligible for the &#147;dividends received&#148; deduction generally allowed to corporate shareholders
with respect to dividends received from U.S. corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid by a &#147;qualified foreign corporation&#148; are eligible for taxation at a
reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable
year (see discussion above under &#147;&#151;<I>&nbsp;Passive Foreign Investment Company Consequences</I>&#148;), we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not
apply. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-United</FONT> States corporation (other than a corporation that is
classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with
the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b)&nbsp;with respect to any dividend it pays on common
shares that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Canada for purposes of, and are eligible for the benefits of, the U.S.-Canada Treaty, although there can be no
assurance in this regard. Further, the IRS has determined that the U.S.-Canada Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion above
under &#147;&#151;&nbsp;<I>Passive Foreign Investment Company Consequences</I>,&#148; if the U.S.-Canada Treaty is applicable, such dividends will generally be &#147;qualified dividend income&#148; in the hands of individual U.S. Holders, provided
that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale, Exchange
or Other Disposition of Unit Shares or Warrant Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion above under &#147;&#151;<I>&nbsp;Passive Foreign Investment Company
Consequences</I>,&#148; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of Unit Shares or Warrant Shares in an amount equal to the difference, if any,
between the amount realized (i.e.,&nbsp;the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holder&#146;s adjusted tax basis in the Unit Shares or Warrant Shares. Such
capital gain or loss generally will be long-term capital gain taxable at a reduced rate for <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the Unit
Shares or Warrant Shares were held by the U.S. Holder for more than one year. Any capital gain of a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The
deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of Unit Shares or Warrant Shares will generally be gain or loss from sources within the United States for U.S. foreign tax
credit purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Medicare Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders
that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the
disposition of Units, Warrants, Unit Shares or Warrant Shares. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income
and gains in respect of your investment in Units, Warrants, Unit Shares or Warrant Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in Units, Warrants, Unit Shares or
Warrant Shares, including, among others, IRS Form&nbsp;8938 (Statement of Specified Foreign Financial Assets). As described above under &#147;<I>Passive Foreign Investment Company Consequences</I>&#148;, each U.S. Holder who is a shareholder of a
PFIC must file an annual report containing certain information. U.S. Holders paying more than US$100,000 for Units may be required to file IRS Form&nbsp;926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment.
Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends on and proceeds from the
sale or other disposition of Units, Warrants, Unit Shares or Warrant Shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder
(1)&nbsp;fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption, or (2)&nbsp;is described in certain other categories of persons. However, U.S. Holders that are corporations generally
are excluded from these information reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a
U.S. Holder&#146;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S.
Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR IS URGED
TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN UNITS, WARRANTS, UNIT SHARES OR WARRANT SHARES IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_18"></A>AGENT FOR SERVICE OF PROCESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles A. Rowland, Jr., the President and Chief Executive Officer and a director of Aurinia Pharmaceuticals Inc., and Gregory Ayers, Hyuek Joon Lee, David
Jayne and Lorin Jeffry Randall, each a director of Aurinia Pharmaceuticals Inc., reside outside of Canada and have appointed an agent for service of process in Canada, as set out in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:54.20pt; font-size:8pt; font-family:Times New Roman"><B>Name of Person</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:96.00pt; font-size:8pt; font-family:Times New Roman"><B>Name and Address of Agent</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles A. Rowland, Jr., Gregory Ayers,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hyuek Joon Lee, David Jayne and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lorin Jeffry Randall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borden Ladner Gervais LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1200 Waterfront
Centre</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Burrard Street, P.O. Box 48600</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vancouver, British
Columbia, Canada V7X 1T2</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Stephen P. Robertson</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchasers are advised that it may not be possible for investors to enforce judgments obtained in Canada against any person or
company that is incorporated, continued or otherwise organized under the laws of a foreign jurisdiction or resides outside of Canada, even if the party has appointed an agent for service of process </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_19"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> under the U.S. Securities Act of 1933, as amended,
relating to the offering of our securities, of which this prospectus supplement forms a part. This prospectus supplement does not contain all of the information set forth in the registration statement, certain parts of which are omitted in
accordance with the rules and regulations of the SEC. Reference is made to such registration statement and the exhibits thereto for further information with respect to us and the common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to file with the various securities commissions or similar authorities in each of the applicable provinces and territories of Canada, annual
and quarterly reports, material change reports and other information. We are also an SEC registrant subject to the informational requirements of the U.S. Securities Exchange Act of 1934, as amended, and, accordingly, file with, or furnish to, the
SEC certain reports and other information. Under the multi-jurisdictional disclosure system adopted by the United States and Canada, these reports and other information (including financial information) may be prepared in accordance with the
disclosure requirements of Canada, which differ from those in the United States. You may read and copy any document we file with or furnish to the SEC at the SEC&#146;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549.
You may also obtain copies of the same documents from the public reference room by paying a fee. Please call the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> or contact them at www.sec.gov for further information on the public reference room and copying charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_20"></A>ENFORCEABILITY OF CERTAIN CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a corporation incorporated and existing under the laws of the Province of Alberta. Most of our officers and directors and some of the experts named in
this prospectus supplement are not residents of the United States, and many of our assets and all or a substantial portion of assets of such persons are located outside of the United&nbsp;States. We have appointed CT Corporation System as our agent
for service of process in the United States. We have also filed with the SEC, concurrently with the registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> relating to the accompanying prospectus, an appointment of agent for
service of process on Form <FONT STYLE="white-space:nowrap">F-X.</FONT> Under the Form <FONT STYLE="white-space:nowrap">F-X,</FONT> we appointed CT Corporation System as our agent for service of process in the United States in connection with any
investigation or administrative proceeding conducted by the SEC and any civil suit or action brought against or involving us in a United States court arising out of or related to or concerning the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, it may be difficult for United States investors to effect service of process within the United States upon those officers or directors who are not
residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon Aurinia Pharmaceuticals&#146; civil liability and the civil liability of such officers or directors under United States
federal securities laws or the securities or &#147;blue sky&#148; laws of any state within the United States. We have been advised by our Canadian counsel, Borden Ladner Gervais LLP, that, subject to certain limitations, a judgment of a United
States court predicated solely upon civil liability under United States federal securities laws may be enforceable in Canada if the United States court in which the judgment was obtained has a basis for jurisdiction in the matter that would be
recognized by a Canadian court for the same purposes. Aurinia Pharmaceuticals has also been advised by Borden Ladner Gervais LLP, however, that there is substantial doubt whether an action could be brought in Canada in the first instance on the
basis of liability predicated solely upon United States federal securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters in connection with the Offering will be passed upon on our behalf by Borden Ladner Gervais LLP with respect to Canadian legal matters
and by Cooley LLP, Palo Alto, California with respect to U.S. legal matters and on behalf of the Underwriters by Stikeman Elliott LLP with respect to Canadian legal matters and by Goodwin Procter LLP, with respect to U.S. legal matters. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_22"></A>INTEREST OF EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The partners and associates of Borden Ladner Gervais LLP (Canadian counsel for Aurinia Pharmaceuticals), as a group, beneficially own, directly or indirectly,
less than one percent of the outstanding securities of Aurinia Pharmaceuticals. The partners and associates of Stikeman Elliott LLP (Canadian counsel for the Underwriters), as a group, beneficially own, directly or indirectly, less than one percent
of the outstanding securities of Aurinia Pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers LLP, our auditor, issued an auditor&#146;s report dated March&nbsp;18,
2016 in respect of our consolidated financial statements, which comprise the consolidated statements of financial position as at December&nbsp;31, 2015 and December&nbsp;31, 2014, and the consolidated statements of operations and comprehensive loss,
consolidated statements of changes in shareholders&#146; equity (deficit) and cash flows for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2014, and the related notes. PricewaterhouseCoopers LLP has advised us that they are
independent with respect to Aurinia Pharmaceuticals Inc. within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Alberta and the rules of the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_23"></A>STATUTORY RIGHTS OF WITHDRAWAL AND RESCISSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain of the provinces of Canada provides purchasers with the right to withdraw from an agreement to purchase securities. This
right may be exercised within two business days after receipt or deemed receipt of a prospectus or a prospectus supplement relating to the securities purchased by a purchaser and any amendments thereto, irrespective of the determination at a later
date of the purchase price of the securities being distributed. In several of the provinces, the securities legislation further provides a purchaser with remedies for rescission or, in some jurisdictions, revision of the price or damages if the
prospectus or a prospectus supplement relating to the securities purchased by a purchaser and any amendments thereto contain a misrepresentation or is not delivered to the purchaser, provided that the remedies for rescission, revision of the price
or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s
province for the particulars of these rights or consult with a legal adviser. Rights and remedies may also be available to purchasers under U.S. law; purchasers may wish to consult with a U.S. lawyer for particulars of these rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchasers are cautioned that the statutory right of action for damages for a misrepresentation contained in this prospectus supplement, the base shelf
prospectus or any amendment hereto or thereto is limited, in certain provincial securities legislation, to the price at which the Offered Units are offered to the public. This means that, with respect to the Warrants, under the securities
legislation of certain provinces, if the purchaser pays additional amounts upon conversion, exchange or exercise of the security, those amounts may not be recoverable under the statutory right of action for damages that applies in those provinces.
The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province for the particulars of this right of action for damages or consult with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_24"></A>ELIGIBILITY FOR INVESTMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of Borden Ladner Gervais LLP, Canadian legal counsel to Aurinia Pharmaceuticals, and Stikeman Elliott LLP, Canadian legal counsel to the
Underwriters, based on the provisions of the Tax Act, as of the date hereof, the Unit Shares, Warrants and Warrant Shares, if issued on the date hereof, would be &#147;qualified investments&#148; under the Tax Act for trusts governed by a
&#147;registered retirement savings plan&#148; (&#147;<B>RRSP</B>&#148;), &#147;registered retirement income fund&#148; (&#147;<B>RRIF</B>&#148;), &#147;deferred profit sharing plan&#148;, &#147;registered education savings plan&#148;,
&#147;registered disability savings plan&#148;, or <FONT STYLE="white-space:nowrap">&#147;tax-free</FONT> savings account&#148; (&#147;<B>TFSA</B>&#148;), as those terms are defined for the purpose of the Tax Act, provided that (i) the Unit Shares
and Warrant Shares are listed on a &#147;designated stock exchange&#148; as defined in the Tax Act, which currently includes the TSX and NASDAQ, and (ii) in the case of the Warrants, Aurinia Pharmaceuticals is not a &#147;connected person&#148;
under the Plan. For this purpose, a connected person under a Plan is a person who is an annuitant, beneficiary, employer or subscriber under, or a holder of, the Plan and each person who does not deal at arm&#146;s length with that person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Unit Share, Warrant or Warrant Share, that is a qualified investment for an RRSP, RRIF or TFSA (a &#147;<B>Registered Plan</B>&#148;) may nevertheless be a
&#147;prohibited investment&#148; (within the meaning of the Tax Act) for the Registered Plan, in which case the annuitant or holder of the Registered Plan will be subject to penalty taxes set out in the Tax Act. A Unit Share, Warrant or Warrant
Share generally will be a prohibited investment for a Registered Plan if the annuitant or holder of the Registered Plan: (i)&nbsp;does not deal at arm&#146;s length with Aurinia Pharmaceuticals for the purposes of the Tax Act; or (ii)&nbsp;has a
&#147;significant interest&#148; (as defined in the Tax Act for purposes of the prohibited investment rules) in Aurinia Pharmaceuticals. Unit Shares and Warrant Shares generally will not be a prohibited investment for a Registered Plan if such
securities are &#147;excluded property&#148; (as defined in the Tax Act) for trusts governed by a Registered Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any person who intends to hold Unit
Shares, Warrants or Warrant Shares in a Registered Plan should consult his or her own tax advisers regarding the application of these rules to his or her particular circumstances. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_25"></A>CERTIFICATE OF AURINIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;22, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The short form prospectus,
together with the documents incorporated in the prospectus by reference, as supplemented by the foregoing, constitutes full, true and plain disclosure of all material facts relating to the securities offered by the prospectus and this supplement as
required by the securities legislation of British Columbia, Alberta and Ontario. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>(signed) Charles A. Rowland, Jr.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>(signed) Dennis Bourgeault</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Charles A. Rowland, Jr.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Dennis Bourgeault</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">On Behalf of the Board of Directors </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>(signed) Richard Glickman</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>(signed) Gregory Ayers</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Richard Glickman</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Gregory Ayers</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supp309486_26"></A>CERTIFICATE OF THE UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;22, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the best of our knowledge,
information and belief, the short form prospectus, together with the documents incorporated in the prospectus by reference, as supplemented by the foregoing, constitutes full, true and plain disclosure of all material facts relating to the
securities offered by the prospectus and this supplement as required by the securities legislation of British Columbia, Alberta and Ontario. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORMARK SECURITIES INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="54%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>(signed) Marwan Kubursi</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Marwan Kubursi</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No securities regulatory authority has expressed an opinion about these securities and it is an offence to
claim otherwise. This short form prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully for sale and therein only by persons permitted to sell such securities. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission. These securities may not be
offered nor any offers to buy be accepted prior to the time the registration statement becomes effective. This short form prospectus shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Information has been incorporated by reference in this short form prospectus from documents filed with securities commissions or similar
authorities in Canada.</I></B><I> Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of Aurinia Pharmaceuticals Inc. at 1200 Waterfront Centre, 200 Burrard Street, P.O. Box
48600, Vancouver, British Columbia V7X 1T2, Canada, Telephone: (604)&nbsp;632-3473 and are also available electronically at www.sedar.com and www.sec.gov. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHORT FORM BASE SHELF PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>New Issue and Secondary Offering</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>October 16, 2015</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g52n09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>US $250,000,000 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Subscription Receipts </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This short form base shelf
prospectus (the &#147;<B>Prospectus</B>&#148;) relates to the issue and sale from time to time, during the 25-month period that this Prospectus, including any amendments hereto, remains effective, of common shares (&#147;<B>Common Shares</B>&#148;)
in the capital of Aurinia Pharmaceuticals Inc. (&#147;<B>Aurinia</B>&#148; or the &#147;<B>Company</B>&#148;), warrants to purchase Common Shares (&#147;<B>Warrants</B>&#148;) or subscription receipts that entitle the holder to receive upon
satisfaction of certain release conditions, and for no additional consideration, Common Shares (&#147;<B>Subscription Receipts</B>&#148;), (collectively, the &#147;<B>Securities</B>&#148;) or any combination of such Securities in one or more series
or issuances, with a total offering price of such Securities, in the aggregate, of up to US$250,000,000 (or its equivalent in Canadian dollars or any other currency). The securities may be offered by the Company or by the Company&#146;s
securityholders. The securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the sale and set forth in an accompanying prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Shares are listed on the Nasdaq Stock Market, or NASDAQ, under the symbol &#147;AUPH&#148; and on the Toronto Stock Exchange, or TSX, under the
symbol &#147;AUP&#148;. On October 15, 2015, the last trading day prior to the filing of this Prospectus, the closing price of the Common Shares was US$2.93 on NASDAQ and CDN$3.74 on the TSX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information permitted under securities legislation to be omitted from this Prospectus will be contained in one or more prospectus supplements (each, a
&#147;<B>Prospectus Supplement</B>&#148;) that will be delivered to purchasers together with this Prospectus. Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes of
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities legislation as of the date of the Prospectus Supplement and only for the purposes of the distribution of the Securities to which the Prospectus Supplement pertains. You should read
this Prospectus and any applicable Prospectus Supplement carefully before you invest in any Securities issued pursuant to this Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless
otherwise specified in an applicable Prospectus Supplement, the Company&#146;s Warrants and Subscription Receipts will not be listed on any securities or stock exchanges or on any automated dealer quotation system. There is currently no market
through which the Company&#146;s Securities, other than the Common Shares, may be sold and purchasers may not be able to resell such Securities purchased under this Prospectus. This may affect the pricing of the Company&#146;s Securities, other than
the Common Shares, in the secondary market, the transparency and availability of trading prices, the liquidity of these Securities and the extent of issuer regulation. See &#147;Risk Factors&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities may be sold pursuant to this Prospectus through underwriters, dealers or agents designated from time to time or directly by the Company at
amounts and prices and other terms determined by the Company. In connection with any underwritten offering of the Securities, the underwriters may over-allot or effect transactions which stabilize or maintain the market price of the Securities
offered. Such transactions, if commenced, may discontinue at any time. See &#147;Plan of Distribution&#148;. A Prospectus Supplement relating to a particular offering of Securities will set out the names of any underwriters, dealers or agents
involved in the sale of the Securities, the amounts, if any, to be purchased by underwriters, the plan of distribution for such Securities, including the net proceeds the Company expects to receive from the sale of such Securities, if any, the
amounts and prices at which such Securities are to be sold and the compensation of such underwriters, dealers of agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s registered
office is located at #201, 17904 &#150; 105 Avenue, Edmonton, Alberta T5S 2H5, Canada. The Company&#146;s head office is located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8, Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agent for Service of Process </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory
Ayers, Hyuek Joon Lee, David Jayne, Charles Rowland and Stephen Zaruby are directors of the Company and reside outside of Canada. Each of these directors has appointed the following agent for service of process in Canada: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Person</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and Address of Agent</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory Ayers, Hyuek Joon Lee, David Jayne,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Charles Rowland and Stephen Zaruby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borden Ladner Gervais LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1200 Waterfront
Centre</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Burrard Street, P.O. Box 48600</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vancouver, BC V7X
1T2</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention&nbsp;: Stephen P. Robertson</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in the Securities involves a high degree of risk. You should carefully read the &#147;<A HREF="#toc309486_9">Risk Factors</A>&#148; section
beginning on page 8 of this Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company is permitted under a multijurisdictional disclosure system adopted by the securities
regulatory authorities in Canada and the United States to prepare this Prospectus in accordance with the disclosure requirements of Canada. Prospective investors in the United States should be aware that such requirements are different from those of
the United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Owning the Securities may subject you to tax consequences both in Canada and the United States. Such tax consequences are not
described in this Prospectus and may not be fully described in any applicable Prospectus Supplement. You should read the tax discussion in any Prospectus Supplement with respect to a particular offering and consult your own tax advisor with respect
to your own particular circumstances. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your ability to enforce civil liabilities under the U.S. federal securities laws may be affected adversely
because the Company is incorporated under the provincial laws of Alberta, most of the Company&#146;s officers and directors and the experts named in this Prospectus are Canadian residents or residents outside of the United States, and a substantial
portion of the Company&#146;s assets and the assets of its officers, directors and experts are located outside of the United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the
U.S. Securities and Exchange Commission, or SEC, nor any state securities regulator has approved or disapproved the Securities offered hereby or passed upon the accuracy or adequacy of this Prospectus. Any representation to the contrary is a
criminal offence. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No underwriter has been involved in the preparation of this Prospectus or performed any review of the contents of this
Prospectus. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_2">PRESENTATION OF FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_4">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_5">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_6">EXCHANGE RATE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_7">CORPORATE STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_8">SUMMARY DESCRIPTION OF BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_9">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_10">CONSOLIDATED CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_11">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_12">PRIOR SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_13">TRADING PRICE AND VOLUME</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_14">DESCRIPTION OF COMMON SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_15">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_16">DESCRIPTION OF SUBSCRIPTION RECEIPTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_17">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_18">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_19">CERTAIN INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_20">AUDITORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_21">TRANSFER AGENTS AND REGISTRARS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_22">AGENT FOR SERVICE OF PROCESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_23">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_24">WHERE CAN YOU FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_25">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_26">CANADIAN PURCHASER&#146;S STATUTORY AND CONTRACTUAL RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309486_27">CERTIFICATE OF AURINIA PHARMACEUTICALS INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this Prospectus and any applicable Prospectus Supplement and on the other
information included in the registration statement of which this Prospectus forms a part. The Company has not authorized anyone to provide you with different or additional information. If anyone provides you with different or additional information,
you should not rely on it. The Company is not making an offer to sell or seeking an offer to buy the Securities offered pursuant to this Prospectus in any jurisdiction where the offer or sale is not permitted. You should assume that the information
contained in this Prospectus or any applicable Prospectus Supplement is accurate only as of the date on the front of those documents and that information contained in any document incorporated by reference is accurate only as of the date of that
document, regardless of the time of delivery of this Prospectus or any applicable Prospectus Supplement or of any sale of Securities pursuant thereto. The Company&#146;s business, financial condition, results of operations and prospects may have
changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market data and certain industry forecasts used in this Prospectus or any applicable Prospectus Supplement and the documents
incorporated by reference in this Prospectus or any applicable Prospectus Supplement were obtained from market research, publicly available information and industry publications. The Company believes that these sources are generally reliable, but
the accuracy and completeness of this information is not guaranteed. The Company has not independently verified such information, and the Company does not make any representation as to the accuracy of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Prospectus and any Prospectus Supplement, unless otherwise indicated, all dollar amounts and references to &#147;US$&#148; are to U.S. dollars and
references to &#147;CDN$&#148; are to Canadian dollars. This Prospectus and the documents incorporated by reference contain translations of some Canadian dollar amounts into U.S. dollars solely for your convenience. See &#147;Exchange Rate
Information&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Prospectus and in any Prospectus Supplement, unless the context otherwise requires, references to &#147;Aurinia&#148; or the
&#147;Company&#148;, refer to Aurinia Pharmaceuticals Inc., either alone or together with its subsidiaries. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by
the International Accounting Standards Board or IASB. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_3"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement is forward-looking when it uses what the Company knows and expects today to make a statement about the future. Forward-looking statements may
include words such as &#147;<I>anticipate&#148;, &#147;believe&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;goal&#148;, &#147;may&#148;, &#147;outlook&#148;, &#147;plan&#148;, &#147;seek&#148;, &#147;should&#148;, &#147;strive&#148;,
&#147;target&#148;, &#147;could&#148;, &#147;continue&#148;, &#147;potential&#148;</I> and <I>&#147;estimated&#148;</I>, or the negative of such terms or comparable terminology. You should not place undue reliance on the forward-looking statements,
particularly those concerning anticipated events relating to the development, clinical trials, regulatory approval, and marketing of the Company&#146;s product and the timing or magnitude of those events, as they are inherently risky and uncertain.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities laws encourage companies to disclose forward-looking information so that investors can get a better understanding of the Company&#146;s future
prospects and make informed investment decisions. These statements, made either in this Prospectus or a document incorporated by reference in this Prospectus, may include, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans to fund the Company&#146;s operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intended use of the proceeds from the sale of the Securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning strategic alternatives and future operations; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">summary statements relating to results of the past voclosporin trials or plans to advance the development of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">statements concerning partnership activities and health regulatory discussions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of completion of patient enrolment in the Company&#146;s <FONT STYLE="white-space:nowrap">AURA-LV</FONT> and AURION studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of commencement and completion of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approvals in the United States and Europe for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek additional corporate alliances and collaborative agreements to support the commercialization and development of its product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to demonstrate that voclosporin possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation with first-in-class status for the treatment of LN
(&#147;lupus nephritis&#148;) outside of Japan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to use the LN Phase 2b clinical trial program to gain a clearer understanding of voclosporin&#146;s time to onset of action in patients suffering from LN; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that recent granted formulation patents regarding the delivery of voclosporin to the ocular surface for conditions such as dry eye have the potential to be of therapeutic value;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s belief that voclosporin has further potential to be of therapeutic value in other autoimmune indications and in the prevention of transplant rejection; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s intention to seek regulatory approval in other jurisdictions in the future and initiate clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s anticipated future financial position, future revenues and projected costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans and objectives of management. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements reflect the Company&#146;s current views with respect to
future events and are subject to risks and uncertainties and are necessarily based on a number of estimates and assumptions that, while considered reasonable by the Company, as at the date of such statements, are inherently subject to significant
business, economic, competitive, political, scientific and social uncertainties and contingencies, many of which, with respect to future events, are subject to change. The factors and assumptions used by the Company to develop such forward-looking
statements include, but are not limited to: the assumption that the Company will be able to reach agreements with regulatory agencies on executable development programs; the assumption that recruitment to clinical trials will occur as projected; the
assumption that the Company will successfully complete its clinical programs on a timely basis, including the Phase 2b LN clinical trial currently in progress, to enable the Company to proceed to conduct the required Phase 3 LN clinical trials and
meet regulatory requirements for approval of marketing authorization applications and new drug approvals; the assumption the regulatory requirements will be maintained; the assumption that the Company will be able to manufacture and secure a
sufficient supply of voclosporin to successfully complete the development and commercialization of voclosporin; the assumption that the Company&#146;s patent portfolio is sufficient and valid; the assumption that there is a potential commercial
value for other indications for voclosporin; the assumption that market data and reports reviewed by the Company are accurate; the assumption that the Company&#146;s current good relationships with its suppliers, service providers and other third
parties will be maintained; the assumptions relating to the availability of capital on terms that are favourable to the Company; the assumption that the Company will be able to attract and retain skilled staff; the assumption that general business
and economic conditions will be maintained, and the assumptions relating to the feasibility of future clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important to know that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Actual results could be materially different from what the Company expects if known or unknown risks affect its
business, or if the Company&#146;s estimates or assumptions turn out to be inaccurate. As a result, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Company cannot guarantee that any forward-looking statement will materialize and, accordingly, you are cautioned not to place undue reliance on these forward-looking statements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made may have on the Company&#146;s business. For
example, they do not include the effect of mergers, acquisitions, other business combinations or transactions, dispositions, sales of assets, asset write-downs or other charges announced or occurring after the forward-looking statements are made.
The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Accordingly, the expected impact cannot be meaningfully described in the abstract or
presented in the same manner as known risks affecting the Company&#146;s business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company disclaims any intention and assumes no obligation to update any forward-looking statements even if new information becomes available, as a result of future events, new information, or for any other reason
except as required by law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The factors discussed below and other considerations discussed in the &#147;Risk Factors&#148; section of this
Prospectus could cause the Company&#146;s actual results to differ significantly from those contained in any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such
forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company&#146;s actual results, performance, or achievements to differ materially from any further results, performance or achievements
expressed or implied by such forward-looking statements. Important factors that could cause such differences include, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional capital in the longer term to fund the Company&#146;s development programs and the effect of capital market conditions and other factors on capital availability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures the Company may experience in the conduct of and reporting of results of its clinical trials for voclosporin, and in particular its current LN Phase 2b clinical trial;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals for the initiation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays or failures in obtaining regulatory approvals to market voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties the Company may experience in completing the development and commercialization of voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient acceptance of and demand for voclosporin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties, delays, or failures in obtaining appropriate reimbursement of voclosporin; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties that the Company may experience in identifying and successfully securing appropriate corporate alliances to support the development and commercialization of its product. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results,
levels of activity, performance or achievements. These forward-looking statements are made as of the date of this Prospectus or, in the case of documents incorporated by reference in this Prospectus, as of the date of such documents or, in the case
of any Prospectus Supplement, as of the date of such Prospectus Supplement and the Company disclaims any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_4"></A>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information has been incorporated by reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada which
have also been filed with, or furnished to, the United States Securities and Exchange Commission (the &#147;SEC&#148;).</B> Copies of the documents incorporated by reference in this Prospectus and not delivered with this Prospectus may be obtained
on request without charge from the Company&#146;s Corporate Secretary at 1200 Waterfront Centre, 200 Burrard Street, P.O. Box 48600, Vancouver, British Columbia V7X 1T2, Canada, Telephone: (604)&nbsp;632-3473 or by accessing the disclosure documents
through the Internet on the Canadian System for Electronic Analysis and Retrieval, or SEDAR, at www.sedar.com. Documents filed with, or furnished to, the SEC are available through the SEC&#146;s Electronic Data Gathering and Retrieval System, or
EDGAR, at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents, filed with the securities commissions or similar regulatory authorities in British Columbia, Alberta and
Ontario, and filed with, or furnished to, the SEC are specifically incorporated by reference into, and form an integral part of, this Prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the annual information form of the Company dated March&nbsp;26, 2015 for the fiscal year ended December&nbsp;31, 2014 (the &#147;<B>AIF</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">the amended audited consolidated balance sheets of the Company as at December&nbsp;31, 2014 and 2013, and the consolidated statements of operations, changes in shareholders&#146; equity and cash flows for each of the
years in the two-year period ended December&nbsp;31, 2014, including the notes thereto and the auditors&#146; report thereon, as filed on May&nbsp;15, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">the amended Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December&nbsp;31, 2014, as filed on May&nbsp;15, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">the unaudited comparative consolidated interim financial statements of the Company as at and for the period ended March&nbsp;31, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the period ended March&nbsp;31, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">the unaudited comparative consolidated interim financial statements of the Company as at and for the period ended June&nbsp;30, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations for the period ended June&nbsp;30, 2015; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">the management information circular dated April&nbsp;24, 2015 in connection with the annual general meeting of Aurinia&#146;s shareholders held on May&nbsp;26, 2015. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any documents of the type described in Section&nbsp;11.1 of Form 44-101F1 <I>Short Form Prospectuses</I> filed by the Company with a securities commission or
similar authority in any jurisdiction of Canada subsequent to the date of this Prospectus and prior to the expiry of this Prospectus, or the completion of the issuance of Securities pursuant hereto, will be deemed to be incorporated by reference
into this Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the extent that any document or information incorporated by reference into this Prospectus is filed with, or
furnished to, the SEC pursuant to the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), after the date of this Prospectus, such document or information will be deemed to be incorporated by reference as an exhibit to the
registration statement of which this Prospectus forms a part (in the case of a report on Form 6-K, if and to the extent expressly provided therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
Prospectus Supplement containing the specific terms of any offering of the Securities will be delivered to purchasers of such Securities together with this Prospectus and will be deemed to be incorporated by reference in this Prospectus as of the
date of such Prospectus Supplement and only for the purposes of the offering of the Securities to which that Prospectus Supplement pertains. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any statement contained in this Prospectus or in a document incorporated or deemed to be incorporated by
reference in this Prospectus shall be deemed to be modified or superseded, for the purposes of this Prospectus, to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated
by reference herein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or
supersedes. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an
omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon filing a new annual information form and the related annual financial
statements and management&#146;s discussion and analysis with applicable securities regulatory authorities during the currency of this Prospectus, the previous annual information form, the previous annual financial statements and management&#146;s
discussion and analysis and all quarterly financial statements, supplemental information, material change reports and information circulars filed prior to the commencement of the Company&#146;s financial year in which the new annual information form
is filed will be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of the Securities under this Prospectus. Upon interim consolidated financial statements and the accompanying management&#146;s
discussion and analysis being filed by the Company with the applicable securities regulatory authorities during the duration of this Prospectus, all interim consolidated financial statements and the accompanying management&#146;s discussion and
analysis filed prior to the new interim consolidated financial statements shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities under this Prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_5"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents have been or will be filed with the SEC as part of the registration statement of which this Prospectus forms a part: (i)&nbsp;the
documents listed under the heading &#147;Documents Incorporated by Reference&#148;; (ii)&nbsp;powers of attorney from the Company&#146;s directors and officers; and (iii)&nbsp;the consent of PricewaterhouseCoopers LLP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_6"></A>EXCHANGE RATE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth for each period indicated: (i)&nbsp;the noon exchange rates in effect at the end of the period; (ii)&nbsp;the high and low noon
exchange rates during such period; and (iii)&nbsp;the average noon exchange rates for such period, for one Canadian dollar, expressed in U.S. dollars, as quoted by the Bank of Canada. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 15, 2015, the noon exchange rate as quoted by the Bank of Canada was CDN$1.00 = US$0.7750. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_7"></A>CORPORATE STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical stage pharmaceutical company with its registered office located at #201, 17904 &#150; 105 Avenue, Edmonton, Alberta T5S 2H5, Canada.
The Company&#146;s head office is located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8, Canada and incorporates the clinical, regulatory and business development functions of the Company. The office of the Chief Executive Officer
is located in Bellevue, Washington, U.S.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia Pharmaceuticals Inc. is organized under the <I>Business Corporations Act </I>(Alberta). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Common Shares are currently listed and traded on the NASDAQ under the symbol &#147;AUPH&#148; and on the TSX under the symbol
&#147;AUP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following wholly-owned subsidiaries: Aurinia Pharma Corp. (British Columbia incorporated), Aurinia Pharmaceuticals,
Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s By-Law No.&nbsp;2 was amended at a shareholder&#146;s
meeting held on August&nbsp;
15, 2013 to include provisions requiring advance notice for any nominations of directors by shareholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_8"></A>SUMMARY
 DESCRIPTION OF BUSINESS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, which is a next
generation calcineurin inhibitor (&#147;<B>CNI</B>&#148;). It has been studied in kidney rejection following transplantation, psoriasis and in various forms of uveitis (an ophthalmic disease). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has, since September&nbsp;20, 2013, rebranded, restructured and refocused itself around a strategy
that focuses on the development of voclosporin for the treatment of LN. The mechanism of action of voclosporin, a CNI, has been validated with certain first generation CNIs for the prevention of rejection in patients undergoing solid organ
transplants and in several autoimmune indications, including dermatitis, keratoconjunctivitis sicca (Dry Eye Syndrome), psoriasis, rheumatoid arthritis, and for LN in Japan. The Company believes that voclosporin possesses pharmacologic properties
with the potential to demonstrate best-in-class differentiation with first-in-class regulatory approval status for the treatment of LN outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will also continue to evaluate opportunities for other indications of voclosporin to create shareholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2014, the Company completed a private placement with net proceeds of $48.31 million, the net proceeds of which were to be used to advance the
clinical and non-clinical development of its lead drug voclosporin, as a therapy for LN, and for general corporate purposes. A summary of the anticipated and actual use of proceeds up to and including June 30, 2015 from that financing are set out
below (other than working capital): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected use<BR>of proceeds<BR>for period to<BR>June 30, 2015<BR>(in&nbsp;thousands)<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incurred for<BR>period to<BR>June 30, 2015<BR>(in&nbsp;thousands)<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development of voclosporin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other corporate purposes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate, administration, business development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of drug supply loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of financing milestone to ILJIN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period from the date of the private placement to June&nbsp;30, 2015, the actual use of proceeds was slightly less than
the original estimates. This is primarily the result of actual voclosporin Phase&nbsp;2b clinical trial expenditures to date being less than originally estimated due to the difference in timing of these expenditures. There is not expected to be any
significant impact on the Company&#146;s ability to achieve its business objectives and milestones as a result of this variation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_9"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in Securities involves a high degree of risk. In addition to the other information included or incorporated by reference in this Prospectus or
any applicable Prospectus Supplement, you should carefully consider the risks described below before purchasing Securities. If any of the following risks actually occur, the Company&#146;s business, financial condition and results of operations
could materially suffer. As a result, the trading price of Common Shares could decline, and you might lose all or part of your investment. The risks set out below are not the only risks the Company faces; risks and uncertainties not currently known
to the Company or that the Company currently deems to be immaterial may also materially and adversely affect the Company&#146;s business, financial condition and results of operations. You should also refer to the other information set forth or
incorporated by reference in this Prospectus or any applicable Prospectus Supplement, including the Company&#146;s consolidated financial statements and related notes. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Aurinia&#146;s Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical
Trial Progress and Results &#150; Heavy Dependence on Voclosporin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has invested a significant portion of its time and financial
resources in the development of voclosporin. Voclosporin is currently the Company&#146;s only product. The Company anticipates that its ability to generate revenues and meet expectations will depend on the successful development and
commercialization of voclosporin. The successful development and commercialization of voclosporin will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical programs, and in particular, the Phase 2b LN clinical trial currently in progress; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and other regulatory authorities with a commercially viable label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">securing and maintaining partners with sufficient expertise and resources to help in the continuing development and eventual commercialization of voclosporin for autoimmune indications and/or transplant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining suitable manufacturing and supply agreements to ensure commercial quantities of the product through validated processes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance and adoption of the product by the medical community and third-party payors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that
the Company may decide to discontinue the development of voclosporin at any time for commercial, scientific, or regulatory reasons. If voclosporin is developed, but not marketed, the Company will have invested significant resources and its future
operating results and financial conditions would be significantly adversely affected. If the Company is not successful in commercializing voclosporin, or significantly delayed in doing so, its business will be materially harmed and the Company may
need to curtail or cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Goals and Time Frames </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sets goals for, and makes public statements regarding, timing of the accomplishment of objectives material to its success, such as the commencement
and completion of clinical trials, anticipated regulatory approval dates, and time of product launch. The actual timing of these events can vary dramatically due to factors such as delays or failures in clinical trials, the uncertainties inherent in
the regulatory approval process, and delays in achieving product development, manufacturing, or marketing milestones necessary to commercialize its product. There can be no assurance that the Company&#146;s clinical trials will be completed, that
regulatory submissions will be made or receive regulatory approvals as planned, or that the Company will be able to adhere to the current schedule for the validation of manufacturing and launch of its product. If the Company fails to achieve one or
more of these milestones as planned, the price of the Company&#146;s Securities could decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Assurance of Successful Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not completed the development of any therapeutic products and in particular, voclosporin, and therefore there can be no assurance that any
product will be successfully developed. The Company&#146;s therapeutic product has not received regulatory approval for commercial use and sale for any indication, in any jurisdiction. The Company cannot market a pharmaceutical product in any
jurisdiction until it has completed thorough preclinical testing and clinical trials in addition to that jurisdiction&#146;s extensive regulatory approval process. In general, significant research and development and clinical studies are required to
demonstrate the safety and effectiveness of its products before submission of any regulatory applications. The Company may never obtain the required regulatory approvals for its product in any indication. Product candidates require significant
additional research and development efforts, including clinical trials, prior to regulatory approval and potential commercialization, however, there can be no assurance that the results of all required clinical trials will demonstrate that these
product candidates are safe and effective or, even if the results of all required clinical trials do demonstrate that these product candidates are safe and effective, or even if the results of the clinical trials are considered successful by the
Company, that the regulatory authorities will not require the Company to conduct additional clinical trials before they will consider approving such product candidates for commercial use. Approval or consent by regulatory authorities to commence a
clinical trial does not indicate that the device, drug, or treatment being studied can or will be approved. Preparing, submitting, and advancing applications for regulatory approval is complex, expensive, time intensive and entails significant
uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the Company&#146;s completed preclinical studies and clinical trials may not be indicative of future clinical trial results.
A commitment of substantial resources to conduct time-consuming research, preclinical studies, and clinical trials will be required if the Company is to complete the development of its product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that unacceptable toxicities or adverse side effects will not occur at any time in the course of preclinical studies or human
clinical trials or, if any products are successfully developed and approved for marketing, during commercial use of its products. The appearance of any such unacceptable toxicities or adverse side effects could interrupt, limit, delay, or abort the
development of the Company&#146;s product or, if previously approved, necessitate their withdrawal from the market. Furthermore, there can be no assurance that disease resistance or other unforeseen factors will not limit the effectiveness of the
Company&#146;s product. Any products resulting from the Company&#146;s programs are not expected to be successfully developed or made commercially available in the near term and may not be successfully developed or made commercially available at
all. Should the Company&#146;s product prove to have insufficient benefit and/or have an unsafe profile, its development will likely be discontinued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
future performance of the Company will be impacted by a number of important factors, including, in the short-term, its ability to continue to generate cash flow from financings, and in the longer term, its ability to generate royalty or other
revenues from licensed technology and bring new products to the market. The Company&#146;s future success will require efficacy and safety of its product and regulatory approval for the product. Future success of commercialization of any product is
also dependant on the ability of the Company to obtain patents, enforce such patents, avoid patent infringement, and obtain patent extensions where applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company will have significant additional future capital needs and there are uncertainties as to the
Company&#146;s ability to raise additional funding. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will require significant additional capital resources to expand the Company&#146;s
business, in particular the further development of the Company&#146;s product candidate, voclosporin. Advancing the Company&#146;s product candidate, market for the Company&#146;s product, or acquisition and development of any new products or
product candidates will require considerable resources and additional access to capital markets. In addition, the Company&#146;s future cash requirements may vary materially from those now expected. For example, the Company&#146;s future capital
requirements may increase if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company experiences unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either the Company or its competition;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company experiences scientific progress sooner than expected in its discovery, research and development projects, if the Company expands the magnitude and scope of these activities, or if the Company modifies the
Company&#146;s focus as a result of its discoveries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company is required to perform additional pre-clinical studies and clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company elects to develop, acquire or license new technologies, products or businesses. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company could
potentially seek additional funding through corporate collaborations and licensing arrangements or through public or private equity or debt financing. However, if capital market conditions in general, or with respect to life sciences companies such
as the Company, are unfavourable, the Company&#146;s ability to obtain significant additional funding on acceptable terms, if at all, will be negatively affected. Additional financing that the Company may pursue may involve the sale of Common Shares
which could result in significant dilution to the Company&#146;s shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If sufficient capital is not available, the Company may be required to
delay the Company&#146;s research and development projects, which could have a material adverse effect on the Company&#146;s business, financial condition, prospects or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative Cash Flow </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had negative
operating cash flow for the financial year ended December&nbsp;31, 2014. The Company anticipates that it will continue to have negative cash flow as it continues its development of voclosporin. To the extent that the Company has negative operating
cash flow in future periods, it may need to allocate a portion of its cash reserves to fund such negative cash flow. The Company may also be required to raise additional funds through the issuance of equity or debt securities. There can be no
assurance that the Company will be able to generate a positive cash flow from its operations, that additional capital or other types of financing will be available when needed or that these financings will be on terms favourable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents and Proprietary Technology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents and
other proprietary rights are essential to the Company&#146;s business. The Company&#146;s policy has been to file patent applications to protect technology, inventions, and improvements to its inventions that are considered important to the
development of its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s success will depend in part on its ability to obtain patents, defend patents, maintain trade secret
protection and operate without infringing on the proprietary rights of others. Interpretation and evaluation of pharmaceutical patent claims present complex and often novel legal and factual questions. Accordingly, there is some question as to the
extent to which biopharmaceutical discoveries and related products and processes can be effectively protected by patents. As a result, there can be no assurance that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patent applications will result in the issuance of patents; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional proprietary products developed will be patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will provide adequate protection or any competitive advantages; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents issued will not be successfully challenged by third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents issued do not infringe the patents or intellectual property of others; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that the Company will be able to obtain any extensions of the patent term. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of pharmaceutical,
biotechnology, medical device companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to the business of the Company. Some of these
technologies, applications or patents may conflict with or adversely affect the technologies or intellectual property rights of the Company. Any conflicts with the intellectual property of others could limit the scope of the patents, if any, that
the Company may be able to obtain or result in the denial of patent applications altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, there may be uncertainty as to whether the Company
may be able to successfully defend any challenge to its patent portfolio. Moreover, the Company may have to participate in interference proceedings in the various jurisdictions around the world. An unfavorable outcome in an interference or
opposition proceeding could preclude the Company or its collaborators or licensees from making, using or selling products using the technology, or require the Company to obtain license rights from third parties. It is not known whether any
prevailing party would offer a license on commercially acceptable terms, if at all. Further, any such license could require the expenditure of substantial time and resources and could harm the business of the Company. If such licenses are not
available, the Company could encounter delays or prohibition of the development or introduction of the product of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials for
the Company&#146;s product candidates are expensive and time-consuming, and their outcome is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the Company can obtain regulatory
approval for the commercial sale of any product candidate currently under development, the Company is required to complete extensive clinical trials to demonstrate its safety and efficacy. Clinical trials are very expensive and difficult to design
and implement. The clinical trial process is also time-consuming. If the Company finds a collaboration partner for the development of voclosporin, the clinical trials are expected to continue for several years, although costs associated with
voclosporin may well be shared with the Company&#146;s collaboration partner. The timing of the commencement, continuation and completion of clinical trials may be subject to significant delays relating to various causes, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s inability to find collaboration partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s inability to manufacture or obtain sufficient quantities of materials for use in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining regulatory approvals to commence a study, or government intervention to suspend or terminate a study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays, suspension, or termination of the clinical trials imposed by the institutional review board or independent ethics board responsible for overseeing the study to protect research subjects at a particular study
site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment and enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertain dosing issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of medical investigators to follow the Company&#146;s clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variability in the number and types of subjects available for each study and resulting difficulties in identifying and enrolling subjects who meet trial eligibility criteria; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scheduling conflicts with participating clinicians and clinical institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in maintaining contact with subjects after treatment, which results in incomplete data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of efficacy during the clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s reliance on clinical research organizations to conduct clinical trials, which may not conduct those trials with good clinical or laboratory practices; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other regulatory delays. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of pre-clinical studies and initial clinical trials are not
necessarily predictive of future results, and the Company&#146;s current product candidate may not have favourable results in later trials or in the commercial setting. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pre-clinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to
understand the side effects of product candidates at various doses and schedules. Success in pre-clinical or animal studies and early clinical trials does not ensure that later large scale efficacy trials will be successful nor does it predict final
results. Favourable results in early trials may not be repeated in later trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of companies in the life sciences industry have suffered
significant setbacks in advanced clinical trials, even after positive results in earlier trials. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Negative or inconclusive
results or adverse medical events during a clinical trial could cause a clinical trial to be delayed, repeated or terminated. In addition, failure to construct appropriate clinical trial protocols could result in the test or control group
experiencing a disproportionate number of adverse events and could cause a clinical trial to be repeated or terminated. Pre-clinical data and the clinical results the Company has obtained for voclosporin may not predict results from studies in
larger numbers of subjects drawn from more diverse populations or in a commercial setting, and also may not predict the ability of the Company&#146;s product to achieve its intended goals, or to do so safely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will be required to demonstrate through larger-scale clinical trials that voclosporin is safe and effective for use in a diverse population before
the Company can seek regulatory approvals for its commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical and post-approval trials. If voclosporin fails to
demonstrate sufficient safety and efficacy in ongoing or future clinical trials, the Company could experience potentially significant delays in, or be required to abandon development of, the Company&#146;s product candidate currently under
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company&#146;s industry is subject to health and safety risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company produces a product for human ingestion. While the Company takes substantial precautions such as laboratory and clinical testing, toxicology
studies, quality control and assurance testing and controlled production methods, the associated health and safety risks cannot be eliminated. Products produced by the Company may be found to be, or to contain substances that are harmful to the
health of the Company&#146;s patients and customers and which, in extreme cases, may cause serious health conditions or death. This sort of finding may expose the Company to substantial risk of litigation and liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the Company would be forced to discontinue production of the Company&#146;s product, which would harm the Company&#146;s profitability. Aurinia
maintains product liability insurance coverage; however, there is no guarantee that the Company&#146;s current coverage will be sufficient or that the Company can secure insurance coverage in the future at commercially viable rates or with the
appropriate limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company&#146;s product may not achieve or maintain expected levels of market acceptance, which could
have a material adverse effect on the Company&#146;s business, financial condition and results of operations and could cause the market value of the Company&#146;s Securities to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the Company is able to obtain regulatory approvals for the Company&#146;s product, the success of the product is dependent upon achieving and
maintaining market acceptance. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. Levels of market acceptance for the Company&#146;s product could be impacted
by several factors, many of which are not within the Company&#146;s control, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety, efficacy, convenience and cost-effectiveness of the Company&#146;s product compared to products of the Company&#146;s competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scope of approved uses and marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market approvals and market entry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in, or excessive costs to, manufacture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infringement or alleged infringement of the patents or intellectual property rights of others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative products from the Company&#146;s competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the price of the Company&#146;s product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to market the Company&#146;s product effectively at the retail level. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, by the time any
products are ready to be commercialized, what the Company believes to be the market for these products may have changed. The Company&#146;s estimates of the number of patients who have received or might have been candidates to use a specific product
may not accurately reflect the true market or market prices for such products or the extent to which such products, if successfully developed, will actually be used by patients. The Company&#146;s failure to successfully introduce and market its
product that are under development would have a material adverse effect on its business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
Company is dependent upon the Company&#146;s key personnel to achieve the Company&#146;s business objectives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a technology-driven company,
intellectual input from key management and personnel is critical to achieve the Company&#146;s business objectives. Consequently, the Company&#146;s ability to retain these individuals and attract other qualified individuals is critical to the
Company&#146;s success. The loss of the services of key individuals might significantly delay or prevent achievement of the Company&#146;s business objectives. In addition, because of a relative scarcity of individuals with the high degree of
education and scientific achievement required for the Company&#146;s business, competition among life sciences companies for qualified employees is intense and, as a result, the Company may not be able to attract and retain such individuals on
acceptable terms, or at all. In addition, because the Company does not maintain &#147;key person&#148; life insurance on any of the Company&#146;s officers, employees, or consultants, any delay in replacing such persons, or an inability to replace
them with persons of similar expertise, would have a material adverse effect on the Company&#146;s business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has relationships with scientific collaborators at academic and other institutions, some of whom conduct research at the Company&#146;s
request or assist the Company in formulating its research and development strategies. These scientific collaborators are not the Company&#146;s employees and may have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to the Company. In addition, even though the Company&#146;s collaborators are required to sign confidentiality agreements prior to working with the Company, they may have arrangements with other companies to assist such
other companies in developing technologies that may prove competitive to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incentive provisions for the Company&#146;s key executives include the granting of stock options that vest over
time, designed to encourage such individuals to stay with the Company. However, a low share price, whether as a result of disappointing progress in the Company&#146;s development programs or as a result of market conditions generally, could render
such agreements of little value to the Company&#146;s key executives. In such event, the Company&#146;s key executives could be susceptible to being hired away by the Company&#146;s competitors who could offer a better compensation package. If the
Company is unable to attract and retain key personnel the Company&#146;s business, financial conditions and results of operations may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company is exposed to risks relating to the write-down of intangible assets, which comprises a significant portion of the Company&#146;s total
assets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant amount of the Company&#146;s total assets relate to the Company&#146;s intellectual property. As of June&nbsp;30, 2015, the
carrying value of the Company&#146;s intangible assets was approximately US$17.8 million. In accordance with IFRS, the Company is required to review the carrying value of the Company&#146;s intangible assets for impairment periodically or when
certain triggers occur. Such impairment will result in a write-down of the intangible asset and the write-down is charged to income during the period in which the impairment occurs. The write-down of any intangible assets could have a material
adverse effect on the Company&#146;s business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Company were to lose the Company&#146;s
foreign private issuer status under U.S. federal securities laws, the Company would likely incur additional expenses associated with compliance with the U.S. securities laws applicable to U.S. domestic issuers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, as defined in Rule 3b-4 under the Exchange Act, the Company is exempt from certain of the provisions of the U.S. federal
securities laws. For example, the U.S. proxy rules and the Section&nbsp;16 reporting and &#147;short swing&#148; profit rules do not apply to foreign private issuers. However, if the Company were to lose the Company&#146;s status as a foreign
private issuer, these regulations would immediately apply and the Company would also be required to commence reporting on forms required of U.S. companies, such as Forms 10-K, 10-Q and 8-K, rather than the forms currently available to the Company,
such as Forms 40-F and 6-K. Compliance with these additional disclosure and timing requirements under these securities laws would likely result in increased expenses and would require the Company&#146;s management to devote substantial time and
resources to comply with new regulatory requirements. Further, to the extent that the Company was to offer or sell the Company&#146;s Securities outside of the United States, the Company would have to comply with the more restrictive Regulation S
requirements that apply to U.S. companies, and the Company would no longer be able to utilize the multijurisdictional disclosure system forms for registered offerings by Canadian companies in the United States, which could limit the Company&#146;s
ability to access the capital markets in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative actions, potential new accounting pronouncements, and higher insurance costs are
likely to impact the Company&#146;s future financial position or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future changes in financial accounting standards may cause
adverse, unexpected revenue fluctuations and affect the Company&#146;s financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with greater frequency and are expected to occur in
the future. Compliance with changing regulations of corporate governance and public disclosure may result in additional expenses. All of these uncertainties are leading generally toward increasing insurance costs, which may adversely affect the
Company&#146;s business, results of operations and the Company&#146;s ability to purchase any such insurance, at acceptable rates or at all, in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company relies on third parties for the supply and manufacture of voclosporin, which can be unpredictable in terms of quality, cost and
availability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s drug, voclosporin, requires a specialized manufacturing process. Lonza Ltd. is currently the sole source
manufacturer of voclosporin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities require that drugs be manufactured in accordance with the current good
manufacturing practices regulations, as established from time to time. Accordingly, in the event the Company receives marketing approvals for voclosporin, it may need to rely on a limited number of third parties to manufacture and formulate
voclosporin. The Company may not be able to arrange for its product to be manufactured on reasonable terms or in sufficient quantities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers of
pharmaceutical products often encounter difficulties in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, stability, quality control and assurance, and shortages of
qualified personnel, as well as compliance with strictly enforced federal, provincial and foreign regulations. The Company relies on a limited number of third parties to manufacture and supply raw materials for its product. The third parties the
Company chooses to manufacture and supply raw materials for its product are not under its control, and may not perform as agreed or may terminate their agreements with the Company, and the Company may not be able to find other third parties to
manufacture and supply raw materials on commercially reasonable terms, or at all. If either of these events were to occur, the Company&#146;s operating results and financial condition would be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, drug and chemical manufacturers are subject to various regulatory inspections, including those conducted by the FDA, to ensure strict compliance
with good manufacturing practices (&#147;GMP&#148;) and other government regulations. While the Company is obligated to audit the performance of the Company&#146;s third-party contractors, the Company does not have complete control over their
compliance. The Company could be adversely impacted if the Company&#146;s third-party manufacturers do not comply with these standards and regulations. For non-compliance, the regulatory authority may levy penalties and sanctions, including fines,
injunctions, civil penalties, failure of the government to grant review of submissions or market approval of drugs, or cause delays, suspension or withdrawal of approvals, product seizures or recalls, operating restrictions, facility closures and
criminal prosecutions. Any of this will have a material adverse impact on the Company&#146;s business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anticipated Revenues may be derived from Licensing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company anticipates that its revenues in the future may be derived from products licensed to pharmaceutical and biotechnology companies. Accordingly, these
revenues will depend, in large part, upon the success of these companies, and the Company&#146;s operating results may fluctuate substantially due to reductions and delays in their research, development and marketing expenditures. These reductions
and delays may result from factors that are not within the Company&#146;s control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the regulatory environment, including governmental pricing controls affecting health care and health care providers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing pressures; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors affecting research and development spending. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of Operating Profits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and anticipates that its losses will increase as it continues its development and clinical trials and seeks regulatory approval
for the sale of its therapeutic product. There can be no assurance that it will have earnings or positive cash flow in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at June&nbsp;30,
2015, the Company had an accumulated deficit of $248.48 million. The net operating losses over the near-term and the next several years are expected to continue as a result of initiating new clinical trials and activities necessary to support
regulatory approval and commercialization of its product. There can be no assurance that the Company will be able to generate sufficient product revenue to become profitable at all or on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sustained basis. The Company expects to have quarter-to-quarter fluctuations in expenses, some of which could be significant, due to research, development, and clinical trial activities, as well
as regulatory and commercialization activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company&#146;s business depends heavily on the use of information technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Several key areas of the Company&#146;s business depend on the use of information technologies, including production, manufacturing and logistics, as well as
clinical and regulatory matters. Despite the Company&#146;s best efforts to prevent such behavior, third parties may nonetheless attempt to hack into the Company&#146;s systems and obtain data relating to the Company&#146;s pre-clinical studies,
clinical trials, patients using the Company&#146;s product or the Company&#146;s proprietary information on voclosporin. If the Company fails to maintain or protect the Company&#146;s information systems and data integrity effectively, the Company
could lose existing customers, have difficulty attracting new customers, have problems in determining product cost estimates and establishing appropriate pricing, have difficulty preventing, detecting, and controlling fraud, have disputes with
customers, physicians, and other health care professionals, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse
consequences. While the Company has invested in the protection of data and information technology, there can be no assurance that the Company&#146;s efforts or those of the Company&#146;s third-party collaborators, if any, or manufacturers, to
implement adequate security and quality measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being stolen or corrupted in the event of a security
breach. Any such loss or breach could have a material adverse effect on the Company&#146;s business, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competition and Technological Change </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The industry
in which the Company operates is highly competitive and the Company has numerous domestic and foreign competitors, including major pharmaceutical and chemical companies, specialized biotechnology companies, universities, academic institutions,
government agencies, public and private research organizations and large, fully-integrated pharmaceutical companies which have extensive resources and experience in research and development, process development, clinical evaluation, manufacturing,
regulatory affairs, distribution and marketing. Many of the Company&#146;s potential competitors possess substantially greater research and development skills, financial, technical and marketing expertise and human resources than the Company, and
may be better equipped to develop, manufacture and market products. There is a risk that new products and technologies may be developed which may be more effective or commercially viable than the product being developed or marketed by the Company,
thus making the Company&#146;s product non-competitive or obsolete. There may also be market resistance to the acceptance of the Company&#146;s new product in any indication and a risk that the product, even though clinically effective, is not
economically viable in the commercial production stage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on Partners </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s strategy and success for the research, development, and commercialization of voclosporin in China, Canada, South Africa and Israel is
dependent upon the Company&#146;s partners performing their respective contractual responsibilities. The Company has partnered with 3SBio, Inc. in China and Paladin Labs Inc. in Canada, South Africa and Israel. The amount and timing of resources
such partners will devote to these activities may not be within the Company&#146;s control. There can be no assurance that its partners will perform their obligations as expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The license, research and development agreements with the partners noted above include indemnification and obligation provisions that are customary in the
industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. These provisions may survive termination of
the underlying agreement. The nature of the potential obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on Other Third Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company depends on third parties for the sourcing of components or for the product itself. Furthermore, as with other pharmaceutical companies, the Company
relies on medical institutions for testing and clinically validating its prospective product. The Company does not anticipate any difficulties in obtaining required components or products or any difficulties in the validation and clinical testing of
its product but there is no guarantee that they will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently relies on contract research organizations (&#147;CROs&#148;) for
the conduct of its clinical trials. These CROs operate in accordance with good clinical management practices mandated by the regulatory authorities and are subject to regular audits by regulatory authorities and by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has arrangements for the encapsulation, packaging and labeling of voclosporin through a third party supplier. Contract manufacturers must
operate in compliance with regulatory requirements. Failure to do so could result in, among other things, the disruption of product supplies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing and Distribution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
limited experience in the sales, marketing, and distribution of pharmaceutical products. There can be no assurance that the Company will be able to establish sales, marketing, and distribution capabilities or make arrangements through
collaborations, licensees, or others to perform such activities, or that such efforts would be successful. If the Company decides to market its product directly, the Company must either acquire or internally develop a marketing and sales force with
technical expertise and provide supporting distribution capabilities. The acquisition or development of a sales and distribution infrastructure would require substantial resources, which may divert the attention of management and key personnel, and
have a negative impact on product development. If the Company contracts with third parties for the sales and marketing of its product, the Company&#146;s revenue will be dependent on the efforts of these third parties, whose efforts may not be
successful. If the Company fails to establish successful marketing and sales capabilities or to make arrangements with third parties, the business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Health Care Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both domestic and
foreign markets, sales of the Company&#146;s product, if any, will be dependent in part on the availability of reimbursement from third party payors, such as government and private insurance plans. Third party payors are increasingly challenging the
prices charged for medical products and services. There can be no assurance that the Company&#146;s product will be considered cost effective by these third party payors, that reimbursement will be available or if available that the payor&#146;s
reimbursement policies will not adversely affect the Company&#146;s ability to sell its product on a profitable basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The production and marketing of the Company&#146;s product and its ongoing research and development activities are subject to regulation by
numerous federal, provincial, state and local governmental authorities in Canada, the United States and any other countries where the Company may test or market its product. These laws require the approval of manufacturing facilities, including
adhering to &#147;good manufacturing&#148; and/or &#147;good laboratory&#148; practices during production and storage, the controlled research and testing of products, governmental review and approval of submissions requiring manufacturing,
pre-clinical and clinical data to establish the safety and efficacy of the product for each use sought in order to obtain marketing approval, and the control of marketing activities, including advertising and labeling. The process of obtaining
required approvals (such as, but not limited to, the approval of the FDA in the United States, the European Medicines Agency and Health Canada) can be costly and time consuming and there can be no assurance that future products will be successfully
developed, proven safe and effective in clinical trials or receive applicable regulatory approvals. Potential investors should be aware of the risks, problems, delays, expenses and difficulties which may be encountered by the Company in view of the
extensive regulatory environment which controls its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there can be no assurance that the Company will be able to achieve or maintain regulatory compliance
with respect to all or any part of its current or future products or that the Company will be able to timely and profitably produce its product while complying with applicable regulatory requirements. If the Company fails to maintain compliance,
regulatory authorities may not allow the continuation of the drug development programs, or require the Company to make substantial changes to the drug. Any such actions could have a material adverse effect on the business, financial condition, and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unauthorized Disclosure of Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be an unauthorized disclosure of the significant amount of confidential information under the Company&#146;s control. The Company maintains and
manages confidential information relating to its technology, research and development, production, marketing and business operations and those of its collaborators, in various forms. Although the Company has implemented controls to protect the
confidentiality of such information, there can be no assurance that such controls will be effective. Unauthorized disclosures of such information could subject the Company to complaints or lawsuits for damages or could otherwise have a negative
impact on its business, financial condition, results of operations, reputation and credibility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Hazardous Materials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug manufacturing processes involve the controlled use of hazardous materials. The Company and its third party manufacturing contractors are subject to
regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although the Company believes that its third party manufacturers have the required safety procedures for handling and disposing
of such materials and comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held
liable for any damages that result and such liability could exceed the Company&#146;s resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is currently no market through which the Company&#146;s Securities, other than the Common Shares, may be sold. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in an applicable Prospectus Supplement, the Company&#146;s Warrants and Subscription Receipts will not be listed on any securities
or stock exchanges or on any automated dealer quotation system. There is currently no market through which the Company&#146;s Securities, other than the Common Shares, may be sold and purchasers may not be able to resell such Securities purchased
under this Prospectus. This may affect the pricing of the Company&#146;s Securities, other than the Common Shares, in the secondary market, the transparency and availability of trading prices, the liquidity of these Securities and the extent of
issuer regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Volatility of Share Price </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market prices for the securities of biotechnology companies, including the Company, have historically been volatile. The market has from time to time
experienced significant price and volume fluctuations that are unrelated to the operating performance of any particular company. For example, since January&nbsp;1, 2015, the closing price of the Company&#146;s Common Shares on the TSX has ranged
from a low of CDN$3.74 to a high of CDN$6.65 and the closing price of the Common Shares on NASDAQ has ranged from a low of US$2.79 to a high of US$5.30. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of the Company&#146;s Common Shares could continue to be subject to wide fluctuations in price in response to various factors, many of which
are beyond the Company&#146;s control, including the results and adequacy of the Company&#146;s preclinical studies and clinical trials, as well as those of its collaborators, or its competitors; other evidence of the safety or effectiveness of the
Company&#146;s product or those of its competitors; announcements of technological innovations or new products by the Company or its competitors; governmental regulatory actions; developments with collaborators; developments (including litigation)
concerning patent or other proprietary rights of the Company or competitors; concern as to the safety of the Company&#146;s product; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period-to-period fluctuations in operating results; changes in estimates of the Company&#146;s performance by securities analysts; market conditions for biotechnology stocks in general; and other
factors not within the control of the Company could have a significant adverse impact on the market price of the Company&#146;s Securities, regardless of its operating performance. In the past, following periods of volatility in the market price of
a company&#146;s securities, securities class action litigation has often been instituted. A class action suit against the Company could result in substantial costs, potential liabilities and the diversion of management&#146;s attention and
resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that an active trading market for the Company&#146;s Common Shares will be maintained on the TSX and /or NASDAQ.
Investors may not be able to sell their shares quickly or at the latest market price if the trading in the Company&#146;s Common Shares is not active. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to issue Common Shares in the future. Holders of stock options and warrants may elect to exercise their options or warrants into Common
Shares depending on the stock price. Future issuances of Common Shares, or the perception that such issuances are likely to occur, could affect the prevailing trading prices of the Common Shares. Future issuances of the Company&#146;s Common Shares
could result in substantial dilution to its shareholders. In addition, the existence of Warrants may encourage short selling by market participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of Common Shares could cause a decline in the market price of the Company&#146;s Common Shares. Two of the Company&#146;s major shareholders (venBio and
ILJIN) own an aggregate of approximately 30% of the Company&#146;s outstanding Common Shares as at October 16, 2015. Any sales of Common Shares by these shareholders or other existing shareholders or holders of options may have an adverse effect on
the Company&#146;s ability to raise capital and may adversely affect the market price of its Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of equity securities
by the Company or sales by the Company&#146;s existing shareholders may cause the price of the Common Shares to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of the
Common Shares could decline as a result of issuances of Securities by the Company or sales by the Company&#146;s existing shareholders in the market, or the perception that these sales could occur, during the currency of this Prospectus. Sales of
Common Shares by shareholders might also make it more difficult for the Company to sell Common Shares at a time and price that the Company deems appropriate. With an additional sale or issuance of Common Shares, investors will suffer dilution of
their voting power and may experience dilution in earnings per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company will have broad discretion in the use of the net proceeds of an
offering of the Securities and may not use them to effectively manage the Company&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will have broad discretion over the
use of the net proceeds from an offering of Securities. Because of the number and variability of factors that will determine the Company&#146;s use of such proceeds, the Company&#146;s ultimate use might vary substantially from the Company&#146;s
planned use. Investors may not agree with how the Company allocates or spends the proceeds from an offering of Common Shares. The Company may pursue acquisitions, collaborations or clinical trials that do not result in an increase in the market
value of the Common Shares, and may increase the Company&#146;s losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company does not intend to pay dividends in the foreseeable future.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has never declared or paid any dividends on the Common Shares. The Company intends, for the foreseeable future, to retain its future
earnings, if any, to finance its commercial activities and further research and the expansion of its business. As a result, the return on an investment in Common Shares will likely depend upon any future appreciation in value, if any, and on a
shareholder&#146;s ability to sell Common Shares. The payment of future dividends, if any, will be reviewed periodically by the Company&#146;s board of directors and will depend upon, among other things, conditions then existing including earnings,
financial conditions, cash on hand, financial requirements to fund the Company&#146;s commercial activities, development and growth, and other factors that the Company&#146;s board of directors may consider appropriate in the circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Company may be a passive foreign investment company for U.S. tax purposes, which may result in adverse
tax consequences for U.S. investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors in Common Shares that are U.S. taxpayers should be aware that the Company believes that it was not,
for the financial year ended December&nbsp;31, 2014, a &#147;passive foreign investment company&#148; under Section&nbsp;1297(a) of the U.S. Internal Revenue Code (a &#147;PFIC&#148;). However, there is no certainty that taxation authorities in the
U.S. would agree with the Company&#146;s determination, and there is no certainty that the Company will not be a PFIC at some point in the future. If the Company is determined to be or becomes a PFIC, generally any gain recognized on the sale of the
Common Shares and any &#147;excess distributions&#148; (as specially defined) paid on the Common Shares must be ratably allocated to each day in a U.S. taxpayer&#146;s holding period for the Common Shares. The amount of any such gain or excess
distribution allocated to prior years of such U.S taxpayer&#146;s holding period for the Common Shares generally will be subject to U.S federal income tax at the highest tax applicable to ordinary income in each such prior year, and the U.S.
taxpayer will be required to pay interest on the resulting tax liability for each such prior year, calculated as if such tax liability had been due in each such prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, a U.S. taxpayer that makes a &#147;qualified electing fund&#148; (a &#147;QEF&#148;) election with respect to the Company generally will be
subject to U.S. federal income tax on such U.S. taxpayer&#146;s pro rata share of the Company&#146;s &#147;net capital gain&#148; and &#147;ordinary earnings&#148; (as specifically defined and calculated under U.S. federal income tax rules),
regardless of whether such amounts are actually distributed by the Company. U.S. taxpayers should be aware that there can be no assurance that the Company will satisfy record keeping requirements under the QEF rules or that the Company will supply
U.S. taxpayers with required information under the QEF rules, in the event that the Company is a PFIC and a U.S. taxpayer wishes to make a QEF election. As a second alternative, a U.S. taxpayer may make a &#147;mark-to-market election&#148; if the
Company is a PFIC and the Common Shares are &#147;marketable stock&#148; (as specifically defined). A U.S. taxpayer that makes a mark-to-market election generally will include in gross income, for each taxable year in which the Company is a PFIC, an
amount equal to the excess, if any, of (a)&nbsp;the fair market value of the Common Shares as of the close of such taxable year over (b)&nbsp;such U.S. taxpayer&#146;s adjusted tax basis in the Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above paragraphs contain only a brief summary of certain U.S. federal income tax considerations. Investors should consult their own tax advisor regarding
the PFIC rules and other U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may be unable to
enforce actions against the Company, certain of the Company&#146;s directors and officers, or the experts named in this Prospectus under U.S. federal securities laws. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a corporation organized under the laws of Alberta, Canada. Most of the Company&#146;s directors and officers, as well as the experts named in
this Prospectus, reside principally in Canada or outside of the United States. Because all or a substantial portion of the Company&#146;s assets and the assets of these persons are located outside of the United States, it may not be possible for
investors to effect service of process within the United States upon the Company or those persons. Furthermore, it may not be possible for investors to enforce against the Company or those persons in the United States, judgments obtained in U.S.
courts based upon the civil liability provisions of the U.S. federal securities laws or other laws of the United States. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities based upon U.S. federal
securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities laws. Therefore, it may not be possible to enforce those actions
against the Company, certain of the Company&#146;s directors and officers or the experts named in this Prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_10">
</A>CONSOLIDATED CAPITALIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no material changes in the share and loan capital of the Company, on a consolidated basis, since the
date of the most recently filed unaudited financial statements of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_11"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Company otherwise indicates in a Prospectus Supplement, the Company currently intends to use the net proceeds from the sale of the Securities for
working capital and other general corporate purposes, which includes, but is not limited to, clinical development, regulatory and pre-marketing activities for voclosporin primarily for LN but also potentially for other voclosporin indications and
business development opportunities such as additional product in-licensing transactions. The clinical trial development for voclosporin includes conducting the required Phase 3 clinical program for LN. It is expected that more than 10% of the net
proceeds from any distribution under this Prospectus will be used for research and development. Accordingly, each Prospectus Supplement will include a description of the timing and stage of research and development programs that will be funded by
such proceeds, the major components of such programs (included anticipated costs), a statement of whether the Company is conducting its own research and development, subcontracting for those services or a combination thereof, and the additional
steps required to reach commercial production and an estimate of costs and timing. There may be circumstances where, on the basis of results obtained or for other sound business reasons, a re-allocation of funds may be necessary or prudent.
Accordingly, management of the Company will have broad discretion in the application of the proceeds of an offering of Securities. The Company&#146;s ultimate use might vary substantially from what is stated in this Prospectus or a Prospectus
Supplement and the actual amount that the Company spends in connection with each intended use of proceeds may vary significantly from the amounts specified in the applicable Prospectus Supplement and will depend on a number of factors, including
those referred to under &#147;Risk Factors&#148; and any other factors set forth in the applicable Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of proceeds allocated
to working capital will be used to fund corporate, administration and business development activities in support of the research and development activities undertaken by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had negative cash flow from operating activities for the year ended December&nbsp;31, 2014 as it commenced its Phase 2b trial for LN during 2014
and expects that the proceeds from any distribution under this Prospectus will primarily be used to fund expected negative cash flow from operating activities as the Company continues with its voclosporin clinical development program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More detailed information regarding the use of proceeds from the sale of Securities will be described in any applicable Prospectus Supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_12"></A>PRIOR SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Prospectus Supplement will describe prior sales of the Company as required in a Prospectus Supplement with respect to the issuance of
Securities pursuant to such Prospectus Supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_13"></A>TRADING PRICE AND VOLUME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Shares are listed on the TSX in Canada (trading symbol: AUP) and on NASDAQ in the United States (trading symbol: AUPH). The Common Shares began
trading on the NASDAQ on September&nbsp;2, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the reported high and low prices (in Canadian dollars)
and volume of Common Shares traded for each month on the TSX. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TSX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Month</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Price&nbsp;Range&nbsp;(CDN$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;High&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">557,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 1 to 15, 2015(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">October&nbsp;15, 2015 was the last trading day prior to the date of this Prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth, for the periods indicated, the reported high and low prices (in United States dollars) and the volume of shares traded for each month on NASDAQ. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Month</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price&nbsp;Range&nbsp;(US$)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total&nbsp;Volume</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,895,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">961,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 1 to 15, 2015(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">October 15, 2015 was the last trading day prior to the date of this Prospectus. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_14">
</A>DESCRIPTION OF COMMON SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue an unlimited number of Common Shares, without nominal or par value. As of October
16, 2015, 32,287,419 Common Shares are issued and outstanding. In addition, 5,916,114 Common Shares are reserved for issuance upon exercise of existing warrants and 2,670,192 Common Shares have been reserved for issuance pursuant to outstanding
options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Common Shares are entitled to one (1)&nbsp;vote per share held at meetings of shareholders, to
receive such dividends as declared by the Company and to receive a share of the remaining property and assets of the Company upon dissolution or winding up of the Company. The Common Shares are not subject to any future call or assessment and there
are no pre-emptive, conversion or redemption rights attached to such shares. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_15"></A>DESCRIPTION OF WARRANTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may issue Warrants to purchase Common Shares. The Company may issue Warrants independently or together with other Securities, and
Warrants sold with other Securities may be attached to or separate from the other Securities. Warrants will be issued under and governed by the terms of one or more warrant indentures (each a &#147;<B>Warrant Indenture</B>&#148;) between the Company
and a warrant trustee (the &#147;<B>Warrant Trustee</B>&#148;) that the Company will name in the relevant Prospectus Supplement. Each Warrant Trustee will be a financial institution or trust company organized under the laws of Canada or any province
thereof and authorized to carry on business as a trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary of some of the provisions of the Warrants is not complete. The statements made in
this Prospectus relating to any Warrant Indenture and Warrants to be issued under this Prospectus are summaries of certain anticipated provisions thereof and do not purport to be complete and are subject to, and are qualified in their entirety by
reference to, all provisions of the applicable Warrant Indenture. Prospective investors should refer to the Warrant Indenture relating to the specific Warrants being offered for the complete terms of the Warrants. A copy of the form of Warrant
Indenture will be filed by the Company with the applicable securities regulatory authorities in Canada and the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Prospectus
Supplement relating to any Warrants offered by the Company will describe the particular terms of those Warrants and include specific terms relating to the offering. This description will include, where applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and aggregate number of Warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which the Warrants will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency or currencies in which the Warrants will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the Warrants will commence and the date on which the right will expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Common Shares that may be purchased upon exercise of each Warrant and the price at which and currency or currencies in which the Common Shares may be purchased upon exercise of each Warrant;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of any Securities with which the Warrants will be offered, if any, and the number of the Warrants that will be offered with each Security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on or after which the Warrants and the other Securities with which the Warrants will be offered will be transferable separately; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Warrants will be subject to redemption and, if so, the terms of such redemption provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Company will issue the Warrants as global securities and, if so, the identity of the depositary of the global securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Warrants will be listed on any exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material United States and Canadian federal income tax consequences of owning the Warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material terms or conditions of the Warrants. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights of Holders Prior to Exercise </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the exercise of their Warrants, holders of Warrants will not have any of the rights of holders of the Common Shares issuable upon exercise of the
Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may issue
Warrants in whole or in part in the form of one or more global securities, which will be registered in the name of and be deposited with a depositary, or its nominee, each of which will be identified in the applicable Prospectus Supplement. The
global securities may be in temporary or permanent form. The applicable Prospectus Supplement will describe the terms of any depositary arrangement and the rights and limitations of owners of beneficial interests in any global security. The
applicable Prospectus Supplement also will describe the exchange, registration and transfer rights relating to any global security. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modifications
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Indenture will provide for modifications and alterations to the Warrants issued thereunder by way of a resolution of holders of Warrants
at a meeting of such holders or a consent in writing from such holders. The number of holders of Warrants required to pass such a resolution or execute such a written consent will be specified in the Warrant Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may amend any Warrant Indenture and the Warrants, without the consent of the holders of the Warrants, to cure any ambiguity, to cure, correct or
supplement any defective or inconsistent provision, or in any other manner that will not materially and adversely affect the interests of holders of outstanding Warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_16"></A>DESCRIPTION OF SUBSCRIPTION RECEIPTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may issue Subscription Receipts, which will entitle holders to receive upon satisfaction of certain release conditions and for no additional
consideration, Common Shares, Warrants or any combination thereof. Subscription Receipts will be issued pursuant to one or more subscription receipt agreements (each, a &#147;<B>Subscription Receipt Agreement</B>&#148;), each to be entered into
between the Company and an Escrow Agent (the &#147;<B>Escrow Agent</B>&#148;), which will establish the terms and conditions of the Subscription Receipts. Each Escrow Agent will be a financial institution or trust company organized under the laws of
Canada or a province thereof and authorized to carry on business as a trustee. A copy of the form of Subscription Receipt Agreement will be filed by the Company with the applicable securities regulatory authorities in Canada and the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description sets forth certain general terms and provisions of Subscription Receipts and is not intended to be complete. The statements
made in this Prospectus relating to any Subscription Receipt Agreement and Subscription Receipts to be issued thereunder are summaries of certain anticipated provisions thereof and are subject to, and are qualified in their entirety by reference to,
all provisions of the applicable Subscription Receipt Agreement and the Prospectus Supplement describing such Subscription Receipt Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Prospectus Supplement relating to any Subscription Receipts the Company offers will describe the Subscription Receipts and include specific terms relating to their offering. All such terms will comply with the requirements of the TSX and NASDAQ
relating to Subscription Receipts. If underwriters or agents are used in the sale of Subscription Receipts, one or more of such underwriters or agents may also be parties to the Subscription Receipt Agreement governing the Subscription Receipts sold
to or through such underwriters or agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Prospectus Supplement and the Subscription Receipt Agreement for any Subscription Receipts the Company offers will describe the specific terms of the Subscription Receipts and may include, but are not limited to, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and aggregate number of Subscription Receipts offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which the Subscription Receipts will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency or currencies in which the Subscription Receipts will be offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation, number and terms of the Common Shares, Warrants or combination thereof to be received by holders of Subscription Receipts upon satisfaction of the release conditions, and the procedures that will result
in the adjustment of those numbers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conditions (the &#147;<B>Release Conditions</B>&#148;) that must be met in order for holders of Subscription Receipts to receive for no additional consideration Common Shares, Warrants or a combination thereof;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for the issuance and delivery of Common Shares, Warrants or a combination thereof to holders of Subscription Receipts upon satisfaction of the Release Conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether any payments will be made to holders of Subscription Receipts upon delivery of the Common Shares, Warrants or a combination thereof upon satisfaction of the Release Conditions (e.g., an amount equal to dividends
declared on Common Shares by the Company to holders of record during the period from the date of issuance of the Subscription Receipts to the date of issuance of any Common Shares pursuant to the terms of the Subscription Receipt Agreement);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions under which the Escrow Agent will hold all or a portion of the gross proceeds from the sale of Subscription Receipts, together with interest and income earned thereon (collectively, the
&#147;<B>Escrowed Funds</B>&#148;), pending satisfaction of the Release Conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions pursuant to which the Escrow Agent will hold Common Shares, Warrants or a combination thereof pending satisfaction of the Release Conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions under which the Escrow Agent will release all or a portion of the Escrowed Funds to the Company upon satisfaction of the Release Conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the Subscription Receipts are sold to or through underwriters or agents, the terms and conditions under which the Escrow Agent will release a portion of the Escrowed Funds to such underwriters or agents in payment of
all or a portion of their fees or commission in connection with the sale of the Subscription Receipts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">procedures for the refund by the Escrow Agent to holders of Subscription Receipts of all or a portion of the subscription price for their Subscription Receipts, plus any pro rata entitlement to interest earned or income
generated on such amount, if the Release Conditions are not satisfied; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any contractual right of rescission to be granted to initial purchasers of Subscription Receipts in the event this Prospectus, the Prospectus Supplement under which Subscription Receipts are issued or any amendment
hereto or thereto contains a misrepresentation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any entitlement of the Company to purchase the Subscription Receipts in the open market by private agreement or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Company will issue the Subscription Receipts as global securities and, if so, the identity of the depositary for the global securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Company will issue the Subscription Receipts as bearer securities, registered securities or both; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions as to modification, amendment or variation of the Subscription Receipt Agreement or any rights or terms attaching to the Subscription Receipts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the identity of the Escrow Agent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Subscription Receipts will be listed on any exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material United States and Canadian federal tax consequences of owning the Subscription Receipts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the Subscription Receipts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Subscription Receipts will not be shareholders
of the Company. Holders of Subscription Receipts are entitled only to receive Common Shares, Warrants or a combination thereof on exchange of their Subscription Receipts, plus any cash payments provided for under the Subscription Receipt Agreement,
if the Release Conditions are satisfied. If the Release Conditions are not satisfied, Holders of Subscription Receipts shall be entitled to a refund of all or a portion of the subscription price therefor and all or a portion of the pro rata share of
interest earned or income generated thereon, as provided in the Subscription Receipt Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Escrow </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Escrowed Funds will be held in escrow by the Escrow Agent, and such Escrowed Funds will be released to the Company (and, if the Subscription Receipts are
sold to or through underwriters or agents, a portion of the Escrowed Funds may be released to such underwriters or agents in payment of all or a portion of their fees in connection with the sale of the Subscription Receipts) at the time and under
the terms specified by the Subscription Receipt Agreement. If the Release Conditions are not satisfied, holders of Subscription Receipts will receive a refund of all or a portion of the subscription price for their Subscription Receipts plus their
pro-rata entitlement to interest earned or income generated on such amount, in accordance with the terms of the Subscription Receipt Agreement. Common Shares or Warrants may be held in escrow by the Escrow Agent, and will be released to the holders
of Subscription Receipts following satisfaction of the Release Conditions at the time and under the terms specified in the Subscription Receipt Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rescission </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Subscription Receipt Agreement will also
provide that any misrepresentation in this Prospectus, the Prospectus Supplement under which the Subscription Receipts are offered, or any amendment thereto, will entitle each initial purchaser of Subscription Receipts to a contractual right of
rescission following the issuance of the Common Shares or Warrants to such purchaser entitling such purchaser to receive the amount paid for the Subscription Receipts upon surrender of the Common Shares or Warrants, provided that such remedy for
rescission is exercised in the time stipulated in the Subscription Receipt Agreement. This right of rescission does not extend to holders of Subscription Receipts who acquire such Subscription Receipts from an initial purchaser, on the open market
or otherwise, or to initial purchasers who acquire Subscription Receipts in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may issue Subscription Receipts in whole or in part in the form of one or more global securities, which will be registered in the name of and be
deposited with a depositary, or its nominee, each of which will be identified in the applicable Prospectus Supplement. The global securities may be in temporary or permanent form. The applicable Prospectus Supplement will describe the terms of any
depositary arrangement and the rights and limitations of owners of beneficial interests in any global security. The applicable Prospectus Supplement also will describe the exchange, registration and transfer rights relating to any global security.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modifications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Subscription Receipt Agreement will provide for modifications and alterations to the Subscription Receipts issued thereunder by way of a resolution of
holders of Subscription Receipts at a meeting of such holders or a consent in writing from such holders. The number of holders of Subscriptions Receipts required to pass such a resolution or execute such a written consent will be specified in the
Subscription Receipt Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_17"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common Shares may be sold under this Prospectus by way of a secondary offering by or for the account of certain of the Company&#146;s securityholders. The
Prospectus Supplement that the Company will file in connection with any offering of Common Shares by selling securityholders will include the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the names of the selling securityholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number or amount of Common Shares owned, controlled or directed by each selling securityholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number or amount of Common Shares being distributed for the account of each selling securityholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number or amount of securities of the Company to be owned by the selling securityholders after the distribution and the percentage that number or amount represents of the total number of the Company&#146;s
outstanding securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether Common Shares are owned by the selling securityholders both of record and beneficially, of record only or beneficially only; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the selling securityholder purchased the Common Shares being distributed within two years preceding the date of the Prospectus Supplement, the date or dates the selling securityholder acquired the Common Shares; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the selling securityholder acquired the Common Shares being distributed in the twelve months preceding the date of the Prospectus Supplement, the cost thereof to the selling securityholder in the aggregate and on a
per share basis. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_18"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Issue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may sell the Securities offered by
this Prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through underwriters, dealers, placement agents or other intermediaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to one or more purchasers, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with acquisitions by the Company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Prospectus Supplement will set forth the terms
of the offering of the Securities, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters, dealers or other placement agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of, and form of consideration for, the Securities and the proceeds to the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delayed delivery arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting commissions, fees, discounts, and other items constituting underwriters&#146; compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any offering price; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or re-allowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchanges on which the Securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the underwriters named in a Prospectus
Supplement are deemed to be underwriters in connection with the Securities offered by that Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Securities may be sold, from time
to time in one or more transactions at a fixed price or prices which may be changed or at market prices prevailing at the time of sale, at prices related to such prevailing market price or at negotiated prices, including sales in transactions that
are deemed to be &#147;at the market distributions&#148; as defined in National Instrument 44-102 &#150;<I> Shelf Distributions</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under agreements
which may be entered into by the Company, underwriters, dealers and agents who participate in the distribution of Securities may be entitled to indemnification by the Company against certain liabilities, including liabilities under any applicable
Canadian provincial securities legislation, or to contribution with respect to payments which such underwriters, dealers or agents may be required to make in respect thereof. The underwriters, dealers and agents with whom the Company enters into
agreements may be customers of, engage in transactions with, or perform services for, the Company in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
the offering of the Securities, the underwriters may over-allot or effect transactions which stabilize or maintain the market price of the Securities offered at a level above that which might otherwise prevail in the open market. Such transactions,
if commenced, may be discontinued at any time. A purchaser that acquires Securities forming part of the underwriters&#146; over-allocation position acquires those Securities under this Prospectus, regardless of whether the over-allocation position
is ultimately filled through the exercise of the over-allotment option or secondary market purchases. No underwriter or dealer involved in the distribution, no affiliate of such an underwriter or dealer and no person or company acting jointly or in
concert with such an underwriter or dealer will over-allot Securities or effect any other transactions that are intended to stabilize or maintain the market price of the Securities in connection with any distribution of Securities that is an
&#147;at the market distribution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Secondary Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Prospectus may also, from time to time, relate to the offering of Common Shares by certain selling securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders may sell all or a portion of Common Shares beneficially owned by them and offered hereby from time to time directly or through one
or more underwriters, broker-dealers or agents. If Common Shares are sold through underwriters or broker-dealers, the selling securityholders will be responsible for underwriting discounts or commissions or agent&#146;s commissions. Common Shares
may be sold by the selling securityholders in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in
transactions, which may involve crosses or block transactions, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the over-the-counter market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in transactions otherwise than on these exchanges or systems or in the over-the-counter market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through the writing of options, whether such options are listed on an options exchange or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exchange distribution in accordance with the rules of the applicable exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">privately negotiated transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">short sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales pursuant to Rule 144 under the U.S. Securities Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a combination of any such methods of sale; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other method permitted pursuant to applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the selling securityholders effect such
transactions by selling Common Shares to or through underwriters, broker-dealers or agents, such underwriters, <FONT STYLE="white-space:nowrap">broker-dealers</FONT> or agents may receive commissions in the form of discounts, concessions or
commissions from the selling securityholders or commissions from purchasers of Common Shares for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, <FONT
STYLE="white-space:nowrap">broker-dealers</FONT> or agents may be in excess of those customary in the types of transactions involved). In connection with sales of Common Shares or otherwise, the selling securityholders may enter into hedging
transactions with <FONT STYLE="white-space:nowrap">broker-dealers,</FONT> which may in turn engage in short sales of Common Shares in the course of hedging in positions they assume. The selling securityholders may also sell Common Shares short and
deliver Common Shares covered by this Prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling securityholders may also loan or pledge Common Shares to
<FONT STYLE="white-space:nowrap">broker-dealers</FONT> that in turn may sell such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders may pledge or grant a security
interest in some or all of the Common Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell Common Shares from time to time pursuant to this Prospectus or any
Prospectus Supplement filed under General Instruction II.L. of Form F-10 under the U.S. Securities Act, amending, if necessary, the list of selling securityholders to include, pursuant to a prospectus amendment or Prospectus Supplement, the pledgee,
transferee or other successors in interest as selling securityholders under this Prospectus. The selling securityholders also may transfer and donate Common Shares in other circumstances in which case the transferees, donees, pledgees or other
successor in interest will be the selling beneficial owners for purposes of this Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders and any broker-dealer
participating in the distribution of Common Shares may be deemed to be &#147;underwriters&#148; within the meaning of the U.S. Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed
to be underwriting commissions or discounts under the U.S. Securities Act. At the time a particular offering of Common Shares is made, a Prospectus Supplement, if required, will be distributed which will identify the selling securityholders and
provide the other information set forth under &#147;Selling Securityholders&#148;, set forth the aggregate amount of Common Shares being offered and the terms of the offering, including the name or names of any
<FONT STYLE="white-space:nowrap">broker-dealers</FONT> or agents, any discounts, commissions and other terms constituting compensation from the selling securityholders and any discounts, commissions or concessions allowed or <FONT
STYLE="white-space:nowrap">re-allowed</FONT> or paid to <FONT STYLE="white-space:nowrap">broker-dealers.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states,
Common Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states Common Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any securityholder will sell any or all of Common
Shares registered pursuant to the registration statement, of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders and any other person participating in such distribution will be subject to applicable
provisions of Canadian securities legislation and the U.S. Exchange Act and the rules and regulations thereunder, including, without limitations, Regulation M under the U.S. Exchange Act, which may limit the timing of purchases and sales of any of
the Company&#146;s Common Shares by the selling securityholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the Company&#146;s Common Shares to engage in market-making
activities with respect to the Company&#146;s Common Shares. All of the foregoing may affect the marketability of the Company&#146;s Common Shares and the ability of any person or entity to engage in market-making activities with respect to the
Company&#146;s Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once sold under the shelf registration statement, of which this Prospectus forms a part, Common Shares will be freely
tradable in the hands of persons other than the Company&#146;s affiliates. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_19"></A>CERTAIN INCOME TAX CONSIDERATIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Prospectus Supplement may describe certain Canadian federal income tax consequences to an investor who is a non-resident of Canada or
to an investor who is a resident of Canada of acquiring, owning or disposing of any of the Company&#146;s Securities offered thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable
Prospectus Supplement may also describe certain U.S. federal income tax consequences of the acquisition, ownership and disposition of any of the Company&#146;s Securities, offered thereunder by an initial investor who is a U.S. person (within the
meaning of the U.S. Internal Revenue Code), including, to the extent applicable, such consequences related to debt securities payable in a currency other than the U.S. dollar, issued at an original issue discount for U.S. federal income tax purposes
or containing early redemption provisions or other special items. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_20"></A>AUDITORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The auditors of Aurinia Pharmaceuticals Inc. are PricewaterhouseCoopers LLP, Edmonton, Alberta, Canada. PricewaterhouseCoopers LLP has reported on the
Company&#146;s fiscal 2013 and 2014 audited consolidated financial statements, which have been filed with the securities regulatory authorities and incorporated herein. PricewaterhouseCoopers LLP is independent with respect to the Company within the
meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of Alberta. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_21"></A>TRANSFER
AGENTS AND REGISTRARS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The co-transfer agents and co-registrars of Aurinia Pharmaceuticals Inc. are Computershare Investor Services Inc. located at
its principal offices in Calgary, Alberta and Toronto, Ontario and Computershare Trust Company, N.A. located at its principal offices in Golden, Colorado. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_22"></A>AGENT FOR SERVICE OF PROCESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory Ayers, Hyuek Joon Lee, David Jayne, Charles Rowland and Stephen Zaruby are directors of the Company and reside outside of Canada. Each of these
directors has appointed the following agent for service of process in Canada: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:51.50pt; font-size:8pt; font-family:Times New Roman">Name of Person</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Name and Address of Agent</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">Gregory Ayers, Hyuek Joon Lee, David Jayne, Charles&nbsp;Rowland and Stephen Zaruby</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borden Ladner Gervais LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1200 Waterfront
Centre</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Burrard Street, P.O. Box 48600</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vancouver, BC V7X
1T2</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention: Stephen P. Robertson</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchasers are advised that it may not be possible for investors to enforce judgments obtained in Canada against any person or
company that is incorporated, continued or otherwise organized under the laws of a foreign jurisdiction or resides outside of Canada, even if the party has appointed an agent for service of process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_23"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters relating to the Securities offered by this Prospectus will be passed upon for the Company by Borden Ladner Gervais LLP, Vancouver,
British Columbia. The partners and associates of Borden Ladner Gervais LLP, Vancouver, British Columbia beneficially own, directly or indirectly, less than 1% of the Common Shares issued by Aurinia Pharmaceuticals Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_24"></A>WHERE CAN YOU FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to file with the securities commission or authority in each of the applicable provinces of Canada annual and quarterly reports,
material change reports and other information. In addition, the Company is subject to the informational requirements of the Exchange Act, and, in accordance with the Exchange Act, the Company also files reports with, and furnishes other information
to, the SEC. Under a multijurisdictional disclosure system adopted by the United States and Canada, these reports and other information (including financial information) may be prepared in accordance with the disclosure requirements of Canada, which
differ in certain respects from those in the United States. As a foreign private issuer, the Company is exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and the Company&#146;s officers,
directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, the Company is not required to publish financial statements as promptly as
U.S. companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may read any document the Company files with or furnishes to the securities commissions and authorities of the applicable provinces
of Canada through SEDAR and any document the Company files with, or furnishes to, the SEC at the SEC&#146;s public reference room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the public reference rooms. Certain of the Company&#146;s filings are also electronically available on EDGAR, and may be accessed at www.sec.gov. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_25"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a corporation existing under the <I>Business Corporations Act</I> (Alberta). Most of the Company&#146;s directors and officers, and the experts
named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all or a substantial portion of their assets may be, and a substantial portion of the Corporation&#146;s assets are, located outside the United
States. The Company has appointed an agent for service of process in the United States (as set forth below) but it may be difficult for holders of securities who reside in the United States to effect service within the United States upon those
directors, officers and experts who are not residents of the United States. It may also be difficult for holders of securities who reside in the United States to realize in the United States upon judgments of courts of the United States predicated
upon the Company&#146;s civil liability and the civil liability of the Company&#146;s directors, officers and experts under the United States federal securities laws. The Company has been advised that a judgment of a U.S. court predicated solely
upon civil liability under U.S. federal securities laws or the securities of &#147;blue sky&#148; laws of any state within the United States, would likely be enforceable in Canada if the United States court in which the judgment was obtained has a
basis for jurisdiction in the matter that would be recognized by a Canadian court for the same purposes. The Company has also been advised, however, that there is substantial doubt whether an action could be brought in Canada in the first instance
on the basis of the liability predicated solely upon U.S. federal securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company filed with the SEC, concurrently with the Company&#146;s
registration statement on Form F-10 of which this Prospectus is a part, an appointment of agent for service of process on Form F-X. Under the Form F-X, the Company appointed CT Corporation System, 111 Eighth Avenue, New York, New York 10011 as the
Company&#146;s agent for service of process in the United States in connection with any investigation or administrative proceeding conducted by the SEC, and any civil suit or action brought against or involving the Company in a U.S. court arising
out of or related to or concerning the offering of securities under this Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_26"></A>CANADIAN PURCHASER&#146;S STATUTORY AND CONTRACTUAL RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain of the provinces of Canada provides purchasers with the right to withdraw from an agreement to purchase securities. This
right may be exercised within two business days after receipt or deemed receipt of a Prospectus or a Prospectus Supplement relating to the securities purchased by a purchaser and any amendments thereto. In several of the provinces, the securities
legislation further provides a purchaser with remedies for rescission or, in some jurisdictions, revision of the price or damages if the Prospectus or a Prospectus Supplement relating to the securities purchased by a purchaser and any amendments
thereto contain a misrepresentation or is not delivered to the purchaser, provided that the remedies for rescission, revision of the price or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of
the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for the particulars of these rights or consult with a legal adviser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an offering of Warrants or Subscription Receipts, investors are cautioned that the statutory right of action for damages for a misrepresentation contained
in the Prospectus is limited, in certain provincial securities legislation, to the price at which the Warrants or Subscription Receipts are offered to the public under the Prospectus offering. This means that, under the securities legislation of
certain provinces, if the purchaser pays additional amounts upon conversion or exchange of the security, those amounts may not be recoverable under the statutory right of action for damages that applies in those provinces. The purchaser should refer
to any applicable provisions of the securities legislation of the purchaser&#146;s province for the particulars of this right of action for damages or consult with a legal adviser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Original purchasers of Warrants or Subscription Receipts (if offered separately) will have a contractual right of rescission against Aurinia in respect of the
exercise of such Warrant or Subscription Receipt. The contractual right of rescission will entitle such original purchasers to receive, in addition to the amount paid on original purchase of the Warrant or Subscription Receipt the amount paid upon
exercise upon surrender of the underlying securities gained thereby, in the event that this Prospectus (as supplemented or amended) contains a misrepresentation, provided that: (i) the exercise takes place within 180 days of the date of the purchase
of the Warrant or Subscription Receipt under this Prospectus; and (ii) the right of rescission is exercised within 180&nbsp;days of the date of purchase of the Warrant or Subscription Receipt under this Prospectus. This contractual right of
rescission will be consistent with the statutory right of rescission described under section 131 of the <I>Securities Act</I> (British Columbia), and is in addition to any other right or remedy available to original purchasers under section 131 of
the <I>Securities Act</I> (British Columbia) or otherwise at law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Original purchasers are further advised that in certain provinces the statutory right
of action for damages in connection with a prospectus misrepresentation is limited to the amount paid for the security that was purchased under a prospectus, and therefore a further payment at the time of exercise may not be recoverable in a
statutory action for damages. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province for the particulars of these rights, or consult with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309486_27"></A>CERTIFICATE OF AURINIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 16, 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This short form prospectus, together
with the documents incorporated in this prospectus by reference, will, as of the date of the last supplement to this prospectus relating to the securities offered by this prospectus and the supplement(s), constitute full, true and plain disclosure
of all material facts relating to the securities offered by this prospectus and the supplement(s) as required by the securities legislation of British Columbia, Alberta and Ontario. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ S<SMALL>TEPHEN</SMALL> W. Z<SMALL>ARUBY</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ D<SMALL>ENNIS</SMALL> B<SMALL>OURGEAULT</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Stephen W. Zaruby</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Dennis Bourgeault</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">On Behalf of the Board of Directors </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ R<SMALL>ICHARD</SMALL> G<SMALL>LICKMAN</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C<SMALL>HARLES</SMALL> A. R<SMALL>OWLAND</SMALL>, J<SMALL>R</SMALL>.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Richard Glickman</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Charles A. Rowland, Jr.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,111,111 Units </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309486g07r64.jpg" ALT="LOGO">
 </P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Book-Running Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright &amp; Co. </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Manager
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:23pt; font-family:Times New Roman" ALIGN="center"><B>Cormark Securities Inc. </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g309486g07r64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309486g07r64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>44&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             /4   )R          $                          0
M           "<@   /4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   /4     4F=H=&QO;F<   )R    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #U
M     %)G:'1L;VYG   "<@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     3A"24T$#      -'0    $   "@    /P   >
M '8@   - 0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ /P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M5)3NI+%ZI];NB]+R7XF2^PY%8!?6RMQC<-[?>[;5]'^6L_\ \<;H9,"G)/\
M9K_]+I*9?6SIY9:WJ+1^C< R\CL1_-V._K_S?_;:\^#GY%I+0;+;27;&#<=?
MY+5ZUT_J73.MX;W8[A?2Z:[ZGM@B1[JKJK/WFN_J/52WZOU4S]BK8VO_ $0
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M&POZF)^1B7U7^J_2<GI^/U3-8[+OO:#MN.ZMH;^C8QM7Y[6,;M_3>HE]8?\
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M1012DDDDU#__V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!   #
M     0ML   ! 0 #     01X   ! @ #    !    )X!!@ #     0 %   !
M$@ #     0 !   !%0 #     0 $   !&@ %     0   *8!&P %     0
M *X!*  #     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $
M 0   .@   $@  @ "  (  @ /0D    G$  ]"0   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-CHQ,CHR," Q,#HR-SHU,P  !)    <
M   $,#(R,: !  ,    !__\  * "  0    !   "<J #  0    !    ]0
M       & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@
M P    $  @   @$ !     $   %^ @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 8!-30 J    "  , 0
M P    $+;    0$  P    $$>    0(  P    0   "> 08  P    $ !0
M 1(  P    $      14  P    $ !    1H !0    $   "F 1L !0    $
M  "N 2@  P    $  @   3$  @   !X   "V 3(  @   !0   #4AVD !
M  $   #H   !(  (  @ "  (   #P     $   /      4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,3(Z,C @,3 Z,C<Z-3,   20   '
M    !# R,C&@ 0 #     ?__  "@ @ $     0   G*@ P $     0   /4
M        !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H
M  ,    !  (   (!  0    !   !?@("  0    !              /
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M 0$! 0$! 0$! 0$!_\  $0@ .P"6 P$1  (1 0,1 ?_$ !T   $%  ,!
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M35>$+-AR6,D&C^T4K&C-(Y)<:==.GQ@_4:7&>8MF+AOQCUO2H8J>L5UURM$
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M2&C"VB!<,O-E$(6EY;)S21TQATQATQB'INL=:ZZ5(KU]KVCT5<Q\;ZNJFU.
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?$\S,Y[1P; %RQ51N=E4A1OY9<SUB[.&PZ8PZ8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g309486g11h44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309486g11h44.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ < )A P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M           '!08("@$$"0,""__$ $\0  $#! $!! 8' P<("04!  4#! 8
M 0('"-41&%>7$A,4%1F6%B%45I*5U@DQMA<X05%V=]0B-E58<;73UR,D-#=A
M<X&1LB4F,E*QT?_$ !X! 0 !! ,! 0             $ @,%!@$'" D*_\0
M6!$  00! 00$" <,!P8$!@,! P$"! 4 !@<1$A,44I&2%1@A45:5T=4(%QDQ
M4]36(B,R05155Y26L=/C)&%Q<I.TTA8U-G5VM24S8G0)-X&RP? T0D7A_]H
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M^5D&Z%3C?UG=Y?;C<GF3L3'=LXZ^ 6E?*R#="IQOZSN\OMQN3S)V)CNV<=?
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M]'9-%3L4V,2^AQ%H3FS0I*Y,<$N;8JGW;8&]C Z:2!(8_33(DE#C*+E+O6[
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M+CC"(HGM8X#AR!2$)N<UW'Y0M;P;VHJ.=O7\2[)I^_\  8[9&,/S[&&"*"0
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MZ07=Y8UVUGF3,X?V;/\ /CXZ_P!LWG\,'JT/:=_P%J7_ -BS_-1\[I^#M_\
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M?"CPF,@E. B/C7)$<9P7/3AFLJG@U0Q34F:TK9<KHLJ%J2]K)$J1 IZZ%43
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M!SH#VQHDL331CE5LI=PSC<UPU3>KE>QJ)Q.:BTFU[I6/*J81[$P)5[83JJH
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M?OXW,&BD<]SGN=VY'/=ORD"M%BF1)",NI&K+WT> 1(7$PI.4*HYMK'RPR*A
MS(L6;ME%FS!Z21=+CF[ET@PS;).G."M,:OIHDALL2"=*9&2&.3(F%F'%$1R.
MZ.$LLYWA"YR-<08G,:5S6.(CG,:J7;"\U;9P7UDI9+*XE@^V- @U4:JAR;-[
M%'T^5&JX4,,J4,;GC >0PKXXR$8!1M*1'563;8WG,L<LY0[)&R:PMF$?R9]"
MP><V,AV+5)BW%R&=XQ[&9R,?<>@@.<-#QTB@]'-T![S!=F@DAA9BT]!"W)$8
M, FE><<0<Z0D !B/4CBQJ]9*P8I.:YQ6/CQQ.&5SBC5I'.<LJQU3K:W1SK,L
MB9))&%#/9&IH3KF9$"-@F1I]VE>EO8 Y(Q@(*=-D,-'&R.9KPL:Q*Q(][<AY
M<Z?/Y"3>D29"$YZX<&,M?15L;Q@F;!85G%FAIG%6Y4<'S%N%QF34>\:VN.64
M8WO[+E=*]B+I_3<-@QQA,$(4Y+-H4L9C@+8(1IDEO ^6X)3(5K2HXC'_ 'QJ
M$_#3?DNPUOK^U(<\^0:1)D4RZ>)+6@JQS4I% ^*M8*8&K'*CQ%C$?&40##18
M[E"OWI>'*:UW%R 9(C<6QV3)O@L17@(:1_1]FI- \*<(.6:D7$SI0/G,AH3$
M<]>B4&#(Z@@U"O'@5M@B*=+LU+KZ73I'%5\>*HSS&V!XW2'I!/.:YI$EFKT,
MD$LA2C&9Q"1W.>=C#O5Q6->D<6K=> 9&04VR8>'4DHH=AT +KB)3$&0+JR+=
MNB+;QH21S&B# &<Q@H9BPQ(R*5XG="^S-U>[D!F"Q%!-M#,]=H$&L-"M) E!
MU6>0YQ%L90V )27W,[&J.!CYG<M=-^,>$!SSU[(@^0<7/!5'S7%5HW*Z<EDX
M;IQWQEGM?S&RUB.D+%Y["HTHW\G>,K!E9PD$-S;'^T>LNCLC(^0QHZ=VGV'%
M3PQ3VTCPK')6)9C@-L>AEC.)&,%92M-&,>.7C#(,PG2V-/-P;:5C"VP5"L@5
MAD9'PN+YWBHX7<-$A/I^Z8XT]RA1W_T<3ZU:PM@KZQN.LX<V98(6<KV4KK*Z
MEITEI7(*.DZ42=+_ *64W/F&W<Z2_GG+]_-N3FD3<XO"WC5W"W=8U#>:MU4Z
MM??+*GNIZT%/6.\%QXRPZJ)OZ)7BZ'#C_P!#B\3^B@=Q#C\PG):SF$XJW?<&
M_P#)OFE<Y);O%(;;7JDA^C[/Z9J0:S>S'Z*9SGW/],LP7NS'$+<?D=NWN QQ
M 7PN%M9C:PE+IU'(J1XJ,2;X22-TDG04G\7,Z8D#G="21S?O_,Z/Q=(_I&_G
M??,G+JW7BL5%FV7.=4)0NL.@!\,.I4'R?!:W?1/"ZPNC(D-0+.X%@HD%4Z(B
M!RIAM\\D8Z/U<, 263!&FE7Y0GJRPF,C![B&/3MU;R!46]:@DGN>,CR754DB
M#QPZ;R%3.ZIE)\IV96M'T_IF22V+(BQ3OO1B%;<Z48C9PX^[HR%&^0HT6+PH
MD5PVL=&1-P%&GDR1#UQM#KP:9C0+"RABT<>3)TST6MC )3FG<?3WQC"@M,J6
M"O>MBPQ"CGN<KIC3+N7/TIOCD0J'0CRA)WD#;;&SVXW%?R>1/%BCLM17)52:
M)M\8I9/$[G;*[?)U:WULO1'WQ]AQQ;V)I[3:'=)03.D.K$IG&\)3.-U6B;D@
MJ[IF]8Z;N+@^D^^;^8JNSEVN-H#X;(#I!5A#U NJAQ?]GZI LU&YRO=<-&E6
MC4G+O5BE^=0_>%3D(@\C5N<V6S8342QQ/#P^Q4V*4T"C@UQP4XF+.M)*+Q6#
MLF" UK[L-,D'8V[!JUNPPNX9M+HL7CMLOE'1ZLA()B='(:L4CH)RFYAXZECO
MBE5#/(XK^: CF%YCW\Q>%[^(C&/;K@YFHQ N8H$G1XFH&A9<0X\-8\.:V-.%
M91D?$" <8?1I@6%C<@0N0G&(/ $I1OE?7O(WE#JB"D]::YF,MB$(,Y%LRP,/
M'1J.!%4XULQ*.'C[,$H4<.7++%-G9TH]R<(-46[=LHBBW0P3P]EIG2EQ8"M;
M.%#FSP<E R#R2N42 ?S!-8-)"":UI%5_ @^%SW.<]'*YRKM-!M!VEZ6I).G-
M/6UK4TLQ93I4*)7QV-D/FB0,DACNA.DD(0*-$A'&4@Q,&,;F,&Q&]%_OGD@1
MDD8F#F12+&41%]$"@@ZSBH@:26)P!+-O"R,@<#@#7*7OHRV46:B'<M]]N&C5
MPZ;8*>H=.$U;@]/:8%%EPF18RQ)HYHC1WRS%&T5B[BG"C-+(?T(<IZ->9D/D
M->]K'*G$QJI8/KC:'(L:VV)86"6=4:IDQ)P:N)&DOD43%'3R)Y(\$2VQJT;G
MBB%M>F$$(A!-=RR/:Z.S4CVE(AQ40:5D9 <<F9'89AJJ+4QQ)30JAFV>R!YF
MDR347>*(*KII8YYW;M+.GEVB*&3UU=;) BU,8H3 ;&&6/!%6A>A45100N1XX
MS$<]4:Q'(U7*B<3^ ?&YW+9PX"98:GL(TJ',=8GC3;B1J"6)T5R)(N)0U$:>
M96!:YYG#<]K45RC%S3*)C%,57WA!=P;\UH%#QZ#ECP . GC;9X9FA%ACKW?L
M!D(< 64K07( W;KWLS$.G+!HMFME@U164]0FGGEZ50["ET]:'-)GACR#2*]U
M4=[I96<RN>9LA\1S1'8WDO,QI'HC45RHG$JIY,RU)JS76G(<2!2RIT&) O!Z
MDB"961B\B]#$)!#:,>>$4G2@Q"D )[GJ@V/=P-:J[\F+5G*[=$%>*920,ZFH
MYC"Y_$HB+)0N(. \35V9, LQF9&\=+0<J$D+,\_&/;$ 1-LDUS7+*/VSIJJU
MP26PEMI"CGL1(IF02$GUTV:84Z:T\Q*J$>#!%TD,\1XSXXRCY<@3U>C0H-S'
MH_>W;=,;4=8TAG+8PRW,8-/>U57%D4]2^)5KJ2WAV]Q(\'RJ65"GAG'C&0\&
M2-@G$E*<91."UCXSF^V9P<VV.W% 82GJ*4"687%@OKZ,LHS@D=%"\1SN5MQT
M<!!  DT65NJ^6]QA1J#9?/!5.RK_  6(N<K IX *8E+8SEN8AGGYC;*424JQ
MRE4C(;B29!Y!@!;PC;SSE<YJ*B\(U:)FNW.J;N9JN/JZBI6Z4LX@H?(?0UH:
MYK9T:-R"VC(\"##@19DIRN,[H4..P;U:YJ..U\@GQ0WIR+:YYW:GCS5#.%RW
M7F(YM$@S<,A#IZ_<%)N%:!$8_@'982\@[<.I*\9L4")I57*Y%VXM;&UJG4&F
MGHG''CO<DZ'9<UTP[CK.KQM% .^0LE3O6$-C616/(X0&HG+8W*&:VV@C55'-
MG#8M/:T"1QU4,<-E1>G))NH8H3("1!-MI!2%L2B P\Q[E604F#^].1DIB1>#
M2"02$K&I")AP21-'46$W>R(=KW#-*$)R Y@!P.G'$70S]G#/RI-V_9MDT&R;
MKV=NW33XCT&FHDP,^-&C!E1C33QGLEFY<8EDJ+/6-'60L>.V6Y.(PPB8-[U<
M]6<3G*J=K;:%9U4NDGS["573XE1"GB+5Q5-81Z!'-IFSYJ04G325K'<N(>5)
M+($-K!H7@&-K8,^CY[_0A?\ +7G_  :S_2(_TX?\5G^K-)Z!._(I?ZL;_1F;
MG[-\,8;\W^/"[@22013F3S)199BZ22PM]&3UNW-3-+'#&W;>UNW*]K=M[6K1
M-IIPNT'J1K3"<Y8+$1$(Q57^E1_F1%WKG<_P>8<L>V?0#R19(V-MS*Y[P%:U
MO_ALY/*YS41/*J)Y5^?-B#]K^V<N^#\X0:-UW2V4OUW?%%NDHLK>V,J8WRO9
M-/'+.]L;?7>]K=EK?7>O-NQAS6:\@.>YK6]"LO*Y4:GEB/\ QKN3/??PL1D+
ML7NF"&\CUMM/JC!M<]R[K0*KN:U%5=R>5?)Y$S4#^CY[_0A?\M>?\&O9O2(_
MTX?\5G^K/D[T"=^12_U8W^C'T?/?Z$+_ ):\_P"#3I$?Z</^*S_5CH$[\BE_
MJQO]&7*4(['-"HD$*92AZ)@8]Z+AS!5H^]GCK D=(R9\@-PP0Q]1[4=+/R2R
MO;DMDNO;'UGJD6Z:440JP!IAQ)$8:P(,LTB.'Q22"CBBC<55<O%P1PC$U/P4
M:WYM[G*N1DR-13(M5"DK9FBT8#1J@#A'Y=>"1-D61V1D1B<'-G2CR'N\KU>]
M$XN%@VMOPYMW?DC;RA N9D;A><CAPB<&$8XQ82:;"Q5VN30?,98/#-9-*6=U
M6+!R];GBQ!,F[8,'A+%VZ9-5DL>"FT]&=$<$$9K8!2G@!=)(2+!,;C1Y(4,A
MWQ8C]Q"-&Z.$:B80C!<#"/:N<FZKUU8#LV2Y=@1]U'CQ;J6VO"&RN8T51N$"
MWM00QV5F)7A 0S)TL[9)0 +(0I B<SXM]J;Q;QV.Q?)V4?#(<@X:PQ<Q#@QP
M_"FKE?)WFUA<L,@'TJB+5-[GF_:-HX9&(,".>9!DFW>YY+WJ=44+I,F6C!#+
M-<U\YH9IX\:<]C>!'SH8) X<USAH@B.E *I!(@B*X:(W*!ZGUJROKZQ2R31J
M@9!4[Y=1#FSJ812.*X5/:2X![.J&TSG'$.OF1F D.4X4&95?E:8[UY"CA>N
MK=^X4&:@6(NM8M7VNHB3M"'I=^B5*D(^J2B;M=D2)EFS<N_)8JW?O"R*11PX
M4?X8N+1R:?TV0UG(<-J&N6C9:O'9S1+/&$;@A%(04QC7B$%S@C%NY; N436H
M-5;DP&M=?1XNG80S$=&TD^0730CZ?JI*4II1V2I4B Z35E>&3)EB'+/)1RG-
M*8V20CCM0F40#M3><;8QX:-(&U6D0/OI5#\#47&R56'2,HN@[(F8@ZD80JZB
MK]\_:M";M< L.R7+,V993TB31LZ2D2*B@E$DE*(#7S8XXDU02BQ6S8PFN8(,
MUD4X62QC&]XF)(:3A"]X4W">YBPX.IM;5P8$>.>:X53//:5"3*R/8NJ+"2]A
M9$RI)80I1:PYSB%**^"^.KY80RW;Y(AE;]!VV-[#/=JB!$TY?!946G(8V7B@
ML])0\S.N&CPO*A4H. B,B&R!\_'CR*Q=D40?>\A[ C@O@^9-7"5):?3Y>:CA
M 8,\,->< 99H\4T&.U[ PS1(\@48L88R$$T+Q.'RB$$K5&1[5JCZIUQ&Z,YD
MB80\*SE74.;+JHLZQB7$X@C2[2-9S8,BP!/.< )#Y8I+#=) "0CT, 3V4X_L
M/<TH@,;U>?<F24&B!(F8C8-:,,,/=14TLHX-$4":(9(QF\,.%,ERRZY!90DM
MBDH]R7S11R3O1ZVDB6,JUCL"*?-$($H[91%YP0-1H!N$XZA1@&IPA:T;4$U5
M1G"CG;X\Z_UA9T5?IJ<29)I*J1(EU\)]8!.C2ICW$F2&260VRW&EO<KY1"'>
MZ2]&N,KW,8K>]'=K;UBK")C@I,ZDA 'I E 5GT8'&B,#?%%L'3YU""YH*0*Q
M!55^FF6PRCKT;[.:PP-MK)%L;/;6Y5103"3"G%'5UB,8K%!RB@'8#$U6#9/"
M XPS6M&JAW26%X@*H';PKP9?KM3ZWJ@54>%(G,91'/)HGGK(\R11GDO0IBTL
MN;"D2JESY")+3P>:.C)J)-&C9:(; _:V]Q<++Z_8F),C%3TL;SPNSN!;+$'\
MV9K)N&<L6D"XE21?2%HLGCFT+X%<'S;TE,4%D\5E;9\$I]/EG!L2 BNEQX;J
M\#^D.08X#VJU\-L9IDC=&>URH\*A5CO)Q(O"W<!JC7$:GET(9=DRLG6@[R6+
MH(W2#W(GH05J^>^*ZP\(">U%%+24AQ[W(Q[4<Y%NHWR+Y,R2VQ_?LA+E<MO-
M@;39RKN"QA1Q.$(TG@G'L9"X^BUEW^86R::@Q913US-PFFZ04P<X8JVB TSI
M:+X,Z/&"%*9YWU2,L):-@.E*JR5C-Z7PC0^]4*U$X7M56.16JJ9DYFT#:18I
MJ'IT^7)75@X0M2.+1UKGW3*UJ-@)8$\&<9W0^%KHSW.XPO:TC'(1$<D?6G&W
MDI6O-F:QH3)G0!U%7)$%'&@#!Q'7T<5B+T.L/"B6 Q5B\C2R@9TCFRRLNSO;
M!6^>6&&6.2Z!3+#; >T!HK)+);1R)+Y*ME#E)-&="G,0J$9*1#M<C][7^5-R
M*J9@?#6K&VC[D+YL6R+ +6$D0J\4%I*\U>ZJ-#?'AQ01G +7.=#*QP50@=S7
M;U1%2Z-.[LY#\?U#B^G)!)8(YDF#-(X[%QL>N]((#\ELV;95Z3"/G6#5%1PL
MK9JBLFWR5S]:HGDICAEC#NZ'36HTCMNXT6P9%5[@,-**T8W$1J/<@Q'&Q7N1
MJ)QN:KD1-R*B*J+D](ZRV@:#=-?I&?949+%H632Q:X#S2& 5[A#<:3#.5!,<
M1SN4Q[1J]>-S5<B*G,MW;R'G8?$)+3TB-M<%I:KB\<Q@8G(+)SLX[DLQ'_2I
ML#0D_N:2''[TB5!>]_<SI9TMAFP]3G=.D.ATW7GZ1#CQ@/X8;>!LHJQM]?'9
M%A$Z(Z0Z)SXT<8QBD<GGM1B+S.)-^+76>T"[B)"M9UA,$CK5R&)6QVST;>SB
MV5Q'\)CA,LNAV,TYI$J%TOH97$>B@X'*W*1+MH;TG96;FY:9E1HML@/&H_.'
M[@1@DXD82'Y@58X+?9-1J%L68U>,1YSBBWLABY=!V+IY9PX0Q4J_#J:"O# !
M#!$ &K-*DP!M,KFQ3S4D)**/C*[[LK9<EJN=Q*UIB,9PM=NR):ZEUO>2KJ;:
MR[29*U%$KH-T<D1&DL(=0L%U?&.HH[-P8[ZV 1&#1B$+$ 4W,(Q'918?+=JP
M(5,@<4L6%B=A!D([,F6499D4CP-L\P(HC'5R@EZHFTQ?I(/<DVN;?UKIJS75
MOFHS;9)7YL.HL#09$SDE-6G=)@O24\2QSN8HW%:@C#17\M7,17H[<Q[VIN1[
MT6'4VNJ**+;PJM)4:+?PV0+<*UH9#9T(9DD,C%Z5$,YHD.UAE:)6<11B>[>X
M0U;D+#>77(L/L1A.9HXD,\;_ ,H(79\@#N0  8I()M&HWG%HW(7)&T.(6P(!
M17J6J%\V*[==HFNS<(9)OG6>>MSM&::/6$KX+(U>[P:>IC&;(D%2- E2DER8
MS1=-'O&<W$]VXC7->K7M=O&U$W^GVK[08>H 7=P^PO!^'H>I)T0D"#%=/N:Z
MN6LKIY)"5$CA/#B\ F;P$&\+2!(Q6G*JQ]O3:)?="L4<_P DT?B16-H%V[\]
M$=>QJ$NI4F1<M'##$R'@L7C0"U@.#95$<ODR=DE/;WMW9)9O[$S89*@J0T:3
M&^&),P,IP7#CS+*5.9#43'M)R#V$N5(_I"N1Q&\;!)RV< FNXWDP&M]32M8N
MJR?[*0:J37,EC/.JJ&NIBVC9!!/ DR)25E=!_H+1N9'>HC2%YYE))</DB!]'
M7(SE ]D+*5NIA+5I$QFS;9.!7*.C;.7<]8"_<@N6E_1!XIG3H43?(>!?F\""
MP%LHJF'NQ]:IZ=+-,Z4'&?#9"AMC$@/JU"DDO"RN(;GEAAWR-\>.<VXD@8%&
MV0Y$4W,W)NJ+M!VEFGALRVUJ^>"Z'J)LI:^.A"WH(O0HUK+W0D;-FPXF^/!/
M,:=T$;G-B<GC=OX:\B>3;,0Z!-Y/(+#7@N< 5DE8@"<+XQS93]0K.XLW?N(X
MJ09Q.3$U52!**LW2$=S>*J.4AB2V>6=^7Z:TL\S)#HL?FL+ D-5)LAK>DU8T
M%7RW#;)0;YD42(,4M['2>!$:XKD1$P+:!M)#$+!'93TC&C74%['5$$C_  ?J
M,[I5W6#,2N<<-5927N/(JQ$97J5SB,C-<JKF/GT?/?Z$+_EKS_@UL?2(_P!.
M'_%9_JS0>@3OR*7^K&_T8^CY[_0A?\M>?\&G2(_TX?\ %9_JQT"=^12_U8W^
MC-^[2^.6&G=3X9XY89X:T@F.>&5KXY8Y8Q85;+'+&_9?'+&]KVO:]K7M>W9?
MZZ^>-XJ+=W"HJ*BVE@J*GE1466;<J+^-%S[I:.16Z1TLUR*BIIRC145-RHJ5
MD5%147RHJ+Y%1?FR2ZQ>;'FE?60R/FW'QH_FYZ#_ +F-8?P4$J"_\-W]YW[U
MR^GS)_8G[L\<OVRG^?FD?[(RS_?(RO*7PB?]Z:9_]A8?Y@&?1;X$7_#VO?\
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MX-%K%2;/'%&[1YNNE;[3L*ATL.[L8DB4#5EM.66V:CY57(EB5E=?2(;B,+(
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MT9@1^$@R:Z9:5!"+)?'FM<03IL)"@E%"1Z;#!^;P.!3L(I$9=J?3D>U+C(9
M*'G9$B"#QIZN*]E?.&;E0L'9MU6)/!1NCEB3:K,+V]X6R;5FFS-.QP;3(M5:
M15K["AT]#H.ERXXI,ML6-#(X' 5XWN/'&U1&WM;]_&X7_F[V9J1*S6\Z;L%G
MZAT]/9=4VL=;66L5K:Z9)KZQ]A.M #EJ8 SB9#G&(R1%5I7HL4S)"+T?<7.E
M"=YPEV-9Z*W@1&%8O%HC Y?I2>"S0LSGK;9$=UO'L2416+C7)!MA$I:9%.@9
MEA=:[<88SQ?YI)IN43 FBKU16/$+2^IC@/"@5]5/TU:@D@D^![>'3PVGKW2
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M(6F?S:;_ *$IXO>J_P \:>_QK+W;CQU=FWHWKC]3H?M!CX/7(7Q"TS^;3?\
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BZ=J8[R?'7Q]TKYIP;KM.!_5=W5]F-Z>=.U,U&:G98S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g309486g52n09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309486g52n09.jpg
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M 0$! 0$! 0'_P  1" !/ )@# 1$  A$! Q$!_\0 'P !  (#  (# 0
M      D*!@<( PL!! 4"_\0 .Q    8" 0($! ,%!@<      0(#! 4&!P@
M"1$*$A,5%"$Y>",QMR(X05%V%A<Z4K:Y)"5A>;*XP?_$ !X! 0 !! ,! 0
M           # 0('"00&" 4*_\0 /Q$  00"  ,$" ,&! 8#     0 " P0%
M$082(0<3,4$4(C)187&1L8'!\ @C0G*AT0D5,U(6)&."PO%SHN'_V@ , P$
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MG,)CG,<1'FR2Q'#7@BKUXHX((6,CBABC9%%#$QO*R...-K61L:T::QH#6MT
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M6#U=Z.(GCE9 \KU/V!]J$>-JS]G^:L=U5M69+?#EF1VF079]>DXMSG'3&79
M+%/V6^F&Q'MTMN("/B=PJWO%1:'3;%54:&*NF'D P^BNF!%P .W?OYB('-_
M"D$1^7;GT_V<,Q_PMQ;=H/<&5N(\>V!I)TPWZ#W6:?,X]/6@DNQ,!ZNFEC8/
M6=I9%X\R[S69+S'O<?.2[Q.H9N5DA]YT\1.)T0&AQ/0+22.JWE=]_;_EYOR]
M(?Y_+^'_ -[_ /7^7N<YT\I];R]Y_P#7T_#JL8GBDEO^KY>\@_7X?A\?<NIZ
M5@EM3JBZ=N6I4C/3@H)1* #Z#4IR)?(0 0$RJBX]O\OE$!Y]3"99_>.+3ITK
MV^?\+=@>&_$EWP\QX]->_P"UCF&\89_&8YSN\I\,T+'-X%HR.5=#-9:T=0X-
MJU:#=[VV3O6'6B%OW1?3I2R9E:[-7F,]"M40TBCBR-=H@'O=J<HGCW-L]%0/
M*>,KC51XWBE13$'%A7*^:K)*P'XW![3./A5P<W!^.FY[>3,3\U.QVS7IQN$K
M*7,/":V\,=.W?J56]T]I;9]7SOV%=B RW'=#M6SU41XOAAER/A*G*S0O9FRS
MT:7,%CAHU<7 9XZCBT]YDI6V(GL?COWDXG/.*]Y)PB<(G")PB<(G"*'3K=]2
MA[TT=.G&1:"K7W6?LEVN+Q_A*&L33W6,"2*H28N-KEH8CAJL_A:K5&CPAA*L
M1N%EFZJR=F]"0$IBOC9SNUY#J?U\5#%TG.O9M[E?>NH:D=0^+H=2:YQH%7?X
MB?P](+1)&.NM^J%>RCB@DL;W9^B[A<K4">;HP"1TR/AL4U4V1"I'?/42%(^-
MH;S,\CU^NOZ'^ZN4<*!.$3A$X1.$7P( 8!*8 ,4P"!BB " @(=A 0'Y" A\A
M ?D(<$;Z'J#T(/F@)!!!T1U!'0@CP(*Y>LVLU8]R=35*1;0HO%%%GM=\@)PZ
MBJG<5%(P"!VC!4$1$S(I#,!$2@@5DF42GZ+=X+KLMMR.%<*%F.5EAL3261,F
MC<'MEK$ FNX/ <& &+F Y1& 0<EX[M%R#JK<?G"^_$(^Y9==Z]KNBWD[NULC
MTEH;T$I(GUOG,Q((P<,#>FX!-2'5!8>X^0B'G+\A !$JY0,B8H?EY_4$@"(=
MQ[<RSC,]/9K1^FCT:S& RRUV@SG T9(7;(?'+KF;R%Q:?4)/+S'K&5S)J1S2
M4GFX' ^B,9LN<]P/(R5ITZ,1G7>.<&^J-C1<UJSN+USB)-TV=7(J:T8T\@H5
MIH<007],0\I)1TF("= .W[31H;LJ'E!1T*?J('^O+Q=-6B,.+!9(6\IMO'5@
M_P"A&[>G:\))!MI\&;#7#")X!BS%Y^0XD>;(DG=8?1:\ZL2O>7DW)FD$L)/K
M0PD!W0&7DYHSTPU:MF+9NS9-T&C-HBDV:M6R2:#9LW0(5-%!N@D4B2**292I
MI))E*1,A0*4H%  YTM[WRO?)(]TDDCG/>][BY[WN)<YSG.)+G.)))))).RLC
M111011PP1QPPPL;'%%$QL<<4;&AK(XV- :QC&@-:UH#6@   !>?EJD6)7Y_/
M15%NDI56IWUHC:E8W];8IM#OU'D\SAWCB':IL4_Q'IW$@FW1*T3_ &W!C@B3
M]HX<(/CX*)7HP[$]1;8O$.8+!U&\/SF'<@5_)$=#X^B9S#T]AQ:7IRU89/7D
MBA$SP O+I)S:CEL,BA^$F<@MA_;(/'Z\-?=2/# 1R'8\^NU,OPHTX1.$3A%Z
M];?.USG7-ZZV.]2*!*/)#73!=I>XJ4EHI=0\:TH]!D/?]F,GM7*0G:(O;+(Q
M#NF5.627!C/(P>. 24*M)% Q<EO[N,N_B/7^P_-=@^*=T>>XW'6[J+8"CE:<
M]Q8M3\*7]U44AC%:B6L.S3.O][8BQ*F$<:NR#:1I*DL?L=NH;'$4V,4K=$@%
M;"[>V'KO9'YC\1U^JLO=+;>&"ZA6D^']C&2K%*YR$5_8_,4$Q$A"5K,%11;,
M+JP!J03?!,)=<[2X5UJ<QU252S0)UC>LHH %$]O(XCZ'WC]=/FNA=N,LV/ F
MJ6SF=*>RA9&VX7UZS1EFK1]D;/GE=?V/'.-[+<(1E/M(R1AY)U"NI.':H2K:
M/EXM\NQ.NDTD6+@R;E*AZ GX*@ZD#XJ/WHA=07,W4ITYG=A,ZUK&55ND9G"Z
MXU;QF)X6TP58/!5NL4.:8NEF5ON=ZE32RKJT2";M<DTFS.W19D18(*)K*N*J
MZ1H:[0WK0\5Y^MQU <R]-G3:+V&P96L9VJZOLTTC'*L9E>&M,[5RP=E@;I*/
MG2;*H7*BRH2J3BN,2-%S31VB:*KHJS%<YT5$"1M#G:.]:/@N\=.<P6;834?5
MS/=T8P<9<,VZ[X6RW:XZL-G[*ML+)D;'%;M\VRK[.5DYJ4:0C63F'*$4VD9B
M5?(,2().Y)\N51RJ5KAIQ'N)'T*J+U'Q*&^V6%\VZ]XBUBQAE?<1_F56@Z[5
M?%6.\G/(>,QW7#7(<@W[(45(9(LRUBF8PD;6$81%C)4^MQI'%CLUI5/$PR$1
M)/M^OU]=J8Q-&B7:;KKLC>_+73^ZG0Z/6PO5.SI%9UCNI;@2OX7?8[F*;%8W
ME6]&FJ-/WU>;93,E:%CH'L4[4IR!KK=&O-V<[5B-4%9"5?QCH[AY%.?2*QX8
M".0[WX^>OU^O%<A3747VY9^)%J/3V;Y*8$U/E:JYDWV.1HE",^5>IZ>6?+)%
M0O!JV-Z3 +W&LY?TT[$1,4DAC!(,8HHT,5>5O=%VO6!\>OO ^2G W>S;:]:]
M.]G=@Z+'U^5N>%L&9,R;5HRV-)%_6'\]3*G)SL6TGV4/+04JZB%W;))-^WCI
MJ*>*MC*$;OVJHE6*4;1MP'O('U*J[8"Z^_4UWOQ51<7Z-::8XRIM^2/L4YL+
M?"1,_5M=L.0[BZ6.*Q_%1B-ZR@W0&S3E/BV,^XDK5E 8]=^=W'5VL6)RWE6,
M"4QC8T[<XAOD/,]!OR]_P7Y4WUN^KKTVLW8YJ75JU8Q\MAG)+\2(7C&;&.:3
M2<4V<,T)V5I%KI5UMV/++(55N_0DI7'TW'Q%G>H'8D&6@F\BU?KD[MCP>0G8
M\C_^C?X^"M\VR_-FN(++E&FNXR=9ML;3-^JKXWJNH:8;(UAS8H-V;X=9JNXC
M)!(K58?0<-E56JWX2R)S%.4H0.H'QTH;>@YU/<^=4+".<,DY^J6(:C.XTRI%
MT>":X?@+E7XEW$O:E'SRKB60N=^O[Q>1*\=J)IJLWS!L#8I"&:'5 RQBOD8&
M$ ;ZCS_]!?I=7?K*,.G7,8MP'AO$SC8C<7.Z3-?'.+$5Y$L3"QDQ.*56M35C
M9P:*]DL3ZVVI!Y T^F5WX)_/N8J94<3L(5FP)+D8SFV2=-'B?ZJ/*:S9XL@D
M"KDQ+635EJS3:#-GQ/#&QP_GTF()BZ,Q3C'.;I&;=.R-_E[0UM[JPJJA\&B@
MI)"#<2NU#X<SOG^A^2[BZ+/6=E^I.]RWA#.F)X_">U6"F:<M;ZS!>]M:W:(!
M";"K6"3C:[9UGEHI4S3;4JP@+759V4FE&B\Q$.&TNNJXD8V'*V1G)H@[:?#]
M>?S6^NM_OD70+0/*%_KDP6-S+D],^&<&E16!.1:7BYQ[Y-]<&8%$54QQ[5&T
M];VSLR*K+WZ-@(MX)?=T0.5(V\S@/+Q/R'ZTJ1'0^ZF&O72^D<U90R9KKF;,
M>7<JL82H5NTTDM<0B:KC>/<>]S<8V=3;MN]<2%PM"<4\FQ*F=J5O4:]\.MZR
MCXG"Y$C>?0YFC7O\=J9?:?Q*VG.VNNN8];<DZ3;/*T_,-$FJ=(.06H+AS"O7
MJ +P%IC4E9(J0S-1L3>*M$(90?(G+Q#)4X"4@@)1B,M((>W84<'AA=_%]7MQ
MY'4W(\JM%XHVV5C8&&2E3G;-:QGN(26+0'A4G _\'_> Q</,?O$FZ(+RT\]H
M/Q*H-(@!*5\S=MYAXC[*]+U)OIU;\_97M/\ H9>N4/@?D?LN,/$?,?=0Q^$X
M^F';ONRRK_H'#_*J2;V_P"^UXL#Z7U>^ZC$_^CLJ<)#[?X%3 ],/Z;'3Z^R;
M5C]#J-PK'^V[^9WW*JR^%EH<!)[O=3C)CIF@K9J::(I4(].D4R[.'R)EC(TU
M844%! 3) [=8UKHJ^00$X-BE'N " E-,?58/Q^@']U=_X7'5+RQ_XQF@_P!#
M//\ ;TNO"G'^@?G_ .05CWJQ_3'W[^T?//Z<S_"B9[;?YF_<*)?PH%+@(#IF
MV.U1[!NE/7S97)+ZQ28)$^,>%@*[1:]#LE'';U3L8YJR669M1-Z+=U)22Z1"
MJ/7!U"OF]OY ?F5B7BY8UBXZ<6&Y-9LD>0C=R\?(,G8D+Z[=O(8:SV#YNFIV
M\Q4'1FK11=(! JBC1L<P"9$G8JP>T?Y3]PID=='"SOI1X)=N#F4<.NGKC!PN
MH81$RBRVM\&HJ<PB(B)C',8PB(B(B/S'A1_Q_P#=^:@3\'Y^ZAMG]PU?_3:&
MX4L_BWY'[J0OJA;*=(;0S/V+MK-KL;L[WNM#Q;>7Q$QQ]%O+%F8(&*0F*]&3
MSJ/=6FMT>(K3!9],,X.2O3UJFM*)R3NJ-I*8@WBD>5C ]P+6GIY^Y<81_B.=
MF,YE(UTUZ.^T68@E0 (:V33ZS)5M%)7M\/(2A:9BBSPI&1NY1547O<4S3 W<
M9( [")7=T![4C1\/OYC[*/OP_MDRO:^O;OY:<X4*,Q3F*VX;V3L&5,;0JQ%X
MNFWF:V4P1+V6NMETY.9*X+&3*[A(ZXRK\ZJQ%%#N5#G,/"ND $3-'8V-'X:*
MYRZT&9;IU=>L/BG0G!LL=_0\27HFO59>-/,^B$KX_D4'VQ>4W+=$_P"-'TAK
M!.(F0,B=0BD%BMQ),!'W4X*%=&.2,N/GU_#^$?CY?->P%P_BJEX+Q3CC#&.(
MLD+0L5TFLT"H19?(8S2OU2(:0L85PJ0B?Q+U1LS(L_>'("SUZHN[7$RRRAA+
MBGKU/B5L;A%1#\5KI'*XQS!ASJ0XF;O80+L^@<;9<F8 RK)[!97I3,9'$U_!
MZT[.FTA.56%7K9I,JC=*-=8]K14SC(3!1.7(A=L%A^8^7F/S_$JPEJ7LVIU?
MNCG?Y* >1A<S95UOS1K9E2+(H@S;P>>'^+I>DRJJZ1!*A%Q=I5GX2^P[?SF(
MPKEJC6ZRHKMG $*)PY'Z\@=_@J^/AW^JUK+H)B;.>DN[UBF->;G"9WL]]@YR
MXU.UN(H)*0KE3I5OQW9$(*&EI2IV:KS%!4?=YY@SCGQ)=RQ^-0D(Y)J]*65A
M<0YO4$:Z?CU6&>(7ZJ^+>H9A",PAI='V[*N#,"9"K&8-@-@RU6?K%#C["_;3
MF,\94J&-:(^'EWPR<E=;"[<J/(Q@$HO&,G=:2FHJ)GI.-)$PM.W="1ZH\_C]
M/S]ZN#=,/Z;'3Z^R;5C]#J-PH7^V[^9WW*K->%5_>:ZLG]98K_4#8GA2S>$?
MR/V:KI7"@5+RQ_XQF@_T,\_V]+KPIQ_H'Y_^05CWJQ_3'W[^T?//Z<S_  HF
M>VW^9OW"C"\*W]*N/^X7,/\ X53A7S>W^ 6M?%O?33Q3]Y^,OT;V"X58/;/\
MI^X4OFM?TFL _P#;NQ7_ .M<#PH_X_\ N_-0->#\_=0VS^X:O_IM#<*6?Q;\
MC]UP7O=9Z-J7XFN#V(W\JC^<UCG%J7:J%89JMO+958ZM)8&94&J6N.KI&CX)
MACBG,#-:1GXN+9/):.E8MQ:V45(RBT:C)E<WUH2UOM=0?+SW_4?V5DC.?7_Z
M6V&<<O[G!;*5C-UE.P,>H8LPPWE;==[?,JIC[;!)HHQR455U':XD25>V^0A&
MK0HF+^.\%!BX*(1//EKXGH JVOA][]DZP==[;6Y["4Z4Q9F3.N$\]WNPX\LD
M>^@IBO3^3,L8:S.C72Q$N@TE6H,JNJ9RQ9/FJ#Y*';D.Y;I'35*0I) .[;RG
M8! W\@1OZJZ%C'1?3#"N0"97Q%JIK[C/)R9)<B>0J/B6D5JZ$+/I*H3GELL3
M#-9<HS"#A=&3,#L#/DEUDW(J$54 Q0%SB-$DCW$G2ZJX5$X1:ZRKB'%>=*1*
MXTS1CFDY7QY.+1SB8I&0ZS#V^JR:\1(-I:*7?04ZT?1SE:.DV;209*JMS';.
MVZ*Z)B*$*8" D=0='WCHL3PAK+KMK1'3T/KQ@_%>$(FT/6DE9(S%=%KE%CYV
M18(*-63^59UR/CV[YXU;+*-T7+A-19-$XI%.!  H%4DGQ)/S.UI78/IN:'[5
M68MVV!U4PWDN[>1!)>Z2M5;Q]PD$&J9$FK:8M, >)GIMJT2(5)HUEY!ZW:I=
MTT$DR&,42J'.;X.(^&^GT68QNC.FD1A977*/U;P,A@AS*,IU_B8V+Z@O19:>
MCED7#*P3=?<Q2S&<L""[=!8L[+IO98RJ*2AWACID$"IS.WO9W[]G?U7152J=
M8H55K5&I%>AJE3*; 0]5J55KL<UAZ_6JU7X]O$P4!!Q+%)!E%P\/&-&L?&Q[
M-%%JR9MT6[=)-),A0*BU/A[5S6[7N6N4]@G ^),/3>15V;J^RV-:!6:9(W-S
M'N9-XQ7L[R C6*\VLS=S4PY;*2!W!D5Y-^JF)3NEA.522?$DZ\-G>EOCA46B
M5=7M;U\X-MF5L$8E5V)9MS-&F<5*!63Y6;-35E>F&;H7LT:-D21-473FLBF2
M1 @P3A:+$/@U#(B5=G6MG7NWT^BVC<J94LBU.R4.^UJ#N=)N,+(UNUU.S1;.
M;KMDK\NU48RL+-Q$@BX8R<7(LUE6KUB[05;N6ZATE4SD,("5%B6'\'X;U\IY
M<>X*Q;0,/T0DF^FB4_&U4A:96BR\GZ(2,F6&@&;&/!\^!NA\6Z!#UE_12]0Y
MO(7L522>I))^/5?4S1@'!VQU49T7/^(L<9II<=.M+0PJF3Z= W>OL[(P8R48
MRG6T38F,@Q1EFD=,RS%N_31*Y1:23Y!-0J3I8IR D>!(^1TLVBJ54(*F1N.H
M6L0,508>L,Z5$TR/BV;2L1M0CXI."85AC"((DCVT"SAD4HIM%HMR,T8],C1-
M$J!0(!46NL):VZ^:U0TS7=>L)XMPC V*32FI^&Q91JY18R9ET6J;%&3DV5<C
MX]N]?),DDVI'3A-18K=,B0' A0*!5))\23\SM>+/.L^O>T531H^Q6&,<9GJS
M1R=['1.0ZI$64D,_53!%22@'4@V5?5^341*"!Y*%=,'QD.Z(N!2,8@D!(\"1
M\BN?\&=+_I[:UVMI>\)ZA80I%WC5P<Q%R3I[6>M4$Y >_P 37;#:#S<M7G'8
M1**\([8*BF(IB?TQ$O"J7N/BXD>[?3Z+>P:L:U%SB;9DF!,1)[$G3])3.*>/
MZPGE91+^S):7Z:M\)&ELJI!J!2U@2J2)BC D)$B L2E1 J;.M;.O=OI]%OOA
C43A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g309486g79i39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309486g79i39.jpg
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M=K8:(S$WF+?8)#5T=;,E)C(S-+1!46%Q8WBAI;C4\/_$ !X! 0 !!0$! 0$
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % $'R/*)%#H6^2&(X_?LIR=
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M<K+68U 0-K5V<5IRA8OLI0B(.LM5J#U2JP]W/.--,&,06B]T * % "@!0 H
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MH+)4@".UCB0G&7*'MBQ7VP16L 7&@!0 H 4 * % "@!0 H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 4;@K$@0+5P4BM>)&E4*K(4 "C%RRY!0S
M=[(RSCDY)BH_:[F0 P\D S1!"(P%K[:P!C7#$M1S.#IG=O;G= BLY/"<@;NF
M3I1K+6<E)PSTH"%:JXTY9AXD@S#-ROOM,J*" 02K&" ,K4 * % "@!0 H 4
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M\SI:]8R*_P"/8/YC4OHJA\T?=;?[E:U\;V?_ )FR/CVK[0'Y+!0 H 4 * %
M"@!0!LKA/,K-!(+EN#2HAS5(9$CB\WQZ:VWMNS#F?'K^F61)S/N,0;%L+DS.
M$C:9.20(H]:0)K,+,"J;4)A/+UVAO5"H4>?$4TAR,N7 J1.EO2*)4HZD3&DW
M$=\AI]N,]$4HC2VK/$9877"5Z-8RU\2AT2U=%J:9+C-09IE:H"HY]E"MA9^<
MV]2I"[S+#!DQ'Y\6I)0:%O(T925I=CL*1L*BU'8()6+7211@V709;C'3;&&_
M"I[8;8MDFV-Y-CITRA)!."LL+,&\I21C)0[/B)>H?9./*AQ$A3IPK9'=+S;E
MF;0*;0U&E)AU!NJVGEN5U+I7R(-4B5-JE12:0>>/1%RZ86CN(1'B%2$JC*4:
M(N+OFLH=B$NO2JA3%5:BO6;R=TQBQBXQDB%6+.U*@2;35$Y+J2A_[39IMH3*
M:R\Y.JBK3J;J+;1/5 VK WYPBR:2:D0NF5CGF+Y)@6:&W&R<QBE193&\Y$E4
M&<&LA<G$R[LRF#88S9$O1-87!A9KMX$[4N5E+3!CDN4&6J+9@VJ03$NEU"AN
MU112(AJD,TV'4&W5-J)_"^1296<;<>-N0_G36ZVA2"(H#%M*8W4<HA2K4+F4
MRT5"MA&LXA4*J$B#,M!5*)(BMO-G"QPU'!IV9?9C$_!AFP3<5YU+RE'[03,V
M$H0S8D8SSA/3!CMGU M>4H\3'G%.DSBY3]B<$D,=BBE":R<U(28M9X^$^6B:
M72*MT42R1J0C=SB6X%*A1*[/?K,A*<Q(J3UG':3)5):6N@M4Z0VN<R9I5B):
MB;>DFF&3K4MV8J*ZYF4J=.ZAVPL718EE(2EZ;!L_%MY&M/ 3 D-M6UDUZ ^U
M1Y:$.-YM3*%/1*>2ZL<253(]+;J,5C2EHCIR8DU28<;4LE=$9XFV6BQ-DF'D
MH8X.>)L>RB1&O6%5<#DK.Q+TO"V,WZ1MD'D"2:L;&ZCA[6-O9#8RL;;NSB4E
MU:K)UIU45IQ&=A[,4N8I<G8Y51B128KB*A%>D-*S-5CQG9\9<%^0R4UTG9"9
M3;N:;-?1LY3+(QFZA*9<.-5/4K:.DH8IYUQN@U*H*F6.=H52BPGVBE6;G5&-
M19[59@P92Z1%5'AKICT;2I"6X4YZGL92RZ>3O;&T,('/!N=(K/,1QN,GML9?
M\VY*EF07V.9 9RDX%#4E:V91*X([)7!>X6DT9+QFF:&@E8%"P'+)[5E:I#Q1
M8\AZ0;5?H$NGUF5*)V5'H5+ATZ/)IKQJ,GENOIB5!E;;;>BRSJJGWU-FY(2C
M2R<I5G*IFZE-A1829-BK:TNN63IM-7&ITZV=HJI7YM/KT-*$KB-18BZG0Y34
MB1(V2IJ;.MQ8B'R9A..YXD>K+3XZ9+@LL:9,M0(8U(,GJI(<XQ9^7K7D,QTX
M,>/(\Y1MP"UA7L;&@E3-O1XAAZ;<AN]_/I.X+KN(F]DYV+8^TC-+J$-Z(VXN
M5&I:(J6I<9M#!P[32*E(:E-&]FGWW(CQ+8G)69DR6@*;;S9./]U4<JE@I-HZ
M)5(E2>88IM0M&[45R*7.??F%5LGL*@0)%.D%&)^%"CU.'F9E'6V252_]MMOO
MY_,PM.L@YSATWP^&(.Y)JK)D6B>.H/')RQDJ43=,X$@(CKL[1R>I5:-"J<9)
M 92SJ PZ3&D#&N8'IV:EJ@XIICQAO;4Z@38-:TUE1(I<N94Y\F ^:%N0J@XJ
M2RS*IRT+<2W&J,1].FQ241-R&&7D))3TDD^1UZVU(K5DMB9:%.6DIE+L]1:=
M6H2'68]8H<=NGRIE/KK;K3+LBH4.IPW"I%24@S>@S)<5YQ:8L!2LKQC/D(AZ
MO"+JXY:*GR+'>/W^(2V/ B,T87QSCDZN:ED$/8'\2(MK<2H@A>UMH%&9.A+Q
MR6='R%3@ );SP.WZ>79Z?-17F6J,=/74ZC&FPY*ID&1'9E0+E1YLF.2S>:5-
M6PWLC*B.*J9IDJ0T9J8S[O44VW-%I+MC)4BU::ZS9Z@SZ35(":76H,V33ZX:
MVY]*@3S93&?126)CA4*FU)A-GR73T.R"2F9HD?6Y;E51'\*RK"[)D%UDT<?I
M'#5R1J U*69A2MB1"?)Y4>>A5@L8<]'34Z/-21R&8<H$@B2ZX1%MCFWE!Z=%
M(3)KD2N2*<S%DQHTYM;IO)?D+=6XF)$)+B#N)A,!,EU;5R4DY-;WC=:<4/.W
MK4.0+&U.QT*OR:E3YM1I#S,5,5V'!:C-,.5.J+6R\DE+EKK*Z?&:D*-;ALTI
M\TFF-)82-D6U=H6?BV*/D1EI2/;D..-8W%8Z90CR(3B<DTOA6'.3\XNZEH8D
M*I_3ZF2'1X-061M;(Y1Y6041N+>-'S#K=OXZI$@Y3SC#1272:0S29+F;)=JS
M;)J.RPAZ0XB.NRRFF2<SCS[4E"C5B<)?H<9[(E.3#@)IT1F9(.GQCD.R;30&
M=(4UDU)U<B=)ENQ83#LYO*0B3+4QFHT*33W4);P,*9L9\AP9B;,TT(9Q0E9C
M^4X%<(>D,81Y+>F%UE#L- C6+).SR9IC<\BIJU>TJW!8Q%MQ 6YONVJF@U8F
M7I5)\A,:OUBAPE/E.14HEH6YJB?*E,2&8K)+6A$1Z(])ITLD-O):1(-Q1N.9
MU#Y(4VM*82Y]B;+6PK"(AT=V@U.PS]*:5!5:.;!E5.6IAIUVI1*E$IU<I:GG
MXKK[T%,=LF(^CO1%.-R&EJR8GS)HV9UQ#M#RY V*&.%9&A,5)E8)Z^"8H;+3
MM7Y+9'FXBRYR;2WNQ60\"GO!ZDLYB+WC+%S8?9[$Y&ONJ51+;OMJ9FG&=3(G
M4R=+.'L<P4B;"*Q:G9+JL#3IL8J;:%+*4&F0><AMNI./FDQ^D:MADAB/-2J4
MF?&<@T:T%%I::JFN350J1559641H$=!/28R9N&OV'7+6XE<))-51Z,LIFD+F
M]6->M#YC"@!0 H 4 * % "@#MK\BS^^@7]E$[_\ <1^O'LN/^!S^-Z?_ -L@
M?5/W'?\ O@+_ -K5O^+3QU:R[]JY/_$+U]Y*:]8A_B<3\V8_A)'S-5O96I_&
M$WZ2X(]4D:\* % "@!0 H 4 9$Q+D=XQ#DR#Y,8BRE#C"I(UOP$*C8NC=DJ-
M2 3BR+PW",)C<]M]U32X%7 *QB)8>#8_6K6UBF,UFESZ5(-26IT5V.;B?OV5
M+29-OM[Y7.,.8'FSO*Y:$G>-_96T,NREHZ+:.$E#DBCU&-.)ARXV9;3+A'(A
M/D9&2H\V/G8LA-QXF7EEPF-PD^=L.(!O\<@[C((2R,FHZ!RZ#2EZ0KW1Y7X&
MC*B9J'&%+AMP'!>!6;(I$5,K1U9<+ _GK#27=<D/CS*2=Q:[/UMTH\FH-QYS
M[]F:A#GQ&'&VF6[12TP4MSVR=-MHT%%C'!TE']XCI;2;+:TR7U)]<1;>R#"I
M].HDB=184/*%0ZK1*G,8?D2W[#4U=9=D49]4<I$DGG*C4$U?8]_^XSG'E(EO
MLKI\-"XYF#-^.I;:*N>%58L)L;:+++>^XT);'$-E@)SE*:R-G=RC6="M87,L
MO'\DB<25'N*U,\1P$(*+CZ982V1T1\FC4&IP]+:KJ"KLATJ0['JJG6SP'3Z3
M!C/,J2^MN0T9U&+,F()IM;,HYYG)4VIV3AUUK;:6?JQ4N38UX[%PHQVI8FV<
M1'D$3I5JTM9GPYB5PV'H,DDT&HTNENKD/-RZ<5&2FGM/)C4\W)//\RX:=<LZ
MM\@,4EN:X9T+G2+$\A#'9 D58R3G3N#2-M4+KG-Q:QK,F,+0RR!W'&4SBICZ
M8T*,\RS,]K1)HM.HE::H]CJ=(BW-T Z>Y6(QR8RT5514^?%=2C"XI#I0ISD.
MH72E-(DJ(UI+/L-XMG7+7V0DVIRJUZ%4L;]MTUMFRU0*GSVG;--JK=%J$9Q\
MUQTO1E5>CL5.AXJ8W(=I[9DTM6B37C:D4DU&8/>VB5-B=+P8K6,[86U3./$R
MJ+S95DEMQ#C"$2B9/B1"D61.70/*4KCKT[NC-(DJ*8QFY3E-F=01+)*L:E4:
M+9FO,/PWE*)UM#[IO09)Q)<!%+=K56GQ8,=;BT3(=0I,.2PRT_&4Y"E8FH#R
M50XJ'D3ZCE"L7-B52,VWHKKL2,F)6("*G3*T[:*/9.S=%J59FM,-/TJJ4*TU
M3I\R5)A5!MFL4TTR*S#6W5*B]%=JLR:MX#D=XU'L;(0U1XB1.[ZKP3E=.QOB
M62H&:1YC;,@R-AD3@64JD;$@<V!,!J:$C U 0LEV]4Q[W&WRA[>#,=$L=4:8
MQ9A^0IZ2J,RPBT%'4_'7%<?C45VFQ9,9LS1&?<:D*-Y]<AXW)&<2_B)R*PP6
M2U^56A6AEY0X4),6GHGRYCUA[4-PIK518B5&UL6O5*#4)"4.U&$S(A-E'B-0
M8I,0]'<@X%1ZE,F*GCCJJTXNT1RLP(;JHZMFDFS&?&!J8HK6,"%3+\"X[@0)
M?*(LE2&MZY--9E&)N]DMZ10>X0222]CFI;<Y*&9:W#U[=D;3,S*/(<)$E$&+
M14RR3+;1(<1"M#4JB<*)+<63C:H,*7!84XM*6ZA%A2(!N,I?;<+>R,J&3V72
M;4P6#>ISU8J-KETTW*8\]!9<JUA[/T(JK4Z8TTN.^W6:O3:U.0PTXX_1*A5H
M58)B2[$?8.(VU5XE+ES0W24\Z;XDD4-TR1::H$;6ZHYE$)/BG%C8PNN4L?N#
MJUIRT,EC,[0J7$L):L)<Z97!P:WE*(MT&H;IQV2K!PWG8J$P*Q&FVJEP'%NL
MKA3(M7J[TAFDU%MIU1N195/<2UOH,Z?(;;>861LDEW4EE/LJBK1&*DM5<LK4
M*3DVIM98:C2V:O2:G9:S,>#*M-0I$J,V3%2IU;97(227<-<A2)$6:T:9*G(^
MM.'9TP,V/<Q,;_ET,3,R.8RLUHVMALAEI"D!$H8)*;.SA(2 -X'YD/:"D3(J
M6+%+BVMKC,3&Y$!>Y)-_=16X$A^IT61&HVF)IA2'])1-C0U)-423%33TDXHW
M#COI?-<A"$(:=<;A)=6;;2\WYS9&MP(E M=!GVL*E*M"J'#*GO4BH55MQ**G
M J*ZXLV&R9*=#5$2S!==><D1F)%67'92_);SV3%>HQE;\SQ#-<=G;DT/[-$H
MA!YT@94,A5@G"3&\,9R@JVR22(@,C*:<EN,488ZZF2(T4L3*5KP[NBXQI.L3
M6J19E]RAS:%)I[3T=^9-GT]Q]R,@Z>NJ3GSP.QHRCBF]2FIDB2T48M#6E#++
M*">3B'1NY08<>V%(ME3ZY(BSX=)I%$K;$)B>Z5::L]1HB,[&J-0;V03%M%(I
M<*GREU SJC;CTN7)>5&62!C_ !-*=.YD+F*[-+,DD63G=^FKHVN3D">BN+?4
M*/5QL9]XHZ-S7<E3D8*8;C8\DQ7P>>O",0$A@+5L:Q$M(4Z$W0GUQJ4S'@M.
MM-;';Q(G)1*).F,NO8D4S&36%1(SB6[B-9&-%96IY/U4:KOVRB-5"TDJ;69,
M:1(*NGB-VCK=IQK.E28\;"Y: FSD8T&[F%ODHTM*3=-M0D<TUI,8WE.#_,TE
M:[Y$=5;$F\Z<CF3]F@H,D9Q+8P*F=[:/-148YPDS$J=Q1!DZN40WS23KEK<<
M;/W%R!!LY)M0NJZ)7M.-#--91(7HE,33GYYTR@F^:'H[VEH)J>594TYHJ(D[
M3%-MN)*FMM#<V]I^3IJS6R=C-AT/2J_*=@M;)VB578E#*T-M$PB=BS8NQ;JI
M%&595N0SLB]4J1L4V^\PM==D22S5)\U:*)A.LDOSRVOA:#(\R-?7\#65/VMK
MD+<=F9PDC$6^LZ)U+"%0UQ(Q,;+R&X!"4:8"0F&_]Y"%"LS11*';J%3Z5'8=
MCFY2X*8\<WCISSL=Q-#:BR#CO+9,\+LPEE"4Z:EDHU'._NII078U.V.1NKUN
MT4Z9'FI8M%6%SIY145Z-&GQEVPD5""B;#9E((G8M*4VJK(CI0T;1-(HYG44.
M.KT;U'S2,3_*(Y+$%)*IFOCW"\>&:G1.2 B[W"<-0*$R?>Y#N66XB2BDL==C
M$:I9MU*Y&-.M4CWPH-"'O;,P95.I)19B5(>V2KDDB6MIQ68G5NHSXN)3)FUC
M*+)9):$7(;62D)+"DAXKE#K%-KMICJ-)<0[$.@6.@&MMF0PC3*-9"A4:I8&Y
M:4R#;.HT^4IIUV]QYHVWG#SBU$6":Z <0% "@!0 H 4 * % 'Z'[/_NEK_Y<
MB_\ ;%5^;C_X=[_JN?\ >8_?B)^*QOS=G^&D7&L0D!0 H 4 * % "@#J?\IA
MJ8U)X#?<$,6!7=SC+7.VK+3K,9(P:),Z:VGHI?"E>+4D99;Q?#$KB8(.UNB>
M:R-:I?I(J6"<U;*B;V=.78IT-H+DD1\)7^]B)/[S_P!!V Z>Y/(IM@/!\SF"
MU0Y2V78@QI)Y0XJXBM@"IPD3_#&5U>UJF!N)REPA*A4YJU)YT17J#UL;,,$S
M*CC3T0QB"TQE^@!0 H 4 4HUR$L\"4Q8E+4C$$($XU!(3QB%;9"$!(AV,$(5
MKVN&U@WO>U]FU &GNO;"K?J TXR'&KG/FS&B1RD$4<!2MW:53TB2C:'@E:!*
M- C5HCS!K1%[@6.R@(2A"L,016ML5TED[:P,G]99M+4FL]%C,R(ZD9[,7JEM
MFR@\YFGKKE*X,!W\%Y<(\NRPY/'\J-AIUD(]4:H[LN93I13GHJYC:"@RD2#0
M;"'HZE&X2<)*)PL)G>9'P#H;Y)>%>NGC_P!FLA\2UZMNL[&\G_*A:N'Q]N'*
MQX0Z;Y/2M:AR2\*]=/'_ +-9#XEINL[&\G_*A:N#<.5CPATWR>E:U#DEX5ZZ
M>/\ V:R'Q+3=9V-Y/^5"U<&X<K'A#IOD]*UJ')+PKUT\?^S60^):;K.QO)_R
MH6K@W#E8\(=-\GI6M0Y)>%>NGC_V:R'Q+3=9V-Y/^5"U<&X<K'A#IOD]*UJ'
M)+PKUT\?^S60^):;K.QO)_RH6K@W#E8\(=-\GI6M0Y)>%>NGC_V:R'Q+3=9V
M-Y/^5"U<&X<K'A#IOD]*UJ')+PKUT\?^S60^):;K.QO)_P J%JX-PY6/"'3?
M)Z5K4.27A7KIX_\ 9K(?$M-UG8WD_P"5"U<&X<K'A#IOD]*UJ')+PKUT\?\
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M;Y/2M:AR2\*]=/'_ +-9#XEINL[&\G_*A:N#<.5CPATWR>E:U#DEX5ZZ>/\
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M_LUD/B6FZSL;R?\ *A:N#<.5CPATWR>E:U#DEX5ZZ>/_ &:R'Q+3=9V-Y/\
ME0M7!N'*QX0Z;Y/2M:AR2\*]=/'_ +-9#XEINL[&\G_*A:N#<.5CPATWR>E:
MU#DEX5ZZ>/\ V:R'Q+3=9V-Y/^5"U<&X<K'A#IOD]*UJ')+PKUT\?^S60^):
M;K.QO)_RH6K@W#E8\(=-\GI6M0Y)>%>NGC_V:R'Q+3=9V-Y/^5"U<&X<K'A#
MIOD]*UJ')+PKUT\?^S60^):;K.QO)_RH6K@W#E8\(=-\GI6M0Y)>%>NGC_V:
MR'Q+3=9V-Y/^5"U<&X<K'A#IOD]*UJ')+PKUT\?^S60^):;K.QO)_P J%JX-
MPY6/"'3?)Z5K4.27A7KIX_\ 9K(?$M-UG8WD_P"5"U<&X<K'A#IOD]*UJ')+
MPKUT\?\ LUD/B6FZSL;R?\J%JX-PY6/"'3?)Z5K4.27A7KIX_P#9K(?$M-UG
M8WD_Y4+5P;ARL>$.F^3TK6H<DO"O73Q_[-9#XEINL[&\G_*A:N#<.5CPATWR
M>E:U#DEX5ZZ>/_9K(?$M-UG8WD_Y4+5P;ARL>$.F^3TK6H<DO"O73Q_[-9#X
MEINL[&\G_*A:N#<.5CPATWR>E:U#DEX5ZZ>/_9K(?$M-UG8WD_Y4+5P;ARL>
M$.F^3TK6H^J5 39.A1D6'8VQ"1.38P-MBQEBR0 L.UKWO>UA[7;6M>]]BU]C
M9KP=:R<6IPN!Q2EE^11FHO:]L?H<RWFF6FK[\VVAN^ZZ_ DDWW;]U]U]PJZM
M&0* % "@!0 H 4 ?/3Y87+&$)L;C.)/"^)RI;CK(V18B_8QS+B_RDX(2?*F:
M/89ERZ;QY\T80AU&]OD#8)_%B6)TDC0_1-R'.7=OALTCCZP31(K"])'O_P"F
M$_;WKC]NX_W7EOD.ZO36XI'?3I@-V025PF:%UPMBUR13!U02IJ<Y4C7P=C5)
MI$XMDZ<':<-RYZ(- Y*D,S=G26)#U(T\D<E[R6M5G!8?]?T6\,UT * % $57
MR2XE9S1'DEGQY(%8M6$)V]VAG'<-A6X;=0EGA3';00!A;$A*UX, 84;O M&,
M:PH B27$S..>MV37I2)UF"%N6(;G%I$Z%K")0 HE,:D0@L:>7=M277I$IJU:
MX+3"G >^5IMDJ(*< @&K3^YAW_YPP?>)=<3E!_PS*_.(?\=(#J=KY] * % "
M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0!G2#IL?+$,*!);LB9<
M@EC,>X75+"2 /D=>7I8WNR5X-"H !%:.E(D#J6);8@1[:O6EW,$"Z:U=72D4
M=UJEE-T5MUJH1E/&XZA!2H4F2XS(;DF2R)O0R::D$;V#&PZX5YE@(!((\DQB
MK7Q*[U>,)53=*'5&[D#7(BFI\879<\#;%J\XE4!"FM'B&LXL0MV3W/ YQ^PB
MSPF"$=,A-T-QVG'*T!MUF<^W)0;S*8\J)(=DFPZ\I"R:1H:6%$=ZT8TO1+R4
M2KUAC^:"C*:.0PEI"SFNZ^*-YC]P>!J.WJZEO3]NYJA6B/&I2NAB MJ)/1'!
M)2V1F /W(U28(PC45,X+<*FHCE&5)>@,JEYDHZLW(*3*QJ4XTHUMOFT3"5M+
MP(S9I425+,U("[K8LU/<EB3$$J.(#C8BZ&N9T1D+*X(5;HVHG]X1FJE1;HZ(
M6L6XE-K,X#4*35YP4*EV"A//5IB5,AV!'ESJ=%),%E2J?(5(53ID9YIQ]AJ7
M);4XLGY#3'8I8C.FM9NJS3DC-*4XA*PCIL8BB61S%J<7MP9T3.%;=A$M2ISU
MCB$!EKHS#]P-*(&(],(E060EV;JBS[#(,"$N]QPU0*<W-J4=Z4]':C$[HANM
MH6X]<99I2\"D(,UH,EI2C\(2B-)D1'>%SA<.@;VB9SI!,2V90M=24J\D2UN2
M;R3#?F5N,#<"T-QEW SKG)_X5-%P=8#:)N$#?(A#MGIE,I,IF,N94DQENR$M
MO)-UAK-(.7&9,C)TC,KHSK\O2#O9(F#9-..\P%_BL4QV8F0OZU[;B=V$J*%'
MGR21]0: H;=,DPQJP% ;SRC$[@V,2A";<L%C@N2<=BKA.3&"F4^GT4T-3'93
M*<1N).'*FPUJ(C9J2#-PDDRM)H=8B+:7A22R?1<DR4@S"'LT7B*ME;%SA(@D
M+UR63'GIP.;0EWFN96YT4M3(H2*]LN)'(5)#44C?! $V%77G)A%C4)A;.MBP
M*<[%8=>F$EYUN>M:"D1V\T[%9?7'BK:<(W4G-6B.EJ5OL%G5-X3<1OA*SHAB
M] <>E)D(GLXUGG:E"KO(V5"W@6LEGY.Q)5!5DNZ@5N=R&E6WB-7$IG >WNG(
M5)E9!0=@JG4%E:FTS-+4N-5UM.:=%992[%*6B(A:21B)Q[#'<9-3J6WCOP(<
M0XE(?U_7]&/9_AV/+."HY)*41A1X)$>G VO,>*2D*FAH6*FQF$5LF& N^*BV
M\*5[+")LL-4I0[E=:1?83*91L\M34]I25E,6DF)4-+:'(T=QQB+@WS(Y3A,D
MW*3>Q>M;6'.HN >YD&Q>E-=RRIJE<P%(9(2A/.=F]'M%J%X1$-;@6F)"8!<E
M.9%1RTA/9<4K<%Z-402B 4$BY]QTJ@MJDI34T/I2U-0TM4EALR=:DM)8>2A)
M*)UM45:G$)SJ7'GFW$I:2DD8PIC(5C E8>E-E:O<[RI,P$*POD6-) @&4H.,
M?!607<;*FLW>Q:<M9<Q 6C.<2;KP%V1&@56*I5!0XI"JBYAT]$1+FEP%)2R:
M5J.5_8Y_.1U8"0EV]DFU/)-U)$THEA(6.(8N .,&K)0S*PI79*M<D"IW8DHU
M1*P[%MG!N<5YVP48@90/4Q+MM %B<[1]><VF$V,/$3,BTV@I.";DZ*X3<A#K
M[3DF(V;B75T'/,/NKN)345,FI$5Q)-_1'E,*1>HTAB29LL>:[-:A@=R''A$M
M08O2EJTJ@UK4E@2#NGW-'8T@*08E!ET!^_E!QQ(!%*B$*Q*H)OSM4BPF-'<A
MR4OY]*U.MDMM1QUD39X+F\22;,UJS2\ZM2DD:7$-.-K2 @]:D H 4 * % "@
M!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % '?@D_\ 2IO^')_Z8:^M6_P;
M?_H3_P!I *BKP"@!0 H 4 * % '1%Y6A0_8UR)BC(D7RWK>8W"7127QM=!=/
M&J/29I_@"!M:WJ!)E\J=U.K4A2W'+UIKRQD.Z.#@4(&YC9G"82L470('-TD
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M]>!RD .AX7?VW@ZGKB_P/_/_ .Q0;ET^_<O)P]>!RD .AX7?VW@ZGKB_P/\
MS_\ L4&Y=/OW+R</7@<I #H>%W]MX.IZXO\  _\ /_[%!N73[]R\G#UX'*0
MZ'A=_;>#J>N+_ _\_P#[%!N73[]R\G#UX'*0 Z'A=_;>#J>N+_ _\_\ [%!N
M73[]R\G#UX'*0 Z'A=_;>#J>N+_ _P#/_P"Q0;ET^_<O)P]>!RD .AX7?VW@
MZGKB_P #_P __L4&Y=/OW+R</7@<I #H>%W]MX.IZXO\#_S_ /L4&Y=/OW+R
M</7@<I #H>%W]MX.IZXO\#_S_P#L4&Y=/OW+R</7@<I #H>%W]MX.IZXO\#_
M ,__ +%!N73[]R\G#UX'*0 Z'A=_;>#J>N+_  /_ #_^Q0;ET^_<O)P]>!RD
M .AX7?VW@ZGKB_P/_/\ ^Q0;ET^_<O)P]>#-.!=8(<W3RT)MCZ\:V69Q=^$K
MRFSO_P"@&F#O?>GF\V?^;OG9W7?/ZFT_\L>V^CV7(3]UWMU6Z*Q6U]ZFKZ/4
M*MLEZJMF/Q!49.CZ'ZG*7^%TB_.Z5V&#\&O%V/"91<B1V!L[L\=I2JO]^C0M
M%V(T+\92ZK.9_9.7]YFOO,UV6+[Y-V_B!=Y1<*-:L1_HA$9O14H3;IY]V#M]
MP-&5M]KYGBVNVVNVVNV%L;.QLW_MKR.;_P#R':),EQ-J+.:+)?CYSU>X,>9=
M6WCP>HQ6'%AQ8<2L-]V([KQVL?[F(WX[#_JU).>9:=P^ITSPYQ"5X;]G"ONO
MNON*_AN(4O*0 Z'A=_;>#JC>N+_ _P#/_P"Q0S;ET^_<O)P]>!RD .AX7?VW
M@ZGKB_P/_/\ ^Q0;ET^_<O)P]>!RD .AX7?VW@ZGKB_P/_/_ .Q0;ET^_<O)
MP]>!RD .AX7?VW@ZGKB_P/\ S_\ L4&Y=/OW+R</7@<I #H>%W]MX.IZXO\
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MD .AX7?VW@ZGKB_P/_/_ .Q0;ET^_<O)P]>!RD .AX7?VW@ZGKB_P/\ S_\
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M $2/_A4__2!7]+T'\2A_FL?^$@?D[(_&'_\ K._]ZA55*&$* % "@!0 H 4
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M;Y8D-I2=QW%>5Y;V\6]VA\+NJ);KJRON6XM17\-RE&97^_<8YZS#&% "@!0
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MXE,^_P <[XQ?6 <).//UO6C_ (E,^_QSOC%]8!PDX\_6]:/^)3/O\<[XQ?6
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M1_Q*9]_CG?&+ZP'?&D_]*F_X<G_IAKZP;_!H_P#0G_M(!45> 4 * % "@!0
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M-LBPG?51^=)Z@VB\K_@\M/T>OK#CIZ4>GO'';I7N4VR+"=]5'YTGJ#:+RO\
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MG#@GV931(D)ZM//LR)LZN038CM(<.$[0W6HKA/XU)-Q4B6X;>!& X\=*9/\
M>#<0P)U&MWZJJE4XMF(\65#IE'LE6$S)K[K":FQ:UB3/8.)FFG<RW#I;")!.
MN$Z4V:ZNGF4!,=R:>5%VE^.H\GCQQYU.0Q>9,BF:=T+$P&A,)8,('9A$@=2
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MQ39_NUO_ .!2?^W+K],V/P#/_2;_ .PA^!TK\9D?]=W^(H5U91@"@!0 H 4
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M<V?]+ ..3EGF4-['<?G=-LJT'$TSFS_I8!QR<L\RAO8[C\[IME6@XFF<V?\
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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MYQO'H%+.N0;QI0 \XWCT"EG7(-XTH ><;QZ!2SKD&\:4 /.-X] I9UR#>-*
M'G&\>@4LZY!O&E #SC>/0*6=<@WC2@!YQO'H%+.N0;QI0 \XWCT"EG7(-XTH
M ><;QZ!2SKD&\:4 /.-X] I9UR#>-* *-QF2YJ;USHM@LM*1MJ-4O5F!4P@R
MY:5&0-0H'8LN9",,N HL8K  $0Q7MM0VO>]K4 5L#_8>&?PI'?NA'0!*Z %
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MV8L1ER1(=.73UDVRTDUN+-+<M2U84D9W(2I1W7$1GO#>FN:'&A0 H 4 * %
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MG24X'?4R@2Z-O#,59JF,54$/[4Q.*E[:RC')D7NT1FT==H^0%+O\C/\ =?\
MU_J&FO5A*ILFP/C^?QX2^>Y3PW"\G-LT"M1MS=,FPU++R\I.J9C;&$DAM/QF
M[,L';Y C3?\ 9HU&9,;!*5H1.RA.C"IEPW=HS*[VO:_+?O\ ZM\=@-!:% 'Y
M\FHS]X3._P!LN3_YW?*^J*3[%4SXOA?1FQ]Q4#V"HOQ33OH;(JW']VV'?;AD
MG^0L4U:CV8D?%L/Z5.%C?^(97Q- ^G5(3+1%^^-I;^W[$_\ .S+4>T?^'ZU\
M5SOHS@B6Q_PI:/XEJ/T5T?>]7S"/BL* % "@!0 H 4 * % "@!0 H 4 * %
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M,_ZZOX3@V4K3C0!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M* % "@!0 H 4 * % "@!0 H 4 1.>_L--/X3D?W.LH \P/\ 8>&?PI'?NA'0
M!*Z % "@#").$B6R3Y+E\8R-D*)O>5II#YK*#F@O'BXD!L.AS)!B&!K3RC'T
MB*2L+TQ1YK"]7.LJ?=]DC4LSXS7.,"( BCII3QP7 4L$QTI<<+&%,T&B[C-\
M;Q[&"B=R:(X\:TK/'8C,'?(^/,A()9'0MR!"C7(7YH7"6(DMFX9P6U4O1JP7
MBIC6E^!QZ9L\\4O<PD\@:)L/*NWD*R/;T<,PJL+)=/SME=6D88TQ%II4]8O
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M;KG!R(4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M:BPDX:BN+?,KAWGUYJ/' H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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MT>OGD?)84 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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MO?\ T%P^]??^3] [;(F5(B(O'"I>I2+)6!C:PR94W@"6WG/^\B.&!MY82B;
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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MR#EKRX&:\>95R9 &_#6+5Z"#9!F</1+EBZ6A5K4D9D;DRIE:H)#H D*E22B
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MQ<7_ ,8R#(?+@9K9X#CN7DX:Q:<KF9\R*6)#%TMLG1VC3DWH4UTP@NEC174
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MT4GKL82C=GEZ6-YUUK!%75M'90F&$VP"U@S"[7VIH"Q[(:\*M#9BNU2NU67
M@*D1U2S0EPGXJ"-2&FTK+"Z^A>\>]>:;C[5X^8;6V+M-6K3UV?2Z4Y*B+GJ;
M2\F1#;(UM,LI66%Z0VX6%177FDB/M&9#;!J\IUH8>T,D<FO/+>J11!E(D4C/
MM!\G%6;693(F")D+1 /A)1J@)DAE#$W;BC H4!$O"H$2%(0J4$:-=C;2MJ90
MNF+2I]PVFBTF&>-PFG7S25TDR*YIEU=ZKB["Z_$9$?,N9/;8LKCMN45Q*Y3R
MF&$Z73SSCJ6'I)H(REF2;F([SEZC2FY!E?B-)'9>5<\G_P"L.V]P<K^!*R>H
MBU/)*^=0?21EVM;;\A.\\IWI@O,A\IWH7BCROCS_ )Z;V]X:S0D+D0H/DY0)
M.:,HLX(+G)(2>G'LE&EBV2CAAMMMB]]M:]K8VK&VE?;2ZU2UK;65Z5:3#*\B
M,RX%2",M\CX2(8F,GEL9+2'V**XXTX5Z%E+IY$HB,R/>5+(RWR,M\BX (\IW
MH74QYTE1&>F\; RO+#'G-P\Q\G!"E>),AD;DQH[IQ0D*LT2]%$I">$X@@Q.1
M9N$!4<08H2 4#L;:4G4,'2UDZXVZZA&DP^R;94RAQ5^D82PJ?:*XS(SQWI(R
M)5P\GELDOMQCHCA/NM//MMZ73[U-1UL-O+OTO"6!<E@C(S)1YPC21D2C*G:/
M*C:#WYV:V-IS\W+'5Z<432V) P7*)5U3@XJ2D:)/8U1!RB"KGJ3BRK&'&EE
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M^L(-US--$JGR2-QS MS @C;[)6!M:\)7GA0H^ C%OX\FC;UH\#^U"(?-:O\
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M6MLYRHY.$A;K:5YLU&DUIO(B,A F+RH.A.3/C-&V//C<O>I ZMS(SH0P;*!
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MNYN*UPN1;"Q)NX[\4FJ=RW3]*I>Z;GNFTV^T!M]C;;0.SL6O1E16A"$;")/
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M/X<. [L-^(\5Q;E5SXY0* % "@")SW]AII_"<C^YUE 'F!_L/#/X4COW0CH
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ML5)1& %=.I/*N T04%10 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
MH 4 * % "@#A4&C(3GG%)SEAA))II:1.).%0J&6 0P)R!*STJ4)QXK6**$I4
MIT]AB#<X\DO;&! .MN%YRU8.V7H4SS#&TIB$0<LHSACE+0XQR)F+6N,62L X
MBI:'*/.LJ;IK'V]:Y+FN0OK;*(N\L1* 4Y4-$FCJD]A9 KO?U^_VORE^KA'9
M504"@!0 H B<]_8::?PG(_N=90!Y@?[#PS^%([]T(Z )70 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
M"@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M * % "@!0 H 4 * % "@!0 H B<]_8::?PG(_N=90!UC-O\ NY!_P27_ *!=
M %;0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!
M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H HG+_=R_\ X)5_T#*
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g309486g83f14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309486g83f14.jpg
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M 0$! 0$!_\  $0@ NP#K P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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M&G4+2%H6VM"TJ *5)4DA25 [$$$@@[$'%?U(Z'_R.;#\06JSE  \  "S;P
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M[V2.A-<.!W#V5X_86I? (WZ*E]G&3WGVFF!W#V"GL+4O@$;]%2^SC)[S[33
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MD%#K+K2P4.-N(44K0H$*!((KD:=<8<;>9<6TZTM+C;K:BE;:T$*2M"ANE22
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M9^FK!]O- \6=9[!<+*2=#IU&/O/<$[$2JEIGK',,V4JZVYNF^52+F7LW:K5
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M7F[2RH>2VI/*VJ8ECE92XVS$9!CP6%K[VKM0LW-QBT6A(8T_:0&8;2,@27$
MI5+7DGGSE09*R5%*E/+^^/+ V IID13(DF4"$(4"E*4     Z   'A[LS37C
MJYXI3%*8I7X/7H/0 $>@] $>@"/X@$0 1 .OO'H/3\@^[%*U'77R<5PLT3M]
MY'7JLPTMMYO1+!)T(0E'6NF&Z*E?' /]WHRI8A">5MT[HEC5-..6OJE)D#""
M(\,H<QA,HJ0>GH/ZNN/;5X;5X"V;9UAW!<T[E 564VOK#=FM;14V(R,G4MAC
M/R,O-\<K/?7*\2R>HR&@I^^[1GF3.,CWHR<G8HI=*2:A"MBIJ XQZ\_3[:D[
M27#P]-VC<=D[(3JD^\DJ_P <&=/4@92RE>U^<T=K_P!D7SQR59I$-'C.6D3'
MD&"2A%P(T'T=ZW.<W<13.P]&?UU2-V\%!VEO%?<-=V WI*4@[H4W,5]"LMWQ
MI*VL8*W:7VC;%94KIJZ-)WSBO>YK4S)LY!W$1%CKFM;VXCI!U2&[!ZJ0<#&,
M_;;]>_M'GJ'-M^3LM][/O,]?EM61)=LUCFM1H5N^C)0$*C"\KM6:0HL?/(%9
M0O0\M69'3KE:6A6A6C23C;D\%";(O&J-IA0*Z>@CS]Q/LZ_%6=/'G3+C2K/;
M$8"-8CH2[[HMNR:M7JB@HTAJO!V:*K:!H9-EZNBFC9T>9BI>:?%CF:;-9Y,+
M.1%1TLY545360N*4Q2F*5CEOJYM(F)6@).IOI=C((>#\Z281R*G7[V<CQ-4Z
MK9TBH "GW))G[B]2")1ZFPCQGUE8;'8)MHU3HG4NHK+<H_(Y,@Q(IL[+AP6E
M.W4RE.VV8P\$KC.+B!T.MAQGF2 H^TT;9Y\^X,2K7>K;;IL9SF2T^Z[XVL#(
M4E,4-A,EI:,AQ(=*2D\J\'(&NY6,8*I2+<6Q?,2I5B/D^H]'!5T?1U>\ Z%
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M<BVPI/:7>69]V<[>-#:=Y[I.49MQ7S\TV63)DEUXE=63]SRYM?HV;,_NIO\
M[9G6^XO5?XAN/Z _35_]]7X.?YXM$?.H_P"73[GES:_1LV9_=3?_ &S'W%ZJ
M_$-Q_0'Z:>^K\'/\\6B/G4?\NOKV\EIKJ[ZLXFZ6I&PZW)5.VU^GV9M-0$ND
M5&0C5WVXMI33-)TD0ZA4U'$5*1[],O>(BW=HG$ [NF;$:)ARH&EK5$FL.1I+
M(EAUAT<KB.>;(<3S#S90M*AZ%"OAKX6^J=.ZU\(CB-J;2EWA7ZP71[3:K?=K
M<[VT*6F+I"P09!9=P.;LI<9]A>VSC2QYJV79ZFM<J8I3%*8I3%*8I3%*8I3%
M*LO8"*CBJR::11.<R0="@'4?PR__ %XY(ZCUBJ5' /L]M? OR2\GAS:M'(G?
M=FK_ !LV7+0%CW3M*>@Y5I%MCM).'E[S.R$9(M3B]*)VSUDX0<H'$ [DE"FZ
M!UZ9<4.M\J?*Z) .QZX'HKZT:-XT<*H.D-*P9FN]/1Y</3=CBRH[LSE<8DQ[
M7%9?9<3R>2MIU"D+'F4DBK%K_!3RE]39!'572G(*LQX6:O70&%??OX9D%QJ/
MIWLG; :QTVV0"S5CUG)>STZ!/6D+ZP?>K73;TMQYR2XT=S@G&-TD['J.G0]U
M727Q;X&3W>VG:NT7->,*7;>UE^+27?<ZX=EX_ [1YA:_$IO8L^-Q<]A)[)KM
MFU]FG%R%XC^5>(FP2)K[E,1*+1*WC$RVNQE3CFY+&M<2(,"!90*S1);G+BU%
M2;@F0MC76G *$FJ=T:.=G^C\@^K_ '>[:ND>)7@^$NJ-_P"'Q4^HK>48UOR\
MLPTVXK=/BF7%&WH1 *EY)AH3%SV"0@4N*X5^5$@DU$H34_)*'26-%G63BIN8
MCTU30=A=6V%,H1I/HE.:(M3U[9HL3 (Q]A=NIIH*4DX5<GGM&O1\D^<8/F[M
MO5M7._Q4X#2BE4K4^A9*D=N$%]N&\4^-1$6^3RER,HI\8@--PG\8[:(VB,YS
M,H2@>S]YUY5 3-SCJ_DL*C22),-EAG)<7"$JE8WEP3D4G SPKD>)VZ1?VHC@
MJ@*DLCUW.E,$HX6='<[7>.[X)Z8QW=VWJVKC_A.X ^6/NDT'AQDQUI[.'R+8
M5#;MRF5(\6Y5-FWLM0"@C!A--Q2.P0EL>-QPJ\J"Z;/F*^HN1BC&3&O#(L!E
M9,K!\-1577JGI3(LX5JO[,KNG2]?\XD8(99RX5CO1E%E3&CG9]'G_!/GZ^;S
M^>N1'%3@,VMIU&J=#AUGQL,N\L4NM^Z"4HG\CICEQ/CJ$(3+PH>,I0A+W.$I
M ZY'A+Y3V7])"4T]R(?@\CY2*>%=24@L1Y&3CIL^G&#LAYL2.6DX_9M'\T@N
M51.6?MD7L@5RZ3(J$A;0Z8^2?B\WFSMW54SQ6X$1^3L-5:)9[-YA]LMB*DMO
MQ6UM176R&,H<BLN.,QEI(5':6IIDH0HIJTG_ ).?R@DH9J>3XV[@D3L6+2+9
M'?,R.S-(U@D"+&/;&7D5!08LD0!%HU3$J#9$"I(ID( %">U;'0^GH?HKOM<:
M^#; 6&-=Z69#KKC[@:E(;#CSJN9UY80V.9UU7E..*RI:B5*))S6R'R2_"GE9
MIGF/7[UM/1EZH]0:4'9$<YL$ZP0;QZ+Z4K3AI'-3J$=*F\\\<G*B@4"#W*&
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: / ,4KGBE,4IBE,4IBE,4IBE,4IBE,4K_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
